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1. INTRODUCTION
Cardiovascular disease (CVD) is the most common cause of death in the Netherlands, 
accounting for approximately 39,642 deaths each year 1. Worldwide, the number of 
deaths from cardiovascular disease was estimated at 17.3 million in 2008, and it is 
expected to increase to approximately 23.6 million patients by 2030 2. Treatment with 
aspirin, statins and anti-hypertensive agents is currently being recommended for 
primary and secondary prevention of cardiovascular diseases 3. Besides their lipid 
and blood pressure lowering effects, emerging evidence indicates that statins and 
anti-hypertensive agents, specifically angiotensin converting enzyme (ACE) inhibitors 
and angiotensin receptor blockers (ARBs), could also be related to an improvement 
in endothelial dysfunction, anti-inflammatory and immunomodulatory effects 4–23. 
The immune system is a system of biological structures and processes, intended to 
protect the body from potentially harmful substances by recognising and responding 
to a wide variety of agents, from viruses to tumour cells, and distinguish them from 
the body’s own healthy tissue. When the immune system fails to distinguish between 
its own healthy tissue and these potential harmful substances, it results in erroneously 
attacks and destroys healthy body tissue, a condition also known as autoimmunity 24. 
The development of autoimmunity is a multi-factorial process, including genetic, 
epigenetic and environmental factors 25, and despite many years of extensive research, 
exact mechanisms responsible for the initiation of autoimmunity have not been fully 
elucidated. Several studies have demonstrated that environmental factors play a 
major role in this process of initiating autoimmunity 26–30 and may be responsible for 
the increased prevalence of autoimmune diseases in highly industrialised countries 31. 
Environmental factors operating in a genetically susceptible individual may directly 
initiate, facilitate, or exacerbate pathological immune process, induce mutations in 
genes coding for immunoregulatory factors, or modify immune tolerance or regulatory 
and immune effector pathways 31. One of the environmental factors that may be of 
importance in the development or progression of autoimmunity is exposure to certain 
drugs 32. 
2. DRUGS AND AUTOIMMUNITY
Adverse drug reactions may occur in approximately five to fifteen percent of therapeutic 
drug courses 33,34, and in the United States of America (USA) yearly, more than 100 
000 deaths were ascribed to serious adverse drug reactions 34–36. The first cases in 
literature on drug-induced autoimmunity were patients developing various lupus-like 
symptoms after receiving sulphadiazine 37 and hydralazine 38,39. In 1953, approximately 
seven percent of the patients treated with hydralazine developed these lupus-like 
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features, and similar percentages have been observed recently 32,40. In the last 
decade, there has been an increase in reports of drug-induced autoimmunity 41–43. 
Numerous drugs have been reported to be associated with autoimmunity or resemble 
autoimmune disorders (table 1), and these numbers continue to increase as new 
therapeutics are introduced into practice 40,44. There is an increasing number of 
 immunomodulatory drugs on the market, however, only a small group of patients who 
were treated with these drugs over a prolonged period of time, develop a systemic 
drug-induced syndrome 45. For instance, only ten percent of systemic lupus 
erythematosus (SLE) patients in the USA are defined as drug-induced lupus, 
representing an estimation of 15 000 to 30 000 patients per year 40. 
To date, no definite diagnostic criteria for drug-induced autoimmunity are available; 
however, there is a general consensus in setting this diagnosis. According to this 
general consensus, there should be a temporal relationship between continuous 
drug exposure (> one month) and clinical findings. The clinical findings should not be 
present in the patient prior to the use and should be resolved upon cessation of the 
offending drug 32,44–46. In addition, drug-induced autoimmunity was identified when 
Table 1  Drugs associated with lupus-like syndrome
ACE inhibitors Captopril, Enalapril, Lisinopril, Cilazapril
Antiarrthmics Procainamide, Quinidine, Disopyramide, Propafenone, Amiodarone
Antibiotics Isoniazid, Minocycline, Nitrofurantoin
Anticonvulsants Carbamazepine, Ethosuximide, Phenytoin, Primidone, 
Trimethadione
Antihypertensive 
agents
Hydralazine, Methyldopa, Clonidine, Minoxidil, Prazosin
Anti-inflammatory D-Penicillamine, Sulfasalazine, Phenylbutazone
Antipsychotics Chlorpromazine, Chlorprothixene, Lithium carbonate, Phenelzine
Antithyroid Propylthiouracil, Methimazole, Carbimazole
Beta blockers Acebutolol, Atenolol, Labetalol, Pindolol
Biologicals Etanercept, Infliximab, Adalimumab, Ipilimumab (anti-CTLA-4), 
IFN-α, IFN-β, IL-2
Diuretics Hydrochlorothiazide, Chlorthalidone
Statins Atorvastatin, Fluvastatin, Lovastatin, Pravastatin, Simvastatin
Adapted from Borchers et al. 40 , Vasoo 45 , Wiik 46, Rubin 50, Fadel et al.254
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patients showed similar symptoms after re-exposure to the drug 32, or was accompanied 
by the presence of specific antibodies indicative of drug-induced autoimmunity, i.e., 
anti-histone or human neutrophil elastase anti-neutrophil cytoplasmic antibodies 
(HNE-ANCA) 47–49. 
Several hypotheses for the mechanism underlying drug-induced autoimmunity have 
been postulated but none of them have been clearly demonstrated. Currently, 
available data strongly suggest that there is no single mechanism responsible for 
drug-induced autoimmunity. To date, four main mechanisms have been hypothesised 
in the literature 50,51. 
The first mechanism is based on the presumed capacity of either the drug or its 
metabolites to produce stable complexes with self-macromolecules or stimulate 
lymphocytes directly. Essentially, this concept is a drug hypersensitivity mechanism 
in which the drug or its reactive metabolites bind to the protein (hapten), making it 
‘foreign’ and stimulating an immune response against the hapten or possibly 
self-antigens (molecular mimicry) 43,45,52,53. As suggested in several studies, drugs 
or their reactive metabolites are capable of inducing specific T cell responses, 
apparently by the altered self-proteins, however, there is no convincing evidence that 
this results in autoimmune diseases 40,50. 
Secondly, it has been postulated that certain reactive drug metabolites directly cause cell 
death via a non-immune mediated process of direct cytotoxicity 45,52. To date, six drugs 
(i.e. hydralazine, procainamide, isoniazid, quinidine, propylthiouracil and chlorpromazine) 
have been associated with a relatively high incidence of drug-induced lupus-like 
syndrome. These drugs can develop into highly reactive metabolites by myeloperoxidase 
(MPO), an enzyme found in neutrophils and monocytes 54. These reactive metabolites 
may cross-stimulate T cells from healthy individuals 55, stimulate T helper (Th) cells to 
act on B cells 56, thereby enhancing, in the presence of interleukin (IL)-17, the 
production of MPO-ANCA, an autoantibody often associated with drug-induced 
lupus-like syndrome and drug-induced vasculitis 57–60.
A second mechanism of the cytotoxicity of reactive metabolites involves apoptosis 
and NETosis. Vasoo postulated that these reactive metabolites alter degradation and 
clearance of apoptotic cells, which could lead to the loss of self-tolerance 45. Recently, 
it has been demonstrated that these drugs, quinidine and procainamide, could 
indeed inhibit the uptake of apoptotic and necrotic cells by macrophages 61, which 
may increase the autoantibody production against cellular antigens 62. In addition, 
certain drugs including hydralazine, isoniazid, quinidine, or chlorpromazine, but not 
procainamide induce apoptosis of activated peripheral blood mononuclear cells 63. 
Alternatively, ANCA can directly induce NETosis, a unique form of cell death other 
than apoptosis 64,65. In contrast to apoptotic cells, NETotic cells do not display 
‘eat-me’ signals, e.g., phosphatidylserine on the surface of apoptotic cells 66, before 
plasma membrane disruption, preventing clearance of NETotic cells by phagocytosis 
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64. During NETosis, neutrophil extracelllar traps (NETs) are released, which are 
assembled from nuclear chromatin, associated with histones, cytoplasmic and 
granular proteins, including the enzymes elastase and MPO 64,67. NETs trap and kill 
invading microbes extracellularly, even after the neutrophils are dead 65,67. However, 
several studies have demonstrated that impaired regulation of NETs could trigger an 
autoimmune response against components of NETs and induce autoimmune 
diseases 68–70. Recently, Nakazawa et al. showed that the anti-thyroid drug propylth-
iouracil impairs conformation and degradation of NETs, and triggers the production 
of MPO-ANCA antibodies, resulting in the development of MPO ANCA-associated 
vasculitis 71.
The third mechanism in the pathogenesis of drug-induced autoimmunity is based on 
DNA hypomethylation, an epigenetic process where changes in gene expression 
occur without an alteration in the DNA sequence. Several studies have shown that 
both procainamide and hydralazine inhibit DNA methylation in T cells, thereby 
changing the T cell gene expression profiles and T cell function. Inhibition of DNA 
methylation is associated with an overexpression of lymphocyte functional antigen 1 
(LFA-1 or CD11a), an adhesion molecule with important functions in co-stimulation 
and stabilisation of the interaction between T cells and antigen-presenting cells, 
resulting in hyper-responsiveness of T cells to signals that normally do not trigger 
activation, e.g., self-antigens with low-affinity binding to T-cell receptors (TCRs) 72–75. 
Finally, drug-induced autoimmunity may be due to interference with central immune 
tolerance. The thymus provides tolerance by deleting auto-reactive T cells during 
thymus maturation. Two studies in mouse models have shown that during positive 
selection of thymocytes, intra-thymic injections of reactive drug metabolites interfere 
with tolerance to low-affinity (self) endogenous antigens that are normally presented 
by MHC on thymic epithelial cells. As a result, autoreactive T cells are migrated from 
the thymus to the periphery where they provide Th cell function to B cells with the 
potential to produce autoantibodies 76,77.
As described earlier, the confirmation of drug-induced autoimmunity may be achieved 
by re-exposure to the drug. However, deliberate rechallenge is usually not advocated, 
as patients are likely to have a severe response when they are re-exposed to the 
drug. As straightforward as this approach seems, making a diagnosis of drug-induced 
autoimmunity often proves to be challenging in clinical practice 32. Many patients, 
especially elderly patients, may have multiple diagnoses and treatments, or have a 
medical history that is not well documented, which could make it difficult to establish 
an association between the drug in question and the patient’s symptoms. Furthermore, 
various drug-induced autoimmune mechanisms may involve processes that are not 
readily or rapidly reversed, suggesting that withdrawal of the suspected offending 
drug may not modify the clinical course of the disease 44 as has been found in 
lupus-like syndrome where antinuclear antibodies (ANA) and elastase ANCA are 
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persistently positive many months after drug discontinuation 59,78. Another difficulty 
that may be encountered in setting a diagnosis of drug-induced autoimmunity is the 
nature of autoimmune disease. Although each autoimmune disease is unique, many 
share features with other diseases, making it difficult to establish whether the 
presence of autoantibodies is part of the underlying disease or attributable to the 
drug. For example, anti-histone antibodies are not specific for drug-induced 
autoimmune diseases but may also be detected in “idiopathic” rheumatoid arthritis 
(RA) 79. There are a number of drugs (e.g. statins) that have been prescribed as 
powerful modulators of disease processes (e.g. cardiovascular disease), and as a 
consequence physicians and patients are understandably concerned when the use 
of these drugs are discontinued without proof of an adverse effect 44. 
Drug-induced autoimmune disorders are of major concern and often reason for 
withdrawal from the market, especially when high numbers of serious adverse drug 
reactions (ADRs) are identified during post-marketing surveillance. In daily practice, 
it is rather difficult to detect these side effects because they are relatively uncommon, 
its symptoms are generally mild to moderate, appear after prolonged exposure to the 
drug, and may occasionally persist, despite drug discontinuation 44. According to a 
French survey using the French pharmacovigilance system, approximately 0.2% of 
the ADRs are reported or published in literature as systemic autoimmune ADRs 80. 
Not only for pharmacovigilance working parties but also for physicians it is a major 
challenge to set a diagnosis of drug-induced autoimmunity. Nevertheless, it must be 
emphasised that drug-induced autoimmunity can be chronic, with long-term 
morbidity, and therefore may potentially impose a heavy burden on public health.
3. SYSTEMIC AUTOIMMUNITY
Since the initial description of drug-induced autoimmunity, more than half a century 
ago, a wide range of pharmacologic agents have been implicated in interfering with 
specific functions of the immune system and induce autoimmune disorders. 
Drug-induced autoimmune disorders often exhibit heterogeneity in clinical features 
and drugs are capable of eliciting an immune response to certain auto-antigens. 
These symptoms of drug-induced autoimmunity show some resemblance to typical 
systemic autoimmune diseases, e.g., vasculitis 46, scleroderma 81, sjögren’s 
syndrome 82, dermato- and polymyositis 83,84, and lupus-like syndrome 40,45. Indeed, 
lupus-like syndrome has been associated with nearly 100 drugs, including the 
aforementioned drugs hydralazine, procainamide, chlorpromazine, isoniazid, 
methyldopa, minocycline and quinidine 85. On the other hand, several organ-specific 
autoimmune diseases, e.g., membraneous glomerulonephritis 86, autoimmune 
hepatitis 87, thyroiditis 88, haemolytic anamia 89, myasthenia gravis 90, and the skin 
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diseases pemphigus and pemphigoid 91–93 have been reported to be associated 
with drug intake. In this thesis, we focus on the so-called systemic autoimmune 
diseases. 
4. CARDIOVASCULAR DRUGS
As previously described, CVD is the leading cause of death in the Netherlands and in 
the world 1,2. Currently, important interventions to prevent and to treat CVD are 
available, e.g., pharmacological treatment of elevated low density lipoprotein (LDL) 
cholesterol levels 94, elevated blood pressure 95–97 and inhibiting platelet function 
98,99 with statins, anti-hypertensive agents (thiazides, beta blockers, calcium channel 
blockers, angiotensin converting enzyme (ACE) inhibitors, or angiotensin II receptor 
blockers (ARBs)) and aspirin, respectively. Statins, ACE inhibitors and ARBs were 
listed in the top 20 of most prescribed drugs in the USA in the year 2011. With more 
than 260 million prescriptions for statins and other lipid-lowering drugs, these drugs 
were, after antidepressant drugs, the most prescribed drugs whereas ACE inhibitors 
and ARBs were listed as the fifth and sixteenth most prescribed drug with 164 and 86 
million dispensed prescriptions respectively 100. Since statins, ACE inhibitors and 
ARBs are widely prescribed for patients with cardiovascular diseases, and have shown 
to exert immunomodulatory effects 4,14, we focus on these types of cardiovascular 
drugs in this thesis.
5. STATINS
Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors 
have been extensively used in the last decades to reduce cardiovascular morbidity 
and mortality. Several clinical trials have demonstrated that this reduction is due to 
lowering serum lipid levels, specifically low-density lipoprotein cholesterol (LDL-C), 
non-high-density lipoprotein cholesterol (non-HDL-C) and apolipoprotein B which are 
risk factors in cardiovascular diseases 101,102. Statins were first identified as a 
successful therapy in 1976 by Endo et al. 103,104. A subsequent study by Brown and 
Goldstein, winners of the 1985 Nobel Prize in Medicine for discovering the LDL 
receptor and its role in regulating cholesterol 105, demonstrated that statins act as 
inhibitors of HMG-CoA reductase, an enzyme that catalyses the rate-limiting step of 
the cholesterol synthesis pathway in the liver, resulting in an upregulation of LDL 
receptors in the liver and thereby lowering blood cholesterol levels 106,107. Inhibition of 
this enzyme in the mevalonate or cholesterol synthesis pathway reduces the down - 
stream biosynthesis of cholesterol and other intermediate metabolites (figure 1) 108, 
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including the isoprenoids farnesyl and geranylgeranyl pyrophosphate, which are 
important for prenylation (lipid post-translational modification) of cellular proteins, 
such as the GTP-binding proteins Ras and Rho 109. Members of the Ras and Rho 
family are involved in regulation of cell growth, cell-to-cell signalling, cell proliferation 
and apoptosis, and have been proposed to have antineoplastic potential 110–112. 
As described above, statins inhibit the Ras and Rho isoprenylation, thereby resulting 
in an accumulation of the inactive forms of these proteins in the cytoplasm 113. This 
inhibitory effect of statins in cellular metabolism modulates the signalling pathways 
that involve endothelial nitric oxide synthase (eNOS) 114,115, tissue plasminogen 
activator and plasminogen activator inhibitor 1 116,117, endothelin 1 118,119, and apoptosis 
of the smooth muscle cells 120,121. Several studies have shown that statins reduce 
platelet activation and adhesion 122,123, and decrease the biosynthesis of thromboxane A2 
Figure 1  The cholesterol biosynthetic pathway. 
HMG-CoA, 3-hydroxy-3-methylglutaryl coenzyme A; FTI, farnesyltransferase inhibitor; GGTI, geranylgeranyl 
transferase inhibitor.
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124,125. In addition, statins effectively inhibit secretion of pro-inflammatory cytokines, 
tumor necrosis factor alpha (TNF-α), IL-β, IL-6 and IL-8 126–128, chemokine monocyte 
chemoattractant protein 1 (MCP1) 129,130 and matrix metalloproteinase 131,132. Several 
clinical trials addressed the anti-inflammatory effects of statins by measuring 
C-reactive protein (CRP), a biomarker of innate immune responses that has been 
rigorously established as a risk indicator for CVD 133–137. Indeed, results from these 
clinical trials showed that statins decrease levels of CRP 134–136. Since statin therapy 
reduces the incidence of acute and chronic rejection in heart and renal transplant 
patients 138–141, the immunomodulating effects have been further studied. Statins 
have been reported to suppress interferon-γ (IFN-γ)-inducible expression of major 
histocompatibility complex (MHC) class II proteins in endothelial cells, as well as in 
monocytes/macrophages and T cells, but do not affect dendritic cells and 
B-lymphocytes 14,142,143. Another beneficial effect of statins is the effect on the Th1/
Th2 balance, as demonstrated in a murine model of Experimental Allergic Encepha-
lomyelitis (EAE), an animal model mimicking MS16. In this model, statin treatment 
induced secretion of Th2 cytokines (IL-4, IL-5 and IL-10) and transforming factor β 
(TGF-β), whereas secretion of Th1 cytokines (IL-2, IL-12, IFN-γ and TNF-α) were 
suppressed. Similarly, in a murine model of autoimmune retinal disease and in 
patients with acute myocardial infarction, statins decreased the production of IFN-γ, 
whereas no effect on Th2 cytokine production was observed 144,145. Previous studies 
indicated that statins may enhance regulatory T cell (Treg) responses by promoting 
chemokine-dependent recruitment into inflammatory sites or by inducing the 
transcription factor FoxP3 146,147. Recently, it has been suggested that statins skew 
T cell differentiation towards Tregs and away from pro-inflammatory Th17 cells via 
geranylgeranylation of proteins, resulting in promoting Treg differentiation in the 
periphery, while blocking Th17 cell differentiation 148. Statins also down-regulate 
expression of the co-stimulatory molecule CD40 in various cell types, e.g., endothelial 
cells, smooth muscle cells and macrophages 149,150. Interestingly, certain types of 
statins selectively block the β-2 integrin, leukocyte function antigen-1 (LFA-1), thereby 
blocking binding to intercellular adhesion molecule-1 (ICAM-1) and thus reducing T 
cell activation 17. Taken together, these data support that statins possess anti-inflam-
matory and immunomodulating properties that may be beneficial in the treatment of 
immune-mediated disorders other than atherosclerosis. Indeed, beneficial effects of 
statins were observed in clinical trials and experimental models of RA, MS, SLE, 
systemic sclerosis and antiphospholipid syndrome 18–23,151–153.
In general, statins are considered to be safe although the market withdrawal of 
cerivastatin has demonstrated that some serious adverse effects were not detected 
during clinical trials. This is mostly true because rare adverse effects of statins appear 
only many months after starting the therapy 83,154. The most commonly reported side 
effects of statins are marked elevation of liver enzymes and muscular abnormalities 
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155. The spectrum of statin-associated muscular side effects ranges from the more 
common but less severe myalgia (5-10%) to the less common but more severe 
myopathy (0.1%) and its potentially fatal complication, rhabdomyolysis (0.01%) 156. 
Moreover, an increasing number of case reports suggest that prolonged use of 
statins may also trigger auto-immune diseases such as SLE, dermatomyositis, 
polymyositis, vasculitis, polymyalgia rheumatica, myasthenia gravis, guillain barre, 
autoimmune hepatitis and  autoimmune skin diseases 83,92,157–164. Three pathogenic 
mechanisms may be suspected in statin-associated autoimmunity. First, statins are 
potent pro-apoptotic agents and may trigger or exacerbate cellular apoptosis 165, 
thereby releasing nuclear antigens into the circulation, which may foster the production 
of pathogenic autoantibodies 78. Second, as described above, it has been suggested 
that statins induce a shift from a Th1 to Th2 immune response by their direct effect on 
T cells. Promoting a shift from Th1 to Th2 immune responses may dysregulate the 
immune homeostasis and can lead to the breakdown of self-tolerance, precipitating 
autoimmunity 16,83,166. Third, statins may enhance the formation of extracellular traps 
(ETs) by phagocytic cells such as neutrophils, mast cells and eosinophils 167. These 
ETs by phagocytic cells have been shown not only to exert antibacterial effects but 
may also provoke inflammation and pathological release of ETs in inflammatory and 
autoimmune diseases such as psoriasis, vasculitis, SLE and lupus nephritis 168–173.
6.  ANGIOTENSIN-CONVERTING ENZYME INHIBITORS AND 
ANGIOTENSIN II RECEPTOR BLOCKERS
Anti-hypertensive drugs, ACE inhibitors and ARBs, are widely used in the treatment 
of hypertension 174, cardiac failure 175, left ventricular systolic dysfunction 176, acute 
myocaridial infarction 177 and as antiproteinuric drugs in non- and diabetic 
nephropathy 178,179.  The history of ACE inhibitors and ARBs can be traced back to 
the fifties. In 1954, Skeggs et al. recognised for the first time substrates participating 
in the renin-angiotensin system, and in 1956, they reported the purification of an 
enzyme which converted inactive angiotensin I to the active vasoconstrictor 
angiotensin II in the presence of chloride ions from horse plasma 180–182. They named 
this enzyme ACE. It appeared that ACE not only cleaves angiotensin I but is also 
responsible for the degradation of bradykinin 183,184. In 1965, Ferreira showed that a 
non-toxic peptide of the venom from the Brazilian viper, Bothrops jararaca, enhanced 
the effects of bradykinin: smooth muscle contraction, hypotension and increased 
capillary permeability 185. Based on this finding, a novel class of anti-hypertensive 
agents was developed by Ondetti and Cushman in the early seventies: the angiotensin- 
converting enzyme (ACE) inhibitors 186,187. Captopril was the first oral ACE inhibitor 
introduced into clinical practice and was approved by the USA Food and Drug 
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Administration (FDA) in 1981 188. In the subsequent years, orally active ARBs have 
been developed as an alternative to inhibit the effects of angiotensin II. Losartan was 
the first ARB discovered in 1986 and approved by the FDA in 1995 189.
ACE inhibitors inhibit ACE which converts angiontensin I to vasoconstrictor 
angiotensin II, thereby producing vasodilation 190. In contrast to ACE inhibitors, ARBs 
block the effects of angiotensin II through binding to angiotensin II type 1 receptors 
191. The efficacy of both ACE inhibitors and ARBs in hypertension, diabetic 
nephropathy and congestive heart failure is well established, and generally, ACE 
inhibitors and ARBs are well tolerated, with a low incidence of side effects 192. ACE 
inhibitors and ARBs may induce skin rashes, angio-oedema, diarrhoea, cough, 
upper respiratory tract infection, dizziness and renal dysfunction 193–196, although 
ARBs produce these side effects to a much lesser extent than ACE inhibitors. As 
cough is one of the most frequent side effects associated with ACE inhibitors, several 
studies with ARBs have specifically addressed this side effect. The frequency of 
cough in ARB users was significantly lower than that observed in ACE inhibitor users 
197,198, but was comparable to patients that are treated with a diuretic or placebo 
197–202. The adverse effect profile of ARBs is comparable to what is seen in the 
placebo groups 203–205, no class-specific and dose-dependent adverse effects can be 
attributed to the drug itself 205. However, concerns have been raised about possible 
associations between ARBs and increased risks of cancer 206. The mechanism by 
which ARBs increase the occurrence of cancer is unknown. In experimental studies, 
using cancer cell lines, it has been implicated that the renin-angiotensin system is 
involved in the regulation of cell proliferation, tumour growth, angiogenesis and 
metastasis 207,208. In one in vivo study of Walther et al., it was shown that by blocking 
the angiotensin I receptor with losartan, a stimulation of tumour angiogenesis was 
induced 209. 
Recently, much interest has focused on the potential for ACE inhibitors and ARBs to 
exert anti-inflammatory and immunomodulating properties 4–12. The immunomodulatory 
properties of ACE inhibitors and ARBs have been attributed to several mechanisms, 
including anti-proliferative activity 210,211, inhibition of metalloproteases 210 and 
elevation of immunomodulatory prostaglandins 212. In two studies of RA patients 
treated with ACE inhibitors, decreased levels of CRP were found whereas another 
study found decreased levels of erythrocyte sedimentation rate (ESR) in RA patients 
treated with ARBs 10–12. Since the ACE enzyme has been shown to be involved in 
immune functions 213,214 and is elevated in inflammatory conditions 215,216, inhibition 
of ACE itself may have immune suppressive effects. Furthermore, ACE inhibitors and 
ARBs may alter cellular immunity, and inhibit adhesion molecule regulation, 
chemotaxis and production of several proinflammatory cytokines, e.g., TNF-α, IL-1, 
IL-6 and IL-12 4–9. In a study of angiotensin-II-infused hypertensive rats with kidney 
injury, the imbalance between Th1 and Th2 cells was corrected by treatment with 
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ARBs 217. In addition, in the EAE mouse model it was demonstrated that ACE inhibitors 
and ARBs suppress the auto-reactive Th1 and Th17 cells and promote regulatory T 
cells 4. These beneficial effects of ACE inhibitors and/or ARBs result in the prevention 
of nephropathy of insulin-dependent diabetes mellitus 178,218 and anti-inflammatory 
effects in RA 10–12. Similarly, ACE inhibitors and ARBs successfully suppress 
inflammation in experimental conditions, including experimental lupus disease 
219,220, autoimmune myocarditis 221 and encephalomyelitis (EAE) 222. 
On the other hand, it has been demonstrated that the immunomodulating effects of 
ACE inhibitors or ARBs may facilitate autoimmune responses. Several case reports 
have suggested that treatment with ACE inhibitors and/or ARBs may induce the 
development of autoantibodies 223–225 and autoimmune diseases, e.g., lupus-like 
disease, vasculitis and pemphigus 226–247. It has been demonstrated that ACE 
inhibitors enhance Trypanosoma cruzi infection of human monocytes, reduce the 
expression of the modulatory cytokine IL-10 while inducing Th17 cells 248, which have 
been shown to be associated with autoimmunity 249. Finally, two studies have shown 
that ACE inhibitors block activation-induced apoptosis in T cells 250,251, supporting 
the idea that ACE inhibitors may hamper clonal deletion and interfere with maintenance 
of self-tolerance, thereby precipitating autoimmunity. 
7. OBJECTIVE OF THE THESIS
Several studies demonstrated that statins, ACE inhibitors and ARBs are effective in 
reducing the risk of cardiovascular morbidity and mortality 101,102,176,177. In addition to 
their effects on cholesterol levels and blood pressure, recent studies have shown that 
these agents have anti-inflammatory and immunomodulatory properties, which also 
may contribute to the beneficial effects of these drugs in the treatment of cardiovascular 
disease and certain autoimmune diseases 4–23. While much is known about the 
beneficial effects of statins, ACE inhibitors and ARBs, the use of these drugs may also 
adversely influence immune regulation and may therefore facilitate the development 
of autoimmune diseases. In daily practice, it is rather difficult to detect these side 
effects as they are relatively uncommon, may be less severe, appear after prolonged 
use, and may induce persistent immune deviations after cessation of these drugs 
78,252,253. Therefore, the objective of this thesis is to assess the association between 
prolonged use of cardiovascular drugs, particularly statins, ACE inhibitors, and ARBs, 
and the incidence of autoimmune disorders.
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8. OUTLINE OF THIS THESIS
This thesis contains eight studies described in four chapters. The present chapter, 
chapter 1, introduces the topic of this thesis. 
In order to strengthen our hypothesis that certain cardiovascular drugs facilitate 
autoimmune disorders, we have performed three studies, using data on spontaneously 
reported adverse drug reactions collected during use of statins in daily clinical 
practice (chapter 2). In chapter 2.1 and chapter 2.2, respectively, we have assessed 
the association between statin use and the occurrence of autoimmune disorders by 
carrying out a case/non-case approach based on individual case safety reports of 
adverse drug reactions. Chapter 2.1 focuses on lupus-like syndrome while chapter 
2.2 focuses on polymyalgia rheumatica (PMR). One of the individual case safety 
reports included in the study presented in chapter 2.2, we were able to collect 
additional medical information from the reporter. In chapter 2.3, we have described 
the case reports’ nature of statin-associated PMR and giant cell arteritis (GCA) in 
more detail to illustrate the possible causality of statin-associated PMR/GCA. 
As the spontaneous reporting database is primarily used for signal detection 
(hypothesis strengthening) purposes and not for hypothesis testing, we have tested 
our hypothesis in electronic health record databases. In chapter 3, we focus on 
cardiovascular drug use and the incidence of RA, using population-based studies. In 
chapter 3.1, the risk of developing RA associated with different exposure aspects 
(duration, dose, type and potency) of statin use has been evaluated by a case-control 
study. Chapter 3.2 describes the association between the use of statins and the risk 
of RA, with a special focus on describing the patterns of the hazard rates (i.e. the 
absolute risks) of RA with changes in statin exposure by conducting a retrospective 
cohort study. Another approach of testing our hypothesis was to perform a study 
where we have examined whether the use of ACE inhibitors or ARBs is associated 
with incident RA. In chapter 3.3, the use of ACE inhibitors or ARBs and incident RA 
have been investigated in a case-control study among patients with anti-hyperten-
sive drugs.
Chapter 4 focuses on statin use and (auto) immunity. We have assessed the effects 
of statins on innate and adaptive immunity, and self-tolerance by measuring 
serological levels of CRP, neopterin and IgE antibodies, and the presence of 
autoantibodies in serum collected from the general population cross-sectionally and 
longitudinally. 
Chapter 5 addresses the causal relationship of the findings presented in chapter 3.1 
and 3.2 by evaluating the effects of statin administration on arthritis in the collagen 
type II-induced arthritis (CIA) mouse model. 
Finally, in chapter 6 the findings presented in this thesis are discussed and recom-
mendations are given for clinical practice and future research.
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CHAPTER 2.1
ABSTRACT
Objective
Several case reports of lupus-like syndrome suggest that statins could have triggered 
the development of this rare autoimmune disease. However, data on the association 
between statin use and lupus-like syndrome are scarce. We assessed whether there 
was an association between statin use and the occurrence of lupus-like syndrome.
Methods
A case/noncase study based on individual case safety reports listed in the World 
Health Organisation global individual case safety reports database (VigiBase) was 
conducted. According to World Health Organisation adverse reaction terminology, 
cases were defined as reports of lupus-like syndrome. Each case was matched with 
five non-cases by age, sex, and time of reporting. The use of statins was classified 
according to the Anatomical Therapeutic Chemical classification code system. 
Covariates, i.e., use of corticosteroids, immunosuppressive drugs, non-steroidal 
 anti-inflammatory drugs, antidepressants, anti-epileptics, proton pump inhibitors and 
cardiovascular drugs, were determined. Multivariate logistic regression was used to 
calculate the reporting odds ratios with 95% confidence intervals.
Results 
We identified 3 362 reports of lupus-like syndrome as cases and 27 092 reports of 
other adverse drug reactions as non-cases. Statins were more frequently reported as 
suspected drug in cases (3.2%) than in non-cases (1.5%). After adjustment for several 
covariates, statins were associated with the reporting of lupus-like syndrome 
(reporting odds ratios 2.01; 95% confidence intervals 1.61 to 2.51).
Conclusions
We found an association between reporting of statins and lupus-like syndrome. Further 
studies are needed to confirm this finding in more detail and establish causality.
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INTRODUCTION
Since the introduction of lovastatin in 1987, 3-hydroxy-3-methylglutaryl coenzyme A 
(HMG-CoA) reductase inhibitors, or statins, have been shown to be effective in reducing 
the risk of cardiovascular morbidity and mortality in patients with hyperlipidaemia, 
hypertension, or diabetes mellitus type II 1–5. In addition to their cholesterol-lowering 
activity, several studies have shown that statins have anti-inflammatory and immuno-
modulatory properties. These properties may eventually lead to dysregulation of 
immune responses 6–8. Hence, statins may facilitate the development of autoimmunity, 
eventually resulting in autoimmune diseases. An increasing number of case reports 
suggest that statins could trigger the development of lupus-like syndrome (Table 1) 
9–20. Recently, two reviews have summarised the case reports of lupus-like syndrome 
in patients using statins 21,22. Based on these case reports alone, the incidence of 
statin-induced lupus-like syndrome cannot be established. We postulated that this 
possible statin-induced lupus-like syndrome is relevant in daily practice and may 
be reported to pharmacovigilance centres. The aim of our study was to assess 
the association between statin use and the occurrence of lupus-like syndrome by 
carrying out a case/non-case approach based on individual case safety reports 
(ICSRs) of adverse drug reactions (ADRs).
METHODS
Study Population
The association between the use of statins and lupus-like syndrome was evaluated 
using the database of the World Health Organisation Uppsala Monitoring Centre 
(WHO UMC), Sweden. The database (VigiBase) contains the global ICSRs of 
suspected adverse reactions to pharmaceutical products submitted through National 
Pharmacovigilance Centres by 90 countries around the world. In February 2009, this 
database contained more than 4.6 million ICSRs of suspected ADRs 23. At the 
national level, ADRs are reported by health care professionals and in some countries 
by patients and pharmaceutical companies. Details about suspected ADRs such as 
age, sex, reporting date, country, nature of the ADR, suspected drugs, concomitantly 
used drugs, and interacting drugs are available in the VigiBase. ADRs are coded 
according to the WHO Adverse Reaction Terminology (WHO-ART) or the Medical 
Dictionary for Regulatory Activities 23. The suspected drugs are classified according 
to the Anatomical Therapeutic Chemical classification. Information in these reports is 
not homogenous, at least with regard to origin, completeness of documentation, or 
the likelihood that the suspected drugs caused the adverse events 23.
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Table 1  Overview case-reports of lupus-like syndrome
Ref Sex/Age Diagnosis Exposure
statins
Other 
drugs
ANA* Anti- 
DNA
Anti-
histone
Other  
antibodies
Time to 
onset
treatment development
10 F/64 Lupus-like 
syndrome
Lovastatin
20 mg/day
- Pos Neg Neg 2 yr - Prednisone 20 mg/day - resolved in 6 wk
10 M/40 DIL† Lovastatin - Pos Neg Pos 2 yr - Prednisone 20 mg/day - resolved in 6 wk
11 F/70 Lupus-like 
syndrome
Simvastatin 10 mg/day - Pos Neg Neg 18 mo - Prednisone 15 mg/day - resolved in 2 wk
12 M/39 Lupus-like 
syndrome
Simvastatin 20 mg/day - Pos Neg Neg  4 yr - Nifedipine for Raynaud’s symptoms - improved after 2 mo
- at 5 mo mild Raynaud’s 
14 M/79 DIL Simvastatin - Pos Neg Pos 3 mo - Prednisone 40 mg/day - resolved in 2 wk
16 M/78 SLE‡ Pravastatin
40 mg/day
Metoprolol
Nifedipine
Terazocin
Fluoxetine
Lorazepam
Cimetidine
Nitroglycerin 
Pos Pos - - Pos cryoglobulin 
- Pos anticardiolipin
6 yr - Prednisone 50 mg/day, 
- Plaquenil
- disease active at 24 mo
17 F/67 Lupus-like 
syndrome, ARDS§
Fluvastatin
20mg/day
Atenolol 
Aspirin
Pos Pos Neg 1 wk - Methylprednisolone, 
- Cyclophosphamide
- Died due to ARDS
9 M/42 DIL Simvastatin 20 mg/day Metformin
Glipizide
Pos Neg Pos 2 wk - - resolved in 2 wk
13 M/26 DIL Atorvastatin 
20 mg/day
- Pos Neg Pos 1 yr - - resolved in 11 mo
19 F/58 Lupus-like 
syndrome, 
autoimmune 
hepatitis
Atorvastatin Pos - - - Pos Nuc¶ 7 mo - Tacrolimus 3 mg/twice day, 
- Mycophenolate mofetil 1000 mg/twice day, 
- prednisolone 10mg/day
- in remission after 12 mo 
20 M/58 SCLEⅡ Pravastatin Atenolol Pos Neg Neg - Pos Ro/SSA 6 wks - topical corticosteroids - improved in 6-12 wk
20 F/53 SCLE Simvastatin Ibuprofen Pos Neg Neg - Pos Ro/SSA 8 wk - topical corticosteroids - improved in 6-12 wk
15 M/59 Lupus-like 
syndrome
Simvastatin
20 mg/day
- Pos Pos Neg 2 yr - resolved in 12 mo
18 F/82 SCLE Simvastatin Aspirin
Lansoprazole
Pos Neg Neg - Pos Ro/SSA 3 mo - Hydroxychloroquine, 
- Prednisolone, 
- topical corticosteroids
- resolved in 2 wk
*antinuclear antibodies, †drug-induced lupus, ‡systemic lupus erythematosus, §adult respiratory distress  
syndrome, Ⅱsubacute cutane lupus erythematosus, ¶anti-nucleosome antibodies
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Design
A case/non-case approach was used to evaluate the association between the use of 
statins and lupus-like syndrome. In the VigiBase, cases of lupus-like syndrome were 
defined as all available ADR reports containing the following WHO-ART adverse 
reaction terms: “lupus erythematosus (LE) rash,” “LE discoid,” “LE-like butterfly rash,” 
“LE-like discoid rash,” “LE systemic,” “Disseminated lupus erythematosus (DLE),” 
“DLE,” “LE arthritis,” “LE type reaction,” “Lupus erythematosus systemic (SLE),” 
“SLE-like symptoms,” “Systemic lupus erythematosus syndrome,” and “hydralazine 
LE type reaction” (Table 2) 23. These WHO-ART adverse reaction terms were attached 
to the original report by the national pharmacovigilance centre or the reporter of the 
ADR. Reports were only included when data on sex and age were available. Since we 
are interested in incident cases of lupus-like syndrome, ADR reports with the preferred 
terms “LE syndrome aggravated” were excluded from the study. Each case was 
matched with five non-cases by age, sex and calendar year of reporting. Non-cases 
were considered as reports containing other adverse reaction terms than lupus-like 
syndrome, including other autoimmune drug reactions.
Definition of Exposure
Exposure to statins was defined as reports in which the reporter suspected that a 
prescribed statin was a causal factor in the development of lupus-like syndrome. The 
Anatomical Therapeutic Chemical codes for statins were C10AA (HMG-CoA 
reductase inhibitors), C10BA (HMG-CoA reductase inhibitors in combination with 
other lipid modifying agents), and C10BX (HMG-CoA reductase inhibitors and other 
combinations) 24.
Covariates
Concomitant medication, i.e., use of anti-arrhythmic drugs, anti-hypertensive and 
anti-diabetic agents, non-steroidal anti-inflammatory drugs, corticosteroids, disease 
modifying anti-rheumatic drugs, antidepressants, anti-epileptics and proton pump 
inhibitors, associated with lupus-like syndrome were considered as covariates 25.
Statistical Analysis
Characteristics of the cases and non-cases were analysed, using Student’s t test or 
Chi-square test. Means and standard deviations or percentages were obtained for 
continuous and categorical variables, respectively. The strength of the association 
between reporting of statins and lupus-like syndrome was assessed using logistic 
regression analysis and expressed as reporting odds ratios (ROR) accompanied 
with 95% confidence intervals (CI). The ROR provides an estimate of the extent to 
which lupus-like syndrome is reported in association with statins as suspected drug 
relative to reports of lupus-like syndrome in which other drugs were the suspected 
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agent. Covariates that acted as confounders were included in the model if each of 
them induced a change of crude β estimates of the exposure-outcome association 
of at least 10% 26. All tests were 2-sided with a rejection of the null hypothesis at a p 
value of less than 0.05. All the analyses were conducted using SPSS 16.0 statistical 
software (SPSS Inc., Chicago, Illinois, USA).
Table 2   Terms for coding lupus-like syndrome defined by the preferred terms of 
the WHO Adverse Reaction Terminology (WHO-ART) 2007 
High level term Recno* Preferred term Seq† Included term
LE Syndrome 0080 LE Rash§ 004 LE-like butterfly rash
  005 LE-like discoid rash
  003 Lupus erythematosus discoid
 
 0081 LE Systemic‡,§,Ⅱ 005 Disseminated lupus erythematosus
 003 DLE
  004 Hydralazine LE type reaction
  006 LE arthritis
  007 LE type reaction
  012 Lupus encephalitis
  008 Lupus erythematosus systemic
  009 SLE-like symptoms
010 Systemic lupus erythematosus 
syndrome
  
 
0082 LE test abnormal§,Ⅱ 004 LE cells present
     
    
1082 Antinuclear factor 
test positive§,Ⅱ
004 Anti-dsDNA¶
  003 Antinuclear factor
*record number, †sequence, ‡sensitivity analysis 2 with the preferred term (and included term), 
§sensitivity analysis 3 with the preferred term (and included term), Ⅱsensitivity analysis 4 with preferred 
term (and included term), ¶anti-double-stranded DNA
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Sensitivity Analysis
Since the reporters may not always be aware of statin-induced lupus-like syndrome, 
we performed a sensitivity analysis where we expanded our definition of statin use to 
reports where statins were classified as suspected or concomitant drug for an ADR. 
To explore the influence of potential misclassification of patients with an ADR report 
of lupus-like syndrome, we conducted one analysis where we only included ADR 
reports submitted by physicians and three analyses with different definitions of 
lupus-like syndrome (Table 2). First, cases of lupus-like syndrome were defined as 
only a report with the preferred term “LE Systemic” in the database. Second, cases 
were defined as all ADR reports of lupus-like syndrome and ADR reports that listed 
the presence of antinuclear antibodies (ANA) (preferred terms “Antinuclear factor test 
positive,” “Antinuclear factor,” and “Anti-DNA antibodies”) and/or lupus erythematosus 
(LE) cells (preferred terms “LE test abnormal” and “LE cells present”) (Table 2) 23. 
Third, lupus-like syndrome was defined as only a report with the preferred term “LE 
Systemic,” which were verified by the presence of ANA and/or LE cells. 
RESULTS
In VigiBase, we identified 3 362 reports of lupus-like syndrome (cases) that were 
matched with 27 092 reports of other ADRs (non-cases). Of the 3 362 cases of 
lupus-like syndrome, 421 (12.4%) cases listed an ADR of lupus-like syndrome with the 
presence of ANA and/or LE cells. The distribution of baseline characteristics for the 
cases of lupus-like syndrome and non-cases is shown in Table 3. The use of anti- 
arrhythmic drugs, antihypertensive agents and non-steroidal anti-inflammatory drugs 
was more frequently reported in cases of lupus-like syndrome than in non-cases. In 
144 of the 3 362 cases of lupus-like syndrome (4.3%), statins were reported as 
suspected (n = 106) or concomitant drug (n = 38).
Table 4 shows the characteristics of 106 cases of lupus-like syndrome with reported 
statins as suspected drug. The ADR reports were coded with the WHO-ART preferred 
terms “Systemic Lupus Erythematosus,” “DLE,” “LE type reaction,” “SLE-like 
symptoms,” and “LE rash” and “LE-like butterfly rash”. Of the 106 reported cases with 
statins, 22 cases reported positive ANA results of whom no one reported positive 
anti-dsDNA or LE cells results. Most of these cases were reported in the early 1990s 
and originated from the United States of America. Lovastatin and simvastatin were 
more often reported as the suspected drug for the occurrence of lupus-like syndrome 
than other types of statins. The range of time to onset of lupus-like syndrome after 
starting statins was 1 day to 15.8 years (mean, 18.6 months; median, 7.1 months). Of 
the 106 reported cases, 14 listed recovery of lupus-like syndrome, while 17 listed no 
recovery of lupus-like syndrome. In 45 of the 106 cases statin withdrawal was 
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reported, while in 6 cases no change in dose regimen was reported. Of these 45 
cases where statins were withdrawn, 35 listed that lupus-like syndrome abated, while 
6 listed no effect.
Of the specific 35 cases who reported that lupus-like syndrome abated on withdrawal 
of statins, 7 cases reported recovery, whereas 2 cases reported no recovery. Seven 
cases reported a rechallenge with statins of which four resulted in the recurrence of 
lupus-like syndrome.
Table 3   Baseline characteristics of the study population
Characteristics Cases Non-cases p value
( n = 3 362) ( n = 27 092)
Mean Age (SD), y 50.6 ±19.2 50.7 ± 19.5 NA*
Sex, %
 Male 975 (29.0) 7 986 (29.5)      NA* 
 Female 2 387 (71.0) 19 106 (70.5)      NA*
Reported ANA†, % 392 (11.7) - -
Reported Anti-dsDNA‡ 6 (0.2) - -
Reported LE cells§, % 23 (0.7) - -
Statins, %
Suspected 106 (3.2) 407 (1.5) <0.001
Concomitant 38 (1.1) 318 (1.2) 0.768
Co-medication, %
 Anti-arrhythmic drugs, 228 (6.8) 1 140 (4.2) <0.001
 Antihypertensives 626 (18.6) 3 293 (12.2) <0.001
 Antidiabetics 52 (1.6) 615 (2.3) 0.007
 Non-statins Lipid modifying agents 21 (0.6) 147 (0.5) 0.545
 NSAIDsⅡ 122 (3.6) 354 (1.3) <0.001
 Corticosteroids 115 (3.4) 376 (1.4) <0.001
 DMARDs¶ 92 (2.7) 353 (1.3) <0.001
 Antidepressants 112 (3.3) 801 (3.0) 0.229
 Antiepileptics 88 (2.6) 420 (1.6) <0.001
 Proton pump inhibitor agents 68 (2.0) 386 (1.4) 0.007
 Intestinal anti-inflammatory agents 22 (0.7) 66 (0.2) <0.001
*NA indicate not applicable because cases and non-cases were matched by age and sex,  
†antinuclear antibodies, ‡anti-double-stranded DNA, §lupus erythematosus cells, ⅡNSAIDs: 
Non-steroidal anti-inflammatory drugs, ¶DMARDs: Disease-modifying anti-rheumatic drugs
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Table 4   Detailed information on the 106 case reports of lupus-like syndrome  
with statins as suspected drug.
Characteristics No. 
suspected 
statins
Characteristics No. 
suspected 
statins
(n = 106) (n = 106)
Year of reporting Time to onset (days)
1980-1990 9 1-90 22
1990-1999 65 91-365 20
2000-2006 32 > 365 25
Type of statin Not recorded 39
Simvastatin 31 Outcome
Pravastatin 19 Recovered 14
Lovastatin 33 Not (or not yet) recovered 17
Atorvastatin 15 Recovered with sequelae 5
Fluvastatin 4 Died-reaction may be contributory 1
Cerivastatin 3 Not recorded 69
Rosuvastatin 1 Dechallenge (Action)
Country of origin Drug withdrawn 45
Australia 4 Dose not changed 6
Austria 1 Not recorded 55
Belgium 1 Dechallenge (Result)
Canada 3 Reaction abated* 35
Finland 2 No effect observed 6
France 7 Not applicable 8
Germany 9 Not recorded 57
Great Britain 11 Rechallenge (Action)
New Zealand 1 Rechallenge 7
South Africa 1 No rechallenge 16
Spain 3 Not recorded 83
Sweden 4 Rechallenge (Result)
United States of America 59 Reaction recurred 4
Reporter No recurrence 1
General Practitioner 24 Not applicable 16
Physician 8 Not recorded 85
Specialist 3 Causality
Hospital 7 Probable 7
Pharmacist 1 Possible 14
Consumer 1 Not (yet) assessed 3
Other† 62 Not assessed 2
Not recorded 80
* Of the specific 35 ADR reports that reported abatement of lupus-like syndrome, 7 reported that  
the patient recovered after discontinuation of statins, while 2 reported no recovery upon withdrawal  
of statins. † “Other” includes consumer reports and various types of reports from other health 
professionals than physicians or dentists.
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The association between the use of statins and lupus-like syndrome is shown in 
Table 5. Overall, statins were more often reported with lupus-like syndrome than other 
ADRs (adjusted ROR, 2.01 [95% CI 1.61 to 2.51]; p=0.001). The results were similar 
when we conducted the five sensitivity analyses. By changing the exposure to statins 
in suspected or concomitant drug for an ADR, the adjusted ROR for the occurrence 
of lupus-like syndrome was 1.38 (95% CI 1.14 to 1.68; p=0.001). Including only ADR 
reports from physicians did not influence the results (adjusted ROR 1.53 [95% CI 1.08 
to 2.16]; p=0.016). When we restricted our cases of lupus-like syndrome to only ADR 
reports with the preferred term “LE Systemic,” the ROR for the association between 
statin use and the occurrence of lupus-like syndrome was 2.14 (95% CI 1.70 to 2.70; 
p=0.001). Similar results were obtained when we defined lupus-like syndrome as all 
ADR reports of lupus- like syndrome, which could be verified by the presence of ANA 
and/or LE cells (adjusted ROR 2.91 [95% CI 1.85 to 4.56]; p=0.001). Results remained 
similar when we included only ADR reports with the preferred term “LE Systemic” and 
ADR reports in which the presence of ANA and/or LE cells was listed (adjusted ROR 
3.13 [95% CI 1.99 to 4.91]; p=0.001).
DISCUSSION
In the present study, we found a 2-fold increased risk of reporting the use of statins in 
relation to the reporting of lupus-like syndrome compared with other ADR reports in 
VigiBase. Our findings were relatively insensitive to variations in the definition of lupus- 
like syndrome and the inclusion of reports that listed concomitant use of statins.
Several published case reports support the notion that statins could facilitate the 
development of lupus-like syndrome. Fourteen cases of lupus-like syndrome were 
reported in the literature, of whom four were considered drug-induced lupus, six 
lupus-like syndrome, one SLE, and three drug-induced subacute cutaneous lupus 
erythematosus (Table 1) 9–20. The cases in our study and the patients described in 
the published case reports were, on average, 50 years of age and predominantly 
female. Based on all the ADR reports in our study, lovastatin and simvastatin were 
more often reported as the suspected drug for the occurrence of lupus-like syndrome, 
whereas in the published case reports simvastatin was more often reported as the 
suspected drug. Based on the case reports in the medical literature, the course of 
lupus-like syndrome varies from case to case. Clinical improvement was seen in 
some patients within weeks after discontinuation of statins, while other cases showed 
clinical improvements only after treatment with immunosuppressive therapy. In our 
study, several ADR reports listed that the symptoms of lupus-like syndrome abated 
after discontinuation of statins. In these ADR reports, however, we could not ascertain 
whether the clinical improvements were related to statin withdrawal or to treatment 
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with immunosuppressive therapy because the ADR reports did not present 
information on treatment regimes for lupus-like syndrome after discontinuation of 
statins. Suchak et al. reported a patient who developed subacute cutaneous lupus 
erythematosus on rechallenge with simvasatin 18, hence suggesting a causal link. Of 
all the 106 ADR reports of lupus-like syndrome with statins as suspected drug, 4 
reported lupus-like syndrome on rechallenge with statins. 
In several case reports of lupus-like syndrome in the literature, the auto-antibodies 
remained positive months after withdrawal of statins despite clinical improvements. 
In our study, we had no data on laboratory evaluations (e.g. the presence of ANA) 
after the date of onset of lupus-like syndrome. Hence, the true underlying mechanism 
of statin-induced lupus-like syndrome is unclear, although in vitro and animal studies 
demonstrated that statins may exacerbate or trigger cellular apoptosis 27,28 and 
induce a shift in the T helper (Th) 1/Th2 balance leading to B-cell reactivity and 
production of pathogenic auto-antibodies 29,30. Recent studies have suggested that 
Treg cells can be unstable in the periphery and may promote autoimmunity 31,32. 
According to these studies, we hypothesize that statins do not cause autoimmunity 
but may promote a pre-existing autoimmune-prone condition to progress toward 
clinical disease such as SLE 33.
There are several limitations in this study. First, due to underreporting of ADRs, only 
a fraction (<10%) of the actual adverse events that occur are reported 34,35. ADRs 
more likely to be reported than others are ADRs of relatively new drugs, severe ADRs, 
and ADRs that are not listed in the summary of product characteristics 34,36. To 
control for possible time trends of reporting, we matched the non-cases for the 
calendar year of reporting.
Second, protopathic bias 37 could also have influenced the results. Since lupus-like 
syndrome and cardiovascular risk factors such as hyperlipidaemia often coexist 38,39, 
and the diagnosis of lupus-like syndrome is often difficult to assess, lupus-like 
syndrome may already be present before the start of statin therapy. This may result in 
over-reporting of this ADR due to statin use. Data on the medical history of the patient 
are not available in the reports, making it impossible to control for protopathic bias.
Third, the definition of lupus-like syndrome in our study was based on ADRs terms 
used in the ICSRs submitted by physicians, manufacturers, and consumers. In light 
of the heterogeneity of the ADR reports, we may have used a relatively sensitive, but 
non-specific, definition of lupus-like syndrome. The definition of lupus-like syndrome 
in our study could be a collection of several diseases such as SLE, drug-induced 
lupus, and acute, subacute and chronic cutaneous lupus erythematosus. The 
etiology and criteria for diagnosing these diseases are various 25,40,41. A patient is 
diagnosed with SLE when at least four of the eleven criteria from the guidelines from 
the American College of Rheumatology are present 42. Patients with drug-induced 
lupus, however, often do not meet the American College of Rheumatology criteria for 
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SLE 43. We did not have explicit information on the criteria set for making a distinction 
between these diseases, and for diagnosing lupus-like syndrome in our study 
population. To minimise misclassification of lupus-like syndrome, we conducted a 
sensitivity analysis where we defined lupus-like syndrome as a report with the 
WHO-ART preferred term “lupus erythematosus systemic” in which the presence of 
ANA and/or LE cells were listed. The association between statin use and the occurrence 
of lupus-like syndrome was still present. These markers are usually presented in 
>80% of patients with SLE 44. A limitation of this approach is that selection bias could 
have been introduced due to the absence of reporting ANA and/or LE cells in several 
ADR reports. WHO-ART adverse reaction terms do not provide preferred terms for 
negative ANA results, and therefore; we could not make a distinction between negative 
ANA results or underreporting of ANA. Another approach of minimizing misclassification 
of lupus-like syndrome was limiting the heterogeneity of the ADR reports by conducting 
a sensitivity analysis where we only included ADRs from physicians; the association 
between statin use and the occurrence of lupus-like syndrome was still present.
Fourth, we cannot exclude the possibility of unmeasured and/or inadequately measured 
residual confounding. In the present study, we did not account for the confounders 
such as smoking, family history, body mass index, sunlight and/or ethnicity 45,46.
Fifth, selective underreporting of the association between statin use and the 
occurrence of lupus-like syndrome may have occurred because the reporter may not 
always be alert on this possible association, especially when the patient was treated 
with more than one drug. As a result, the ADR of interest may not have been reported 
or the exposure to statins may have been defined as concomitant drug for an ADR. 
Therefore, we conducted a sensitivity analysis with all reports of statins classified as 
suspected or concomitant for an ADR, and we found an association between statin 
use and the occurrence of lupus-like syndrome, although weaker in effect.
To our knowledge, this is the first study to assess the association between statin use 
and lupus-like syndrome in a large spontaneous reporting database. Our findings 
were consistent in various sensitivity analyses with regard to the definition of lupus-like 
syndrome and the exposure to statins.
CONCLUSIONS
The result of this study underlines findings of individual case reports suggesting that 
the use of statins may be associated with the occurrence of lupus-like syndrome. Our 
finding warrants awareness about the possibility of developing lupus-like syndrome 
in patients treated with statins. Additional studies are needed to further confirm our 
finding, establish causality, and perform an analysis of the quantitative risk of lupus- 
like syndrome possibly brought on by statins.
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ABSTRACT
Objective
To assess whether there is an association between statin use and the occurrence of 
polymyalgia rheumatic (PMR) in the spontaneous reporting database of the World 
Health Organisation (WHO).
Methods 
We conducted a case/non-case study based on individual case safety reports (ICSR) 
in the WHO global ICSR database (VigiBase). Case reports containing the adverse 
event term polymyalgia rheumatica (WHOART or MedDRA Preferred Term) were 
defined as cases. Non-cases were all case reports containing other adverse event 
terms. Each case was matched to five non-cases by age, sex, and time of reporting. 
Case reports regarding a statin as suspected or concomitant drug were identified 
using the Anatomical Therapeutic Chemical (ATC) classification. Multivariate logistic 
regression was used to calculate reporting odds ratios (RORs) with 95% confidence 
intervals (CI).
Results
We identified 327 reports of PMR as cases and 1 635 reports of other ADRs as 
non-cases. Among cases, statins were more frequently reported as suspected agent 
(29.4%) compared to non-cases (2.9%). After adjustment for several covariates, 
statins were significantly associated with reports of PMR (ROR 14.21; 95% CI 9.89 to 
20.85).
Conclusions 
The results of this study lends support to previous anecdotal case reports in the 
literature suggesting that the use of a statin may be associated with the occurrence 
of PMR. Further studies are needed to study the strength of the association in more 
detail and to elucidate the underlying mechanism.
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INTRODUCTION
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or 
statins, effectively lower cholesterol levels and significantly reduce the risk of 
cardiovascular events 1. Recently, several studies have shown that these agents have 
anti-inflammatory and immunomodulatory properties which may eventually lead to 
immune dysregulation 2,3. Hence, statins might facilitate the development of 
autoimmunity, eventually resulting in autoimmune diseases. Previously, we observed 
in a population-based study that statins were associated with an increased risk of 
developing RA 4. Furthermore, cases of statin-associated lupus-like syndrome, der-
matomyositis, and vasculitis have been reported 5–11. Moreover, in a study comprising 
data from spontaneous case reports we have found an association between statin 
use and the occurrence of a lupus-like syndrome 12. Three case reports suggested 
that statin use can trigger the development of polymyalgia rheumatica (PMR) 9–11. 
PMR is an inflammatory rheumatic disease predominantly seen in the elderly and 
characterised by muscle pain and morning stiffness in the neck, shoulders, and/or 
pelvic girdle 13,14. The association between statin use and PMR has not yet been 
studied in depth. Therefore, we evaluated the association between statin use and the 
occurrence of PMR, using a case/non-case approach, in Vigibase the database of 
the WHO Uppsala Monitoring Centre containing individual case safety reports 
(ICSRs) of adverse drug reactions (ADRs).
METHODS
Study Population
The association between the use of statins and PMR was evaluated using the 
database of the World Health Organisation Uppsala Monitoring Centre (WHO UMC), 
Sweden. The database (VigiBase) contains the global ICSRs of suspected adverse 
reactions to pharmaceutical products submitted through National Pharmacovigilance 
Centres by 90 countries around the world. When we extracted the data for the present 
study, the database contained more than 4.6 million ICSRs of suspected ADRs 15. 
At the national level, ADRs are reported by health-care professionals, pharmaceutical 
companies, and in some countries by patients. Details about suspected ADRs such as 
age, sex, reporting date, country, nature of the ADR, suspected drugs, concomitantly 
used drugs, and interacting drugs are available in the VigiBase. ADRs are coded 
according to WHO Adverse Reaction Terminology (WHO-ART) or the Medical Dictionary 
for Regulatory Activities (MedDRA) 15. The reported drugs are encoded using the 
WHO Drug Dictionary Enhanced, which includes the WHO Anatomical Therapeutic 
Chemical (ATC) classification 16. Information in these reports is not homogenous, at 
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least with regard to origin, completeness of documentation or the likelihood that the 
suspected drugs caused the adverse events 15. 
Design
A case/non-case approach was used to evaluate the association between the use of 
statins and PMR. In VigiBase, cases were identified as all ICSRs of ADRs containing 
the WHO-ART or MedDRA preferred term ‘polymyalgia rheumatica’ 15. Reports were 
only included when data on sex and age were available. Since we were interested in 
incident cases of PMR, ADR reports with the preferred term ‘polymyalgia rheumatica 
aggravated’ were excluded from the study. Each case was matched to five non-cases 
by age, sex, and calendar year of reporting. Non-cases were reports concerning all 
other adverse reactions.
Definition of Exposure
Exposure to statins was defined as the reporting of statins as a suspected or 
concomitant drug for an ADR. The ATC codes for statins were C10AA (HMG-CoA 
reductase inhibitors), C10BA (HMG-CoA reductase inhibitors in combination with 
other lipid modifying agents), and C10BX (HMG-CoA reductase inhibitors and other 
combinations) 16.
Covariates
Concomitant medication such as drugs with immunomodulatory activity, i.e., use of 
anti-arrhythmic drugs, anti-hypertensive and anti-diabetic agents, non-steroidal anti- 
 inflammatory drugs (NSAIDs), antidepressants, anti-epileptics, and proton pump 
inhibitors were considered as covariates 17.
Statistical Analysis
Characteristics of the cases and non-cases were analysed using Student’s t test, 
Chi-square test or Fisher’s exact test as appropriate. Means and standard deviations 
(SD) or percentages were obtained for continuous and categorical variables, 
respectively. The association between reporting of statins and PMR was assessed 
using logistic regression analysis and expressed as Reporting Odds Ratios (ROR) 
accompanied with 95% confidence intervals (CI). The ROR provides a ratio of the 
odds of exposure in reports of cases and non-cases. The ROR was calculated by 
dividing the numerator (the number of cases with statins as the suspected drug 
divided by the number of cases with another suspected drug) by the denominator 
(the number of non-cases with statins as the suspected drug divided by the number 
of non-cases with another suspected drug). Covariates that acted as confounders 
were included in the model if each of them induced a change of crude β estimates of 
the exposure-outcome association of at least 10% 18. All tests were two-sided with a 
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rejection of the null hypothesis at a p value of less than 0.05. All the analyses were 
conducted using SPSS 16.0 statistical software (SPSS Inc., Chicago, Illinois, USA).
Sensitivity Analysis
We carried out five sensitivity analyses: 1) since reporters may not always be aware 
of statin-associated PMR we expanded the definition of statin use by including reports 
where statins were classified as concomitant (i.e. unsuspected) drug for an ADR. 
To explore the influence of potential misclassification of patients with an ADR report 
of PMR, we conducted four additional sensitivity analyses: 2) including only ADR 
reports reported by physicians, 3) including only ADR reports of patients older than 
50 years 19,20, 4) defining cases of PMR as an ADR with the single WHO-ART or 
MedDRA adverse reaction term PMR in which statins were reported as suspected 
drug, and 5) defining cases of PMR as only ADR of WHO-ART adverse reaction term 
PMR in which statins were reported as suspected or concomitant drug. In the latter 
two analyses, ADRs with two or more WHO-ART adverse reaction terms were excluded 
from the analysis.
RESULTS
Baseline Characteristics
In VigiBase, we identified 327 reports of PMR (cases) that were matched with 1 635 
reports of other ADRs (non-cases). The distribution of baseline characteristics for 
cases of PMR and non-cases are shown in Table 1. Characteristics were similar 
between cases and non-cases except for anti-depressant and anti-arrhythmic drugs 
that were more frequently reported in non-cases than in patients with PMR. In 104 of 
327 cases of PMR, statins were reported as suspected or concomitant drug. Of these 
104 cases, 96 reported statins as suspected drug whereas 8 reported statins as 
concomitant drug. The distribution of statins reported as suspected drug in cases 
and non-cases are presented in figure 1. The characteristics of 96 cases of PMR with 
reported statins as suspected drug are presented in table 2. Most of these cases 
were reported by physicians in the late ‘90s and mainly originated from the United 
States of America, Germany, and Great Britain. Simvastatin and atorvastatin were 
more often reported as the suspected drug than other types of statins. The time to 
onset of PMR after starting statins ranged from 1 day to 5.7 years (mean, 11.9 months; 
median, 3.7 months). In 26 of 96 ADR reports statin withdrawal was recorded. Of 
these 26 reported cases, 8 cases reported that PMR abated while 8 cases reported 
no effect. In six cases, a rechallenge with statins was reported resulting in the 
recurrence of PMR.
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Association between Reporting of Statins and PMR
The association between the use of statins and PMR is shown in Table 3. Overall, 
statins were more often reported in patients with PMR in comparison with patients 
who had experienced other ADRs (adjusted ROR 14.21 [95% CI 9.89 to 20.85]; 
p=0.001).
The results were consistent when we conducted five sensitivity analyses; 1) by 
expanding the exposure definition to statins as suspected or concomitant drug for an 
ADR, the adjusted ROR for the occurrence of PMR was 6.03 (95% CI 4.40 to 8.25; 
Table 1   Baseline characteristics of the polymyalgia rheumatica study population
Characteristics Cases 
(n = 327)
Non-cases
(n = 1 635)
p value
Mean Age (SD), y 67.7 (11.0) 67.7 (11.0) NA*
Age categories, %
< 50 20 (6.1) 100 (6.1) NA*
≥ 50 307 (93.9) 1 535 (93.9) NA*
Sex, %
Male 124 (37.9) 620 (37.9) NA*
Female  203 (62.1) 1 015 (62.1) NA*
Statins, %
Suspected 96 (29.4) 47 (2.9) <0.001
Suspected or Concomitant 104 (31.8) 129 (7.9) 0.08
Co-medication, %
Anti-arrhythmic drugs 9 (2.8) 93 (5.7) 0.03
Anti-hypertensive agents 85 (26.0) 354 (21.7) 0.09
Anti-diabetic agents 14 (4.3) 86 (5.3) 0.46
Non-statins Lipid modifying agents 3 (0.9) 12 (0.7) 0.73
NSAIDs† 7 (2.1) 24 (1.5) 0.34
Corticosteroids 8 (2.5) 25 (1.5) 0.24
DMARDs‡ 4 (1.2) 30 (1.8) 0.64
Antidepressants 4 (1.2) 74 (4.5) 0.003
Anti-epileptics 1 (0.3) 25 (1.5) 0.10
Acid inhibitors 15 (4.6) 59 (3.6) 0.40
*NA indicate not applicable because cases and non-cases were matched by age and sex
†NSAIDs: Non-steroidal anti-inflammatory drugs
‡DMARDs: Disease-modifying anti-rheumatic drugs
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p=0.001), 2) including only ADR reports reported by physicians: (adjusted ROR 14.70 
[95% CI 7.07 to 30.65]; p=0.001), 3) including only ADR reports of patients older than 
50 years: (adjusted ROR 14.01 [95% CI 6.98 to 24.83]; p=0.001), 4) including only 
ADR reports of PMR without other ADRs, in which statins were reported as suspected 
drug: (adjusted ROR 13.90 [95% CI 8.65 to 22.35]; p=0.001), or 5) including only ADR 
reports of PMR without other ADRs and in addition where statins were reported as 
suspected or concomitant drug: (adjusted ROR 5.75 [95% CI  3.74 to 8.83]; p=0.001).
Figure 1  Exposure to statins in cases and non-cases
 1A  Exposure to drugs in reports of other adverse drug reactions (non-cases)
 1B  Exposure to drugs in reports of polymyalgia rheumatica (cases)
Statins: 2.9% 
Other drug
agents: 97.1%  
Statins: 29.4%
Other drug
agents: 70.6%
B
A
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Table 2   Detailed information on the 96 case reports with statins as suspected drug.
Characteristics No. 
suspected 
statins
(n = 96)
Characteristics No. 
suspected 
statins
(n = 96)
Year of reporting Time to onset (days)
1990-1999 59 1-90 35
2000-2006 37 91-365 17
Type of statin > 365 23
Simvastatin 35 Not recorded 21
Pravastatin 8 Outcome
Lovastatin 10 Recovered 15 
Atorvastatin 26 Not (or not yet) recovered 23
Fluvastatin 6 Recovered with sequelae 3
Cerivastatin 6 Not recorded 55
Rosuvastatin 5 Dechallenge (Action)
Country of origin Drug withdrawn 26
Australia 9 Dose not changed 12
Canada 4 Not recorded 58 
Finland 2 Dechallenge (Result)
France 2 Reaction abated 8
Germany 18 No effect observed 8
Great Britain 15 Not applicable 12
Ireland 1 Not recorded 68
New Zealand 3 Rechallenge (Action)
Norway 1 Rechallenge 6
Sweden 3 No rechallenge 20
Switzerland 1 Not recorded 70
The Netherlands 3 Rechallenge (Result)
United States of America 34 Reaction recurred 6
Reporter Not applicable 20
General Practitioner 31 Not recorded 70
Physician 8 Causality
Specialist 5 Probable 3
Hospital 2 Possible 21
Manufacturer 2 Not assessed 10
Consumer 2 Not recorded 62
Other* 2
Not reported 44
* “Other” includes consumer reports and various types of reports from other health professionals then 
physicians.
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DISCUSSION
In the present study, we observed an association between statin use and reporting of 
PMR in VigiBase. In six reports the recurrence had been recorded of PMR after 
re-exposure to statins, which strengthened the suspicion regarding the drug’s causal 
involvement in these patients. In the absence of information on the treatment of the 
PMR, in our study it could not be determined whether clinical improvement was 
related to statin discontinuation or to treatment with corticosteroids. In two previously 
published cases 9–11, however, information on treatment regimes has been provided. 
The observation that clinical improvement had occurred within a month after 
 discontinuation of the statin and without the administration of corticosteroids, was 
highly suggestive of a causal role of the statin in these two patients.
In our study, cases were predominantly older than 50 years and female (67%) which 
is in line with published studies reporting incidence rates of non-drug associated 
PMR 21,22. 
Several limitations of our study need to be addressed. First, data were obtained from 
a spontaneous reporting system without additional clinical assessment or qualitative 
verifications by the authors. For instance, in many ADR reports no information was 
available about the withdrawal of statins, the course of PMR and the response to 
steroid therapy.
Second, there is gross but variable underreporting and it is likely that only a fraction of the 
actual adverse events that occurred (perhaps less than 10%) has been reported 23,24. 
ADRs to relatively new drugs, severe ADRs, and ADRs which are not listed in the summary 
of product characteristics tend to be more often reported 23. To control for possible 
time trends of reporting, we matched non-cases for the calendar year of reporting.
Third, we cannot exclude the possibility of unmeasured and/or inadequately 
measured residual confounding. Furthermore, in VigiBase confounders are difficult 
to determine because they were not always recorded in the reports. Unfortunately, 
with our patients no data were available on vitamin D deficiency, which could be an 
important risk factor for statin-associated muscle complaints 25. Recently, one case 
report 26, case series 27, and two cross sectional studies have found an association 
between vitamin D insufficiency and statin-induced myalgia 28,29. Importantly, vitamin 
D has been shown to modulate the immune response 30. For instance in humans, 
high doses vitamin D therapy results in the inhibition of T helper (Th) 1 and Th17 cells 
and the promotion of Th2 and regulatory T cells 31.
Fourth, reporters may not be aware of the possible association between PMR and the 
use of statins use, and therefore it may not have been reported, or the statin may have 
been regarded as a concomitant drug only. In a sensitivity analysis including all 
reports of statins, suspected or not, the association between statin use and PMR was 
still observed, although somewhat attenuated.
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Fifth, clinical details about the patients with PMR were scarce and we were not able 
to recognise possible diagnostic misclassification 32. The reports in Vigibase of PMR 
were submitted by medical specialists, GPs, manufactures or patients. Information 
on clinical features, such as elevation of the inflammatory markers (erythrocyte 
sedimentation rate (ESR) and C-reactive protein (CRP)), response to steroids and 
disease course, were often not recorded. However, when we only included case 
reports from physicians, the association between statin use and the occurrence of 
PMR was still present.
Since PMR occurs almost exclusively in patients aged 50 years and older 19,20, we 
performed a sensitivity analysis in which we excluded patients who were younger 
than 50 years from the study. We still found an association between statin use and the 
occurrence of PMR.
The symptoms of PMR are very characteristic, although other conditions may mimic 
PMR 13,14. Statins are an established cause of muscular injury and specifically the 
inclusion of cases of myositis, non-specific myalgias, and/or myopathy may have 
occurred, the more so since laboratory findings, i.e., serum CK were often not 
recorded. On the other hand, patients with statin-associated myopathy may have 
normal serum CK levels which make it sometimes difficult to distinguish PMR from 
myopathic syndromes 33. 
As yet, the possible pathophysiology underlying statin-associated PMR is uncertain. 
Recently, it has been postulated that in statin-associated necrotising myopathy, 
statins may induce neo-antigens as a result of muscle damage which are subsequently 
presented to the immune system 34,35. A similar mechanism may be operative in 
statin-associated PMR. 
We believe that the use of a case/non-case approach in a study with ICSRs of ADRs is, 
notwithstanding the limitations of our data, an appropriate approach in pharma-
covigilance and drug safety research 36. To our knowledge, this is the first study to assess 
the association between statin use and the occurrence of PMR in a large spontaneous 
reporting database. Our findings are consistent in various sensitivity analyses.
We postulate that the use of statins may be associated with an increased occurrence of 
PMR. Our study presents a pharmacovigilance signal and supports previous anecdotal 
case reports. We think that further research towards confirming and explaining the 
association between statin use and PMR is warranted.
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CASE REPORT
Background
Statins, or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are widely 
used to prevent cardiovascular diseases and are generally regarded as safe. 
However, adverse reactions, such as myalgia, myositis, rhabdomyolysis, muscle 
weakness and cramps with or without elevated serum creatine kinase levels may 
occur 1. Furthermore, we have recently described that statins may also be associated 
with polymyalgia rheumatica (PMR) 2. 
Case report
A 78-year-old woman presented in December 2003 with muscle pain in the hips and 
shoulders and morning stiffness. She had a history of hypercholesterolaemia treated 
with atorvastatin 10 mg/day for nine months and hypertension treated with candesartan 
8 mg/day and bisoprolol 2.5 mg/day. Laboratory studies revealed an erythrocyte 
sedimentation rate (ESR) of 61 mm/h and platelet count of 487 × 109 cells/L. She was 
diagnosed with PMR and advised to stop atorvastatin therapy. Her symptoms 
gradually resolved. Five months after presentation, ESR was normal at 13 mm/h.
In February 2006, her low-density lipoprotein cholesterol level was 4.5 mmol/L (174 
mg/dL), and therapy with rosuvastatin 5 mg twice weekly was resumed. Symptoms 
of PMR recurred and progressed, and she reported visual disturbances. 
Temporal arteries were tender on palpation. Hematoxylin-eosin staining of a biopsy 
specimen of the temporal artery showed panarteritis comprising lymphocytes, neutrophils, 
eosinophils and macrophages with giant cells (Figure 1). Intimal thickening with clear 
luminal narrowing was also noted (Figure 2). An ESR of 95 mm/h and a C-reactive 
protein (CRP) level of 2 381.0 nmol/L (250 mg/L) were found on laboratory studies. 
Giant cell arteritis (GCA) with PMR was diagnosed. 
Rosuvastatin therapy was discontinued, and the patient was treated with prednisolone 
40 mg/day, the dosage of which was slowly tapered. Her symptoms abated over the 
next few months, and the ESR and CRP level decreased to 6 mm/h and less than 
95.2 nmol/L (10 mg/L), respectively. 
In June 2008, prednisolone therapy was stopped. A few months later, PMR and GCA 
relapsed. This time, relapse was not preceded by statin therapy. Again, the patient received 
corticosteroids, which resulted in a good response until she died in February 2009. 
Discussion
The patient’s presentation strongly suggested statin-induced PMR and GCA. Both 
are part of the same disease spectrum and are associated with the HLA-DRB1*04 
allele3, the presence of which was not determined in this patient. Between 16 to 21% 
of patients with PMR have GCA 3. 
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Of note, PMR in this patient resolved after statin therapy was discontinued and PMR 
and GCA recurred after statin therapy (that is, rosuvastatin) was resumed. This 
sequence of events suggests that statins may trigger PMR and GCA in sensitive 
patients. However, this patient relapsed later without a preceding statin challenge, 
showing that the disease process had become independent of the external trigger, 
which often occurs in drug-induced vasculitis 4.
The mechanism of statin-associated PMR and GCA is not clear. Because many 
patients receiving statins develop myalgia and/or more severe muscle disease 1, mild 
myopathic damage probably plays a role in statin-associated PMR and GCA. In statin- 
associated necrotising myopathy, these drugs have recently been postulated to induce 
neo-antigens as a result of muscle damage, which are subsequently presented to 
the immune system. A similar mechanism may operate in statin-associated PMR 
and GCA 2. Indeed, we recently showed in an animal model that statin use leads to 
dysregulation of immune responses, possibly resulting in autoimmunity 5. In summary, 
we report the first case to our knowledge of GCA combined with PMR that was 
Figure 1  Inflammatory cells. 
Lymphocytes (blue arrow), eosinophils (red arrow), and macrophages and giant cells (black arrow) 
(haematoxylin and eosin preparation, original magnification x100).
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probably induced by a statin, rosuvastatin. Of interest, in this patient, previous use of 
atorvastatin had been followed by a first episode of PMR. We propose that PMR 
should be suspected when a patient receiving statin therapy presents with myalgia 
of the hips and shoulders combined with morning stiffness.
Figure 2   A pan-arteritis of the temporal artery (haematoxylin and eosin preparation, 
original magnification x200). 
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ABSTRACT
Objectives 
Statins offer significant cardiovascular benefits. Their use, however, influences 
immune regulation, which may potentially facilitate autoimmunity, eventually resulting 
in autoimmune diseases such as rheumatoid arthritis (RA). The authors studied 
whether statin use was associated with an increased risk of developing RA by 
conducting a case-control study using the Netherlands Information Network of 
General Practice database.
Methods 
The authors identified 508 patients aged 40 years or older with a first-time diagnosis 
of RA in the period 2001–2006. Each RA case was matched to five controls for age, 
sex and index date, which was selected one year before the first diagnosis of RA. Odds 
ratios for the first-time diagnosis of RA were verified by a referral to a rheumatologist 
and/or at least one prescription of disease-modifying anti-rheumatic drugs and/or 
two prescriptions of corticosteroids after the date of first diagnosis.
Results 
Cases were more often users of statins (15.9%) compared to controls (8.6%). After 
adjustment for cardiovascular risk factors and use of co-medication, statin use was 
associated with an increased risk of incident RA (adjusted OR, 1.71 (95% CI 1.16 to 
2.53); p=0.007). A consistent trend of increasing risk with increased cumulative 
duration, cumulative defined daily doses and number of prescriptions was not 
observed. However, a small trend between the potency of statin treatment and the 
risk of RA was found.
Conclusions 
Statin use seems to be associated with an increased risk of developing RA. Our 
findings should be replicated by additional studies.
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INTRODUCTION
Epidemiological studies have shown an increasing prevalence of autoimmune diseases 
in highly industrialised countries, which cannot be attributed to better diagnosis alone 
but may be due to increased drug use 1,2. Concerns about preventive therapies such 
as statins, which are widely prescribed to reduce the risk of cardiovascular morbidity 
and mortality in patients with hyperlipidaemia, hypertension or diabetes, have been 
raised 3–5. Several studies have shown that statins, in addition to their cholesterol- 
lowering activity, have anti-inflammatory and immunomodulatory properties, suppressing 
the expression of ongoing autoimmune responses 6–11. Such immunomodulating 
effects may hypothetically also facilitate the development of autoimmunity, potentially 
resulting in autoimmune diseases such as systemic lupus erythematosus and 
autoimmune hepatitis 12,13. Recently, a meta-analysis showed an association between 
statins and an increased risk of diabetes 14. As no distinction between the types of 
diabetes was made, no conclusions on mechanisms could be drawn. Several studies 
demonstrated that statins may exacerbate or trigger cellular apoptosis 12,15,16 and 
induce a shift in T helper (Th) 1/Th2 balance, leading to production of autoantibodies 
12,17. An increasing number of case reports suggest that statins can trigger rare 
autoimmune diseases, raising the question on whether these commonly prescribed 
drugs may facilitate the development of more common autoimmune diseases such as 
rheumatoid arthritis (RA). So far, few studies have assessed the risk of developing RA after 
statin treatment. A population-based case-control and cohort study reported that statins 
may be protective against the development of RA in patients with hyperlipidaemia, 18,19 
while two other population-based cohort studies did not observe an association between 
statin use and incident RA 20,21. We conducted a case-control study to determine the 
risk of developing RA associated with different exposure aspects (duration, dose, type 
and potency) of statin use.
METHODS
Study population
We used the Netherlands Information Network of General Practice (LINH), a database 
derived from general practices that register data on morbidity, drug prescriptions and 
referrals in electronic medical records on a continuous basis. The LINH network 
includes 350 000 patients who were registered at 85 practices in 2001-2006 22. For a 
number of practices, data on drug prescriptions were not available before the year 
2001. Prescription data were classified according to Anatomical Therapeutic and 
Chemical (ATC) classification, 23 and morbidity was coded using the International 
Classification of Primary Care (ICPC) 24.
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Case definition
All patients who were first diagnosed as having RA and had a medical history of at 
least one year at index date were included in the study (figure 1). Subsequent 
diagnoses of RA were disregarded. The date exactly one year before the date of the 
first-time diagnosis of RA was subsequently used as the ‘index date’ because the 
diagnosis is usually made after the disease has been symptomatic for some period 
of time 25,26. From the arthritis group (ICPC code L88), we verified the first-time 
diagnosis of RA registered by a general practitioner (GP) if:
1.  The patient was referred to a rheumatologist; or
2.  At least one disease-modifying anti-rheumatoid drug (DMARD; immunosuppres-
sants, aminoquinolines, gold preparations and sulfasalazine) was prescribed after 
the index date; or
3. Two or more prescriptions of systemic corticosteroids (glucocorticoids and 
combinations) were distributed after the index date. Since statins are widely 
prescribed for patients with cardiovascular diseases or cardiac risk factors that 
are more prevalent among older patients, patients younger than 40 years of age 
were excluded from the study. Furthermore, patients were excluded if they had a 
medical record of ankylosing spondylitis (ICPC code L88.2) or were taking at 
least one prescription of DMARDs before the index date, if they had been diagnosed 
by the GP as having RA with no confirmation according to the above-mentioned 
criteria or if they had no registered medical history for one year.
Control selection
Five controls were matched to each RA case on age (within five years), sex and index 
date. Controls were required to be registered in general practice for at least one year 
before the index date to minimise information bias. The exclusion criteria used in case 
selection were applied to controls.
Definition of exposure and potential confounders 
Exposure to statins was defined as the use of any approved and commercially 
available statins (pravastatin, simvastatin, cerivastatin, atorvastatin and fluvastatin) in 
the Netherlands before the index date. The hazard function between statin use and 
RA is unknown; therefore, different aspects of statin use were defined. Statin users 
were patients who had received at least one prescription of statins before the index 
date. We determined the type of statins based on their last prescription before the 
index date. The potency of statins was determined by combining the type and the 
dose of statin into a single potency score to control for the fact that different types and 
doses of statins differ with respect to percentage reduction in total cholesterol (see 
online supplementary table 1) 27. Potency was divided into four categories of 
increasing potency: potencies 2 and 3, potency 4, potency 5, and potencies 6 and 7. 
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CHAPTER 3.1
The expected duration of statin use until the index date was based on treatment time 
and prescribed drug supply (determined by the number of prescribed tablets). We 
calculated the cumulative dose of statins according to defined daily dose (DDD), 
which is the assumed average daily dose of a drug for its main indication in adults 
(see online supplementary table 2) 23. Adherence to statin use was calculated by 
dividing the sum of the days’ supply by the total number of days between the first 
prescription and the last prescription of statins in the year before the index date, 
multiplied by 100%. To determine adherence to statin use, we excluded patients who 
received one prescription of statins and did not use statins one year before the index 
date. Patients who received one prescription of statins before the index date were not 
excluded from other analyses. Potential confounders included prescriptions (in the 
six months before the index date) for non-steroidal anti-inflammatory drugs (NSAIDs), 
corticosteroids, proton pump inhibitors, aspirin, antibiotics and hormone replacement 
treatment, and co-morbidity (diabetes, hyperlipidaemia, hypertension, cardiovascular 
disease and asthma) 28. The ICPC and ATC codes for co-morbidity are presented 
in table 1.
Statistical analysis
Logistical regression conditioned on matching factors was used to study the 
association between statin use and risk of RA. Odds ratios and 95% CI were 
estimated. We evaluated the effects of cumulative duration, cumulative DDDs, 
number of prescriptions, and the specific type and potency of statins on the risk of 
developing RA. In addition to controlling for age, sex and calendar time by matching, 
we adjusted the estimates for the above-mentioned confounders. Furthermore, we 
evaluated the confounding effects of asthma, aspirin and antibiotics, but we did not 
include these covariates in the regression models because we did not observe more 
than 10% differences in the estimate of exposure-outcome association by adding 
each time one of these three variables into the model 29. We examined whether there 
was a linear trend across the categories of the potencies of statins by including the 
categorical variables as ordinal variables in the regression model. P values of ≤0.05 
were considered statistically significant. We used SAS V.9.1 (SAS Institute, Cary, 
North Carolina, USA) to analyse the data. 
We performed 11 different sensitivity analyses to test the robustness of our findings, 
which are presented online (see online supplementary table 3).
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RESULTS
In the study population, 3 074 patients with a first-time diagnosis were identified, of 
whom nine patients did not have a matched control and 642 patients had a medical 
record of ankylosing spondylitis. Of 2 423 patients with RA, 848 patients were referred 
to a rheumatologist, 425 patients received at least one prescription of a DMARD and 
817 patients were treated with two or more prescriptions of systemic corticosteroids 
after the index date. Regarding the 848 patients who were referred to a rheumatologist, 
155 patients were treated with a DMARD after the index date. As a result of verifying 
the first-time diagnosis of RA, we identified 508 eligible cases that were matched to 2 
369 controls. Of the patients with RA, the average age was 63 years, approximately 
67% of the patients were female and 3% of the patients were diagnosed as having 
psoriasis. Fourteen percent of the patients with RA were users of statins. Two patients 
with RA used other lipid-lowering medications. Use of corticosteroids and NSAIDs 
was higher in patients with RA than in controls. The duration of registration with the 
GP was approximately 11.3 years in patients with RA and 10.3 years in controls. The 
baseline characteristics of the study population are presented in table 2.
Table 3 shows the results of analyses with different exposure aspects of statin use. 
Statin use was associated with an increased risk of developing RA (adjusted OR, 1.71 
(95% CI 1.16 to 2.53); p=0.007). Regarding the number of prescriptions, an increased 
risk of developing RA was found for all categories of statin use compared to non-users. 
No trend between an increasing number of prescriptions and an enhanced risk of 
developing RA was observed. We explored the effect of the duration of statin use. 
After adjustment, an increased risk of developing RA was found for different categories 
of the duration of statin use. No clear relation between the duration of statin use and 
an increased risk of developing RA was observed. When data were analysed for 
different levels of DDD, we found no trend between the different DDD groups of 
statins and the risk of developing RA. Regarding confounding effects on the different 
strata of DDD, duration of statin prescriptions and number of statin prescriptions, the 
association between statin use and the risk of developing RA was weaker compared 
to the result of our overall analysis with ever use of statins 30. Categorising exposure 
according to level of adherence did reveal differences in effect. Only patients with an 
adherence rate of more than 80% had an increased risk of incident RA. The 
association between individual statins, their potencies and the risk of RA is shown in 
table 4. 
All types and potencies of statins showed an enhanced risk of incident RA. Regarding 
the potency of statin treatment, we observed a small trend between the different 
categories of the potencies of statin treatment and the risk of RA (p for trend <0.01). 
The results of eleven different sensitivity analyses are presented online (see online 
supplementary table 3).
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Table 2   Baseline characteristics of the study population before index date
 
Baseline Characteristics Case 
(n = 508)
Control 
(n = 2 369)
Sex 
Male, (%) 
Female, (%)
Mean age, y (SD)
Duration registration at general practice in years, (%)*
1 – 5.99
6 – 11.99
≥ 12
165 (32.5)
343 (67.5)
63.4 (12.9)
118 (24.3)
174 (34.3)
194 (38.2)
810 (34.2)
1 559 (65.8)
62.8 (12.8)
487 (23.5)
800 (33.8)
790 (33.3)
Disease history before index date (%)
Diabetes
Hypertension
Cardiovascular disease
Hyperlipidaemia
Hepatic disease
Renal disease 
Asthma
Cancer 
Inflammatory bowel syndrome
Psoriasis
Drug use six months before index date (%)
Corticosteroids 
NSAIDs† 
Statins
Other lipid-lowering agents
Anti-hypertensive agents
Anti-diabetic agents
Aspirin
HRT‡
Antibiotics 
Vaccines
Anti-psychotics 
Antidepressants
PPIs§ 
44 (8.7)
230 (45.3)
125 (24.6)
28 (5.5)
10 (2.0)
8 (1.6)
44 (8.7)
13 (2.6)
4 (0.8)
16 (3.2)
68 (13.4)
145 (28.5)
70 (13.8)
2 (0.4)
182 (35.8)
34 (6.7)
38 (7.5)
31 (6.1)
81 (15.9)
76 (14.9)
3 (0.6)
44 (8.7)
72 (14.2)
167 (7.1)
724 (30.6)
330 (13.9)
89 (3.8)
16 (0.7)
13 (0.6)
57 (2.4)
71 (3.0)
7 (0.3)
33 (1.4)
46 (1.9)
121 (5.1)
163 (6.9)
14 (0.6)
530 (22.4)
115 (4.9)
105 (4.4)
62 (2.6)
199 (8.4)
266 (11.2)
19 (0.8)
89 (3.8)
85 (3.6)
*  Duration of registration with a general practitioner was defined by the date of registry at a general 
practice or the first medical record of the patient. No data on date of registry at a general practice 
before the entrance of this study were available for 314 patients.
†  NSAIDs = Nonsteroidal anti-inflammatory drugs
‡  HRT = Hormone replacement therapy
§  PPIs = Proton pump inhibitors
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DISCUSSION
The findings were consistent with the hypothesis that statin use is associated with an 
increased risk of developing RA. We did not observe a consistent trend of increasing 
risk with increased cumulative duration, increased cumulative DDDs and increased 
number of prescriptions. However, we observed a small trend between the potency 
of statin treatment and the risk of RA. With our baseline characteristics taken into 
account, cardiovascular diseases and cardiovascular risk factors (e.g. hyperlipidaemia) 
may have influenced our results. Our hypothesis was made a priority for this study 
and was supported by several case reports describing the occurrence of autoimmune 
diseases during treatment with statins 12,13. Our findings are not in line with previous 
studies, which found that statins exert a protective effect or no effect on developing 
RA 18–21. In a nested case-control study of 313 patients with incident RA and 1 252 
matched controls aged 40 to 89 years, current statin use was associated with a 
reduced risk of developing RA in patients with a diagnosis of hyperlipidaemia, 
whereas no association was found for patients without a diagnosis of hyperlipidae-
mia 18. Because of limited data on hyperlipidaemia in our study, we analysed the data 
of patients without a medical record for cardiovascular disease, diabetes and 
hypertension, and we still found an increased risk of developing RA associated with 
statin use. Recently, three population-based cohort studies of patients who were 
initially treated with statins have shown conflicting results 19–21. Smeeth et al.21 
reported no effect of statins on the development of RA, whereas Chodick et al. 19 
reported a reduction in the risk of developing RA when patients were treated with 
statins. Both the study of Smeeth et al. 21 and the study of Chodick et al. 19 excluded 
patients with RA in the first year after the index date. In contrast to our retrospective 
study, these two prospective studies hypothetically considered a lag time between 
exposure to statins and incident RA. This could explain the differences between 
these two cohort studies and our results because we found an increased risk of RA 
within six months of statin use. Another prospective population-based cohort study 
of more than two million patients from 368 general practices in England and Wales 
showed no association between statin use and the risk of developing RA 20. In 
comparison with this population-based cohort study, we used a more sensitive 
definition of RA by verifying the patient electronic records with a referral to a 
rheumatologist and/or at least one DMARD prescription and/or two corticosteroid 
prescriptions after the date of the first diagnosis of RA. In the study of Hippisley-Cox 
and Coupland, 20 patients were included as cases if they only had a diagnostic code 
for RA. Using a more inclusive definition of RA may have diluted the association 
between statin use and incident RA.
The underlying mechanisms by which statins may facilitate RA are unknown, and it 
was not possible to investigate them in our study. Statins are suggested to have a 
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direct immunomodulating effect on T cells that may promote a shift in Th1/Th2 
balance, leading to production of autoantibodies 12,17. Statins may affect regulatory T 
cells that are critical for maintaining peripheral tolerance and preventing the 
development of RA 31–33. Recent studies have suggested that regulatory T cells can 
be unstable in the periphery and may promote autoimmunity 34,35. According to 
these studies, we hypothesise that statins do not cause autoimmunity but may 
promote a pre-existing autoimmune-prone condition to progress towards a clinical 
disease such as RA. Another possibility is that self-tolerance is lost due to non-specific 
bystander activation provided by local inflammation (microbial infection), which could 
result in the formation of neo-antigens 36. This mechanism may be induced by statins 
that have been proven to reduce Th1 responses 8.
One of the strengths of our study is the use of a computerised database, allowing us 
to use routinely recorded medical and prescription data from GPs. Consequently, 
recall bias was minimised. Our study contains a relatively large number of patients 
with RA, which allowed an assessment of the association between statins and RA 
with sufficient precision. Finally, we performed a range of sensitivity analyses 
regarding outcome definition, exposure definition, and inclusion and exclusion 
criteria. All these analyses consistently have shown an increased risk of incident RA 
associated with statin use.
Some limitations of this study should be considered. A concern may be the power of 
this study; therefore, we used a definition of RA that is based on GP diagnosis, a 
referral to a rheumatologist or prescriptions of DMARDs or corticosteroids after the 
index date. Thus, we may have used a relatively sensitive but non-specific diagnosis 
of RA because no specific ICPC codes were available for other rheumatic diseases 
(e.g. systemic lupus erythematosus and psoriatic arthritis) that may have attenuated 
the association between statins and RA. However, our results remained unchanged 
when the analyses were restricted to patients with RA who were referred to a 
rheumatologist or who received DMARDs after their first-time diagnosis, or when we 
excluded from the analysis patients with a diagnosis of psoriasis or patients who 
used corticosteroids and NSAIDs before the index date. In addition, we have 
attempted to verify the first-time diagnosis of RA by the GP: if patients were referred 
to a rheumatologist and received at least one DMARD prescription after the index 
date, or if patients were prescribed DMARDs after the index date. Using these two 
criteria for defining RA, we have only included patients who were referred to a 
rheumatologist and were prescribed DMARDs by their GP, or patients who were 
treated with DMARDs by their GP. When DMARDs were prescribed by the 
rheumatologist, the prescription of the patient may not always appear in the LINH 
data set. The LINH database does not provide medical information from the 
rheumatologist, but the Dutch guidelines for optimising GP-medical specialist 
communication enjoin medical specialists to inform GPs of the first results of the 
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diagnostics and treatments of the referred patient 37,38. Due to this possible under-
estimation of patients with RA, we may have introduced selection bias that may 
produce an underestimation of the association. Using computerised prescription 
data from the GP may have introduced an overestimation of actual statin use. 
However, this misclassification is likely to be non-differential between cases and 
controls and, therefore, would probably have resulted in an underestimation of the 
association between statin use and RA. In this study, we found an effect of statin use 
on the risk of developing RA. We observed no effect of past statin use and no trend 
between different groups of duration, DDDs and prescriptions of statins and the risk 
of developing RA. This may be due to the small number of patients in the study. There 
were no available data on dietary intake, physical activity and smoking, and there 
were limited available data on other examinations (e.g. lipid levels, inflammatory and 
immunomodulatory markers (e.g. anti-nuclear antibodies, anti-citrullinated protein 
antibodies)) that may be important confounders. By conducting simulation analyses 
with potential effects of smoking, 39 we estimated the impact of smoking on the 
association between statin use and the development of RA 40.Our findings were 
similar after adjusting for smoking. Nonetheless, we cannot exclude the possibility of 
residual confounding.
Cardiovascular morbidity and mortality are enhanced in patients with RA, and this 
could be due to the inflammatory process and the increased prevalence of traditional 
cardiovascular risk factors such as hyperlipidaemia 41–43. Several studies have 
demonstrated an unfavourable lipid profile in patients with RA 41,44. Therefore, statin 
use could be a proxy for hyperlipidaemia, which may be responsible for an increased 
risk of developing RA in our study. With our baseline characteristics taken into 
account, cardiovascular diseases and cardiovascular risk factors (e.g.  hyperlipidae-
mia) may have influenced our results. Therefore, we should consider that the 
increased risk of RA was due to hyperlipidaemia and not due to statins. Conversely, 
several studies did not find significant differences between the lipid profile of patients 
with RA and the lipid profile of the general population 45–47.These conflicting results 
can be attributed to inflammation and treatment with lipid-lowering drugs 45,46,48. 
Myasoedova et al. 45 reported that reduction of lipid levels in patients with RA is 
unlikely to be solely due to lipid-lowering treatment. Additionally, confounding by 
indication may have affected the results of this study. We have limited information on 
hyperlipidaemia due to under-registration of this diagnosis in the GPs’ records. 
Therefore, to minimise confounding by indication, we conducted a subgroup analysis 
based on cardiovascular risk profile. Statin use was associated with an increased risk 
of incident RA in patients with a low cardiovascular risk profile. With the potency of 
statins taken into account, certain assumptions about disease severity in the patients 
in our study can be made. We believe that a high potency of statins is related to 
severe cardiovascular disease/hyperlipidaemia. Based on this assumption, we would 
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expect the association between the increased potency of statin treatment and the risk 
of developing RA to disappear or to be much more diminished among those cases 
with severe cardiovascular disease and/or hyperlipidaemia. However, we observed a 
small trend between an increased potency of statin treatment and an increased risk 
of RA. Taken together, it is not very likely that hyperlipidaemia is the only risk factor. 
Selection bias might have been introduced in this study because GPs could have 
paid more attention to the comorbidities of patients with RA. Consequently, these 
patients may have an increased probability of receiving statins. A sensitivity analysis 
in which we included controls who were registered and visited the GP showed similar 
results. Additionally, the average duration of registration with the GP is almost equal 
between patients with RA and controls, indicating that the patients in our study had 
similar opportunities to have been prescribed a statin. Differences between GPs 
could have biased the results of our study if there are differences in diagnoses and 
prescribing regimens per practice. However, because of the small number of patients 
with RA per GP, we did not control for general practice effects in our analysis. It is 
likely that statins were prescribed before the first-time diagnosis of RA. In our study, 
we could define the date of onset of RA by the first record of the GP for RA, but the 
date of onset of the RA symptoms is unknown 49. Chan et al. 25 reported that the 
median time between the onset of symptoms and the diagnosis of RA was less than 
one year. To prevent this possible type of bias (protopathic bias) of defining the date 
of onset, we performed several sensitivity analyses by modifying the index date 
exactly two, three and four years before the first-time diagnosis of RA. Our results 
remained unchanged in all sensitivity analyses. Because of the small sample size of 
the study population, we used an index date exactly one year before the first-time 
diagnosis of RA. From approximately 500 000 eligible patients, we ultimately included 
508 patients with RA in our study. Our restricted sample of patients with RA may 
hamper the external validity of the study.
Our study shows that even if statins are effective in suppressing symptoms of ongoing 
autoimmunity, they also seem to be associated with an increased risk of developing 
RA. Our findings should be replicated by additional studies. When confirmed, these 
findings indicate that precaution should be taken when prescribing statins for 
individuals with a low risk of cardiovascular disease.
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Supplementary text S2
Defined Daily Dose (DDD) of statins according to the guidelines of the WHO Collaborating 
Centre for Drug Statistics Methodology,
1 DDD corresponds with:
· simvastatin 30 mg, 
· pravastatin 30 mg, 
· atorvastatin 20 mg, 
· fluvastatin 60 mg, 
· lovastatin 45 mg, 
· rosuvastatin 10 mg 
Supplementary Table S1   Potency convertibility of statins per dose (in mg)
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3. Medium 10 20 40 0.2 22%
4. High 10 20 40 80 0.3 27%
5. High 10 20 40 32%
6. High 20 40 80 37%
7. High 40 80 42%
*Tc = total cholesterol
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Supplementary Table S3   Several sensitivity analyses to test the robustness  
of our findings
Sensitivity analyses Cases Controls Odds Ratio (95% CI) Odds Ratio (95% CI)* p value†
N Statin use N Statin use
Restrict to RA‡ patients referred to a rheumatologist or received at last one 
prescription of a DMARD§ before index date1
327 44 1 240 87 2.12 (1.59 – 3.16) 1.97 (1.15 – 3.36) 0.01
Exclude RA patients with corticosteroid and NSAIDⅡ use before index date2 317 47 1 502 121 2.06 (1.41 – 3.00) 1.72 (1.04 – 2.84) 0.04
Remove RA patients who had a recorded diagnosis of psoriasis3 492 79 2 296 201 2.09 (1.56 – 2.80) 1.54 (1.08 – 2.21) 0.02
Define use of statins as4 
Current statin use
Past statin use
508
70
11
2 369
163
44
2.27 (1.66 – 3.09)
1.40 (0.71 – 2.75)
1.78 (1.18 – 2.68)
1.28 (0.58 – 2.84)
0.006
0.54
Define current use of statins as receipt of at least two prescriptions within 
one year before index date5
508 69 2 369 166 2.19 (1.60 – 2.99) 1.71 (1.13 – 2.58) 0.01
Modify index date by using the date of the first diagnosis of RA set by the 
GP¶ or the date of referral to a rheumatologist6
508 98 2 369 243 2.20 (1.68 – 2.89) 1.44 (0.93 – 2.22) 0.10
Shift the index date exactly two, three and four years before the first-time 
diagnosis of RA7
Two years
Three years
Four years
370
220
98
65
43
24
1 716
1 031
458
161
99
50
2.16 (1.57 – 2.99)
2.43 (1.62 – 3.65)
2.89 (1.63 – 5.15)
1.85 (1.19 – 2.87)
2.15 (1.23 – 3.74)
1.64 (0.73 – 3.68)
0.07
0.007
0.47
Exclude patients who used statins six months after entrance of the study8 458 31 2 238 74 2.11 (1.36 – 3.26) 1.68 (0.98 – 2.91) 0.06
Patients without a medical record for cardiovascular disease, diabetes, and 
hypertension9
239 12 1 515 23 3.50 (1.71 – 7.14) 2.92 (1.33 – 6.40) 0.008
Exclude patients with a diagnosis for hepatic diseases, asthma and 
psoriasis, and antibiotic usage10
378 59 2 081 164 2.15 (1.56 – 2.98) 1.73 (1.12 – 2.65) 0.01
Exclude subjects who did not have a medical history in the general practice 
database11
508 81 1 940 202 1.67 (1.24 – 2.18) 1.65 (1.13 – 2.43) 0.01
*  When appropriate, adjusted for hypertension, cardiovascular disease, hyperlipidaemia and diabetes,  
and the use of NSAIDs, corticosteroids, hormone replacement therapy and proton pump inhibitors. 
† P values are for adjusted odds ratios.
‡ RA = rheumatoid arthritis
§ DMARD = Disease modifying anti-rheumatic drug
Ⅱ NSAID = Non-steroidal anti-inflammatory drugs
¶GP = General Practitioner 
1  Sensitivity analysis: varying the definition of the outcome (RA), specified as first-time diagnosis of RA  
and a referral to a rheumatologist and/or a prescription of DMARDs before index date (irrespective of 
corticosteroids use), a definition used by Jick et al.18.
2  Sensitivity analysis: estimating the association between statin use and the risk of developing RA by 
excluding RA patients who use corticosteroids and NSAIDs prior to the index date to exclude any 
prevalent cases of RA.
3  Sensitivity analysis: investigating the influence of the inclusion of patients with psoriatic arthritis by 
excluding patients with a medical record for psoriasis.
4  Sensitivity analysis: evaluating the association between current and past use of statins and RA by 
classifying current use as receiving at least one prescription of statins within six months before 
index date, and past use as receiving a prescription of statins but discontinued treatment more than 
six months before index date.
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Supplementary Table S3   Several sensitivity analyses to test the robustness  
of our findings
Sensitivity analyses Cases Controls Odds Ratio (95% CI) Odds Ratio (95% CI)* p value†
N Statin use N Statin use
Restrict to RA‡ patients referred to a rheumatologist or received at last one 
prescription of a DMARD§ before index date1
327 44 1 240 87 2.12 (1.59 – 3.16) 1.97 (1.15 – 3.36) 0.01
Exclude RA patients with corticosteroid and NSAIDⅡ use before index date2 317 47 1 502 121 2.06 (1.41 – 3.00) 1.72 (1.04 – 2.84) 0.04
Remove RA patients who had a recorded diagnosis of psoriasis3 492 79 2 296 201 2.09 (1.56 – 2.80) 1.54 (1.08 – 2.21) 0.02
Define use of statins as4 
Current statin use
Past statin use
508
70
11
2 369
163
44
2.27 (1.66 – 3.09)
1.40 (0.71 – 2.75)
1.78 (1.18 – 2.68)
1.28 (0.58 – 2.84)
0.006
0.54
Define current use of statins as receipt of at least two prescriptions within 
one year before index date5
508 69 2 369 166 2.19 (1.60 – 2.99) 1.71 (1.13 – 2.58) 0.01
Modify index date by using the date of the first diagnosis of RA set by the 
GP¶ or the date of referral to a rheumatologist6
508 98 2 369 243 2.20 (1.68 – 2.89) 1.44 (0.93 – 2.22) 0.10
Shift the index date exactly two, three and four years before the first-time 
diagnosis of RA7
Two years
Three years
Four years
370
220
98
65
43
24
1 716
1 031
458
161
99
50
2.16 (1.57 – 2.99)
2.43 (1.62 – 3.65)
2.89 (1.63 – 5.15)
1.85 (1.19 – 2.87)
2.15 (1.23 – 3.74)
1.64 (0.73 – 3.68)
0.07
0.007
0.47
Exclude patients who used statins six months after entrance of the study8 458 31 2 238 74 2.11 (1.36 – 3.26) 1.68 (0.98 – 2.91) 0.06
Patients without a medical record for cardiovascular disease, diabetes, and 
hypertension9
239 12 1 515 23 3.50 (1.71 – 7.14) 2.92 (1.33 – 6.40) 0.008
Exclude patients with a diagnosis for hepatic diseases, asthma and 
psoriasis, and antibiotic usage10
378 59 2 081 164 2.15 (1.56 – 2.98) 1.73 (1.12 – 2.65) 0.01
Exclude subjects who did not have a medical history in the general practice 
database11
508 81 1 940 202 1.67 (1.24 – 2.18) 1.65 (1.13 – 2.43) 0.01
5  Sensitivity analysis: using another definition of current statin exposure that has been postulated by 
Jick et al., studying the association between current statin use and RA. They defined current use of 
statins as receipt of at least two prescriptions within one year before index date.
6  Sensitivity analysis: modifying index date by using the date of the first diagnosis of RA set by the GP 
or the date of referral to a rheumatologist.
7  Sensitivity analysis: shifting the index date exactly two, three and four years before the first-time 
diagnosis of RA because of potential late manifestation of the clinically apparent symptoms of RA. 
This was done both in cases and matched controls.
8  Sensitivity analysis: investigating the influence of statin use started near the beginning of the 
patient’s electronic record by conducting an analysis where we excluded patients who used statins 
six months after entrance of the study.
9  Sensitivity analysis: studying the association between statin use and RA in patients without a medical 
record for cardiovascular disease, diabetes, and hypertension in order to minimise confounding by 
indication.
10  Sensitivity analysis: investigating the influence of the inclusion of patients with a diagnosis for hepatic 
diseases, asthma and psoriasis, and antibiotic usage.
11  Sensitivity analysis: excluding subjects who did not have a medical history in the general practice 
database in order to minimise possible selection bias.
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ABSTRACT
Objective
To examine the association between the use of statins and the risk of rheumatoid 
arthritis (RA), with a special focus on describing the patterns of risks of RA during 
statin exposure.
Methods
A retrospective cohort study using the UK Clinical Practice Research Datalink was 
conducted. All patients aged ≥40 years, who had at least one prescription of statins 
during the period 1995 to 2009, were selected and matched by age, sex, practice 
and date of first prescription of statins to controls (non-users). The follow-up period of 
statin users was divided into periods of current, recent and past exposure, with 
patients moving between these three exposure categories over time. All patients 
were followed up for the development of RA. Time-dependent Cox models were used 
to derive hazard ratios (HRs) of RA, adjusted for disease history and previous drug 
use. 
Results
The study population included 1 023 240 patients, of whom 511 620 were statin users. 
No associations were found between RA and current or past users of statins. 
However, in patients who currently used statins, hazard rates were increased shortly 
after the first prescription of statins and then gradually decreased to baseline level. 
The risk of developing RA was increased in patients who recently used statins, as 
compared to non-users. The risk of RA was highest among women and restart users.
Conclusions
The risk of RA is substantially increased in the first year after the start of statins and 
then diminishes to baseline level. The risk of RA was highest among women and 
restart users. These findings suggest that statins might accelerate disease onset in 
patients (genetically) susceptible to develop RA. Alternatively, confounding by 
cardiovascular risk factors and ascertainment or detection bias may have influenced 
the findings.  
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INTRODUCTION
Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are widely 
prescribed drugs to reduce the risk of cardiovascular morbidity and mortality 1. 
Besides their cholesterol-lowering activity, statins exert anti-inflammatory and immu-
nomodulatory effects, and may suppress the expression of ongoing autoimmune 
responses, e.g., rheumatoid arthritis (RA) and multiple sclerosis 2–10. The immuno-
modulating effects may, on the other hand, facilitate the development of autoimmunity 
potentially resulting in autoimmune diseases, such as RA 11–15.
Six other studies have assessed the risk of developing RA or connective tissue 
disease (CTD) (the majority of the patients were coded with RA) during statin 
treatment, and have shown conflicting results 14, 16–20. Possible explanations for 
these conflicting findings may be attributed to considering a lag-time between statin 
use and incident RA,17,19 using different definitions of RA 14, 17–20 or exposure to 
statins, 14, 16–20 comparing to a control group of non-persistent statin users in stead 
of non-users, 17 controlling for other confounders, 14, 16–20 shifting the date of incident 
RA, 14, 16 propensity score matching on baseline characteristics,20 or conducting 
separate analyses in patients with or without a medical history of cardiovascular risk 
factors 14, 16, 17. Cardiovascular risk factors, including smoking and hormone replacement 
therapy have been associated with RA 21–26. Several studies have demonstrated an 
unfavourable lipid profile before a patient is diagnosed with RA 21, 27. If statin use is a 
proxy for hyperlipidaemia then the increased risk of developing RA in our previous 
study 14 might be explained by hyperlipidaemia rather than by an immunomodulating 
effect of statins. Otherwise, subclinical RA may have been present before the initiation 
of statin treatment since it is well-known that autoantibodies and non-specific 
symptoms may be present long before patients are diagnosed as having RA 28. 
At present, it is unclear to what extent the association between statin use and the risk of 
developing RA is related to statins or if it is merely an association with hyperlipidaemia. 
Moreover, none of the previous studies 14, 16–20 studied the pattern of risks of RA with 
changes in statin exposure. Therefore, we examine the association between the use 
of statins and the risk of RA, with a special focus on describing the patterns of risks 
of RA with changes in statin exposure over time and confounding by cardiovascular 
co-morbidities in a large population-based cohort.
METHODS
Data source
Data were derived from the Clinical Practice Research Datalink (CPRD), previously 
known as the General Practice Research Database, which contains computerised 
medical records of all patients under the care of 625 general practitioners (GPs) in the 
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United Kingdom, representing 8% of the population. The CPRD has been described 
in detail elsewhere 29, 30. The database provides detailed information on demographics, 
diagnoses, prescription details, preventive care provided, specialist referrals, and 
hospital admissions 30. Several independent validation studies have shown that the 
CPRD database has a high level of completeness and validity 31, 32. All research 
undertaken using data obtained from CPRD is approved by, as appropriate, an ethics 
committee, a scientific committee and the National Information Governance Board 
Ethics and Confidentiality Committee.
Study population
We conducted a matched retrospective cohort study among patients aged 40 years 
or older, who had at least one prescription of statins at least one year after the start of 
data collection (period: 1995-2009). The date of the first prescription of statins was 
defined as the index date. Statin users were matched by age, sex, and practice to a 
single patient who did not receive a statin prescription (control) any time during 
follow-up, with the index date of the control being the same as that of the statin user. 
After using a matched random sampling approach, statin users and non-users who 
had been diagnosed with RA, or used disease modifying anti-rheumatic drugs (DMARDs) 
before the index date were excluded. In addition their corresponding non-user or 
statin user was excluded from the study.
Exposure to statins
All prescriptions for statins were identified. Each prescription length was calculated 
by dividing the number of prescribed tablets by the prescribed daily dose. Since 
statin therapy compliance declines substantially over time 33, the time of follow-up 
was divided into periods of current, recent and past exposure to statins, with patients 
moving between these three exposure categories over time 34. Current exposure was 
defined as the time from the date of a prescription until three months after its expected 
duration of use. The expected duration of statin use was defined as three months. 
When the consecutive prescription of statins was prescribed within these three 
months, patients continued to be ‘current users’. We divided current users into ‘de 
novo’ and ‘restart’ users. ‘De novo’ statin users were defined as patients who were 
not moving between the three periods of statin exposure over time. Current, ‘de novo’ 
and ‘restart’ statin users were also classified according to duration of use (≤1 year 
use; >1 year use). Recent exposure was defined as the period of time from three to 
twelve months after the end date of the most recent prescription, and past exposure 
was the period of time from twelve months or longer after the end date of the most 
recent prescription of statins (Figure 1). 
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Clinical outcome
Each patient was followed from the index date up to either the end date of data 
collection, or the date when the patient left the general practice, died, or was first 
diagnosed with RA (identified from the CPRD Read codes) whichever date came first. 
Patients were considered as having a diagnosis of RA if the first-time diagnosis 
registered by GPs was verified by at least one prescription of DMARDs during 
follow-up, adapted from an algorithm proposed by Thomas et al. 35. Patients who did 
not meet the algorithm criterion during follow-up were censored at the last date of 
data collection, or date when they left the practice, or date of death, whichever came 
first. When RA occurred or when a patient was previously referred to a rheumatologist, 
the date of the first-time diagnosis of RA or referral to a rheumatologist was defined 
as the event date.
Potential confounders 
A list of potential confounders before the index date was assembled, which included 
body mass index (BMI), smoking and alcohol status (a record of currently smoking 
or drinking, ex-smoker or -drinker, or never smoked or drank before; missing data in 
Figure 1   Three examples of time-dependent exposure to statins in  
patients A, B and C. 
0 3 3 
Current use 
6 9 3 0 >12   
= 0 
Current use 
Recent use 
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Current use Recent use 
Current use 
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both variables were treated as a separate category in the analyses), and a history of 
hypertension, diabetes mellitus, hyperlipidaemia, cardiovascular disease, asthma, 
inflammatory bowel and thyroid disease, and cancer 23, 36, 37. Patients were classified 
as diabetes mellitus when they had a diagnosis of diabetes mellitus or when they 
received anti-diabetic therapy. Hypertension was defined as using anti-hypertensive 
drugs or a diagnosis of hypertension. Data on the use of non-steroidal anti-inflammatory 
drugs (NSAIDs), aspirin, proton pump inhibitors (PPIs), antibiotics, hormone replacement 
therapy, antidepressants, anticonvulsants, anti-psychotics, anti-arrhythmic and other 
lipid-lowering agents within six months before the index date were considered as 
potential confounders 38. 
Statistical analysis
We estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) for the risk of 
developing RA among statin users, using a time-dependent Cox proportional hazards 
model (SAS 9.2. PHREG procedure). First, we assessed the risk of RA between 
current, recent and past users versus non-users of statins. Second, a descriptive 
analysis of the pattern of changes in the risk of RA (hazard rates) in current statin 
users compared to non-users (with past and recent users defined as time = 0) was 
performed. The risk of RA was plotted against the time since the first prescription of 
current statin use and visualised using smoothing spline regression 39, which has 
been advocated as an alternative to categorical analysis 40. 
Potential confounders were included in the final model if they independently changed 
the β coefficient for statin use by at least 5%. To examine residual confounding due 
to the omission of confounding variables from the adjustment model 41, we included 
all potential confounders in the model. 
Because of potential confounding effects due to the presence of cardiovascular 
diseases or related risk factors, the analysis was stratified according to history of 
cardiovascular diseases, hypertension and diabetes. According to a NICE clinical 
guideline lipid modification 42, statins could have been prescribed to patients with 
diabetes mellitus, or low socioeconomic status, or a family history of cardiovascular 
disease or a high-risk ethnicity, regardless of their lipid levels, and therefore; we 
conducted a subgroup analysis in patients with or without a medical history of hyper-
lipidaemia. The incidence of RA progressively increases with age, but steadily 
declines after 65 years 43, and women are two to three times more affected with RA 
than men 43. Therefore, age- and sex-stratified analyses for the evaluation of effect 
modification were carried out. 
Sensitivity analysis
We evaluated the impact of potential case misclassification by changing the definition 
of RA into patients with a first-time diagnosis of RA with a referral to a rheumatologist 
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or one prescription of DMARDs. Secondly, we defined RA as the first-time diagnosis 
of RA with a referral to a rheumatologist, or at least one prescription of DMARDs and/
or at least two prescriptions of corticosteroids, a definition we used in a previous 
study 14. Thirdly, we identified RA as having another medical record of RA after the 
first-time diagnosis 44. 
As previously illustrated by two population-based cohort studies 17, 19, it is advisable 
to take into account a lag time between the onset of RA and the diagnosis. We 
therefore excluded the first year following the initiation of statin treatment. 
Because of potential late manifestation of the clinically apparent symptoms of RA, we 
considered the date of RA exactly one year before the first-time diagnosis of RA as 
suggested by Jick et al.16. 
Lastly, by limiting bias due to ‘peeking into the future’, we considered patients as 
having RA when they were treated with at least one prescription of a DMARD and 
referred to a rheumatologist within a time span of two years after their first-time 
diagnosis.
RESULTS
After excluding 40 320 patients who were younger than 40 years, 31 460 patients with 
a medical history of RA and 12 968 patients with prescriptions of DMARDs before the 
index date, 511 620 statin users and 511 620 non-users were enrolled in the study 
(Figure 2). Due to matching, statin users and non-users had similar distributions of 
age (statin users: mean age, 63.0 years and non-users: mean age, 62.8 years) and 
sex (statin users and non-users: 48% women). Statin users were more often diagnosed 
with cardiovascular diseases, hyperlipidaemia, hypertension, diabetes and cerebro-
vascular events. Remarkably, smoking was not different between statin users and 
non-users. However, ex-smoking was higher in statin users than non-users. Based 
on the high prevalence of cardiovascular risk factors and/or disease in statin users, 
aspirin, anti-hypertensive and anti-diabetic agents were more prescribed in statin 
users compared to non-users. Furthermore, statin users were more likely to have 
used NSAIDs, PPIs, antibiotics and antidepressants than non-users. The baseline 
characteristics of the statin users and non-users are presented in Table 1.
Current users did not show a risk of developing RA (HRadj, 1.08; 95% CI, 0.94 to 1.24) 
(Table 2). However, current statin users who continued the therapy for ≤ 1 year had a 
1.3-fold increased risk of developing RA, adjusted (adj) HR, 1.29; 95% CI, 1.08 to 
1.55.  The HRadj for ‘de novo’ users and ‘restart’ users were 1.01; (95% CI, 0.87 to 1.17) 
and 1.18; (95% CI, 1.01 to 1.38), respectively.  Restart users who continued the therapy 
for ≤ 1 year had also a 1.3-fold increased risk of RA (HRadj, 1.25; 95% CI, 1.03 to 1.53) 
108
CHAPTER 3.2
whereas ‘de novo’ users showed no risk of developing RA (HRadj, 1.17; 95% CI, 0.95 
to 1.44). Risk of RA was 1.4-fold increased with recent statin use, as compared to 
non-users (HRadj, 1.41; 95% CI, 1.12 to 1.79). No association was found between past 
statin users and incident RA.
Figure 3 shows that the risk of RA was substantially increased in the first year after 
the first prescription of statins compared to non-users. The HRadj was 2.96 (95% CI, 
2.51 - 3.49). After one year of statin exposure, the risk of RA declined to baseline level 
(> 1 year: HRadj, 0.92; 95% CI, 0.69 – 1.23). Similar results were obtained when we 
included all potential confounders in our model.
Figure 2   Flow chart Study population. 
CPRD, Clinical Practice Research Datalink; RA, rheumatoid arthritis; DMARD, disease modifying anti-
rheumatic drug 
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Table 1   Baseline characteristics of statin users and non-users
Baseline characteristics Statin users 
(n = 511 620)
Non-users
(n = 511 620 )
Duration of follow-up (years)
Mean (SD) 3.4 (2.5) 3.1 (2.6)
Sex, n (%)
Women 244 870 (47.9) 244 870 (47.9)
Age (years)
Mean (SD) 63.0 (12.1) 62.8 (12.5)
Age by category, years (%)
40-49 69 713 (13.6) 74 284 (14.5)
50-59 147 001 (28.7) 156 841 (30.7)
60-79 237 736 (46.5) 216 749 (42.4)
80+ 57 170 (11.2) 63 746 (12.4)
BMI (kg/m2)
Mean (SD) 26.9 (8.4) 21.0 (11.6)
Smoking status, n (%)
Non-smoker 213 102 (41.7) 230 927 (45.1)
Ex-smoker 161 885 (31.6) 109 645 (21.5)
Smoker 114 085 (22.3) 99 340 (19.4)
Unknown smoking status 22 548 (4.4) 71 708 (14.0)
Drinking status, n (%)
Non-drinker 63 872 (12.5) 53 309 (10.4)
Ex-drinker 32 104 (6.3) 20 384 (4.0)
Drinker 352 827 (68.9) 317 067 (62.0)
Unknown drinking status 62 817 (12.3) 120 860 (23.6)
Drug use within previous 6 months, n (%)
Antihypertensive agents 317 494 (62.1) 121 220 (23.7)
Fibrates 8 436 (1.6) 881 (0.2)
Ezetimibe 1 943 (0.4) 130 (0.03)
Anti-diabetic agents 120 353 (23.5) 18 200 (3.6)
Anti-arrhythmic agents 20 207 (3.9) 11 051 (2.2)
Aspirin 142 209 (27.8) 36 003 (7.0)
NSAIDs 197 750 (38.7) 86 106 (16.8)
Proton pump inhibitors 82 939 (16.2) 46 820 (9.2)
Hormone replacement therapy or oral contraceptives 21 219 (4.1) 20 598 (4.0)
Oral corticosteroids 16 815 (3.3) 14 684 (2.9)
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In Table 3, we present several potential factors that may have influenced the risk of 
developing RA after statin exposure. We found an effect modification by sex. In 
women, current and recent statin use was associated with incident RA, whereas no 
associations were found in men. The effect of developing RA in women who currently 
used statins was only observed in the first year of current statin use. We only observed 
an increased risk of developing RA in patients without a medical record of hyperlipi-
daemia, hypertension and diabetes who currently used statins for less than one year 
or who were recent users. No other effect modifiers for the association between 
current, recent and past statin exposure and incident RA were found. 
Table 1   Continued
Baseline characteristics Statin users 
(n = 511 620)
Non-users
(n = 511 620 )
Drug use within previous 6 months, n (%)
Antibiotics 46 267 (9.0) 35 564 (7.0)
Anticonvulsants 10 648 (2.1) 7 957 (1.6)
Antipsychotics 5 355 (1.0) 6 025 (1.2)
Antidepressants 113 390 (22.2) 93 400 (18.3)
History of disease ever before, n (%)
Hypertension* 317 523 (72.4) 194 097 (33.2)
Hyperlipidaemia 151 380 (29.6) 12 492 (2.4)
Diabetes† 120 681 (23.6) 18 355 (3.6)
Cardiovascular diseases 171 581 (33.5) 46 357 (9.1)
     Stroke or TIA 52 336 (10.2) 13 671 (2.7)
Psoriasis 19 719 (3.9) 16 212 (3.2)
Inflammatory bowel disease 5 074 (1.0) 5 034 (1.0)
Cancer 34 369 (6.7) 39 229 (7.7)
Thyroid Disease 52 212 (10.2) 35 735 (7.0)
COPD 20 583 (4) 20 283 (4)
Asthma 60 252 (11.8) 52 152 (10.2)
Dementia 4 937 (1.0) 8 342 (1.6)
Depression 71 029 (13.9) 48 201 (9.4)
NSAIDs, non-steroidal anti-inflammatory drugs; COPD, Chronic Obstructive Pulmonary Disease; 
TIA, Transient Ischaemic Attack; SD, standard deviation
* Diagnosis of hypertension or use of antihypertensive agents 
† Diagnosis of diabetes mellitus or use of anti-diabetic therapy 
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Table 2   Risk of rheumatoid arthritis in statin users compared to non-users 
RA
(n)
IR * age- and sex-adjusted
HR (95% CI)
fully adjusted
HR (95% CI) †
No statin use 579 3.7 1.00 1.00
Past statin use 105 4.9 1.33 (1.08 – 1.64) 1.20 (0.96 – 1.49)
Recent statin use 101 5.6 1.60 (1.27 – 2.02) 1.41 (1.12 – 1.79)
Current statin use 837 4.3 1.24 (1.10 – 1.38) 1.08 (0.94 – 1.24)
  ≤ 1 year 386 11.5 1.47 (1.25 – 1.73) 1.29 (1.08 – 1.55)
  > 1 year 451 2.8 1.15 (1.02 – 1.31) 1.00 (0.86 – 1.16)
‘de novo’ statin use 464 4.1 1.16 (1.02 – 1.31) 1.01 (0.87 – 1.17) 
  ≤ 1 year 172 15.8 1.33 (1.10 – 1.61) 1.17 (0.95 – 1.44)
  > 1 year 292 2.9 1.09 (0.95 – 1.26) 0.94 (0.80 – 1.11)
‘restart’ statin use 373 4.7 1.34 (1.17 – 1.54) 1.18 (1.01 – 1.38)
  ≤ 1 year 214 9.4 1.42 (1.19 – 1.70) 1.25 (1.03 – 1.53)
  > 1 year 159 2.8 1.27 (1.06 – 1.52) 1.10 (0.91 – 1.34)
RA, rheumatoid arthritis; IR, incidence rate (per 10 000 person-years); HR, hazard ratio; CI, confidence interval
*  Incidence rate is calculated for each recency of statin use by dividing the number of events by the person 
time within each given recency of use.
†  Adjusted for age, sex, smoking, cardiovascular diseases, hyperlipidaemia, hypertension, diabetes and 
use of non-steroid anti-inflammatory drugs. 
Figure 3   Risk of rheumatoid arthritis in current statin users versus non-users,  
by time since the first statin prescription. 
Solid bold line and circles: adjusted hazard ratios. Solid lines: 95% confidence bands.
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Performing different sensitivity analyses did alter our findings slightly. However, when 
we depicted the five patterns of changes in the risk of RA during current statin use, no 
differences in the patterns of the five sensitivity analyses were observed. Only, the 
sensitivity analysis where we excluded the first year after initiation of statin treatment, 
the pattern of risks of RA during statin use was slightly attenuated. No difference in 
the risk of developing RA was observed between current users who continued the 
Table 3   Confounding and modifying effects of rheumatoid arthritis risk in statin users vs. non-users
adjusted HR (95% CI)†
RA IR* Past statin use Recent statin use Current statin use Current statin use Current statin use
(n) ≤ 1 year > 1 year
By age, y
40-50 131 2.6 2.17 (0.91 – 4.32) 1.60 (0.66 – 3.86) 1.31 (0.76 – 2.26) 1.07 (0.54 – 2.15) 1.41 (0.80 – 2.50)
51-60 475 4.1 1.13 (0.76 – 1.70) 1.63 (1.06 – 2.50) 0.96 (0.73 – 1.25) 1.31 (0.93 – 1.84) 0.82 (0.61 – 1.10)
61-80 938 5.1 1.09 (0.81 – 1.48) 1.21 (0.87 – 1.69) 1.02 (0.85 – 1.22) 1.23 (0.97 – 1.56) 0.95 (0.78 – 1.15)
>80 78 2.0 1.23 (0.51 – 2.94) 1.51 (0.59 – 3.88) 0.95 (0.53 – 1.71) 1.08 (0.52 – 2.25) 0.87 (0.45 – 1.69)
By sex
Women 1 021 5.4 1.21 (0.92 – 1.58) 1.71 (1.27 – 2.31) 1.19 (1.00 – 1.42) 1.51 (1.20 – 1.91) 1.08 (0.90 – 1.31)
Men 601 3.0 1.21 (0.83 – 1.74) 1.00 (0.66 – 1.52) 0.90 (0.71 – 1.14) 1.00 (0.75 – 1.33) 0.86 (0.67 – 1.10)
By any previous history of disease
No previous cardiovascular disease 1 138 3.9 1.26 (0.99 – 1.62) 1.37 (1.02 – 1.84) 1.02 (0.86 – 1.20) 1.21 (0.97 – 1.50) 0.93 (0.77 – 1.12)
Previous cardiovascular disease 484 4.8 0.96 (0.59 – 1.57) 1.33 (0.83 – 2.12) 1.06 (0.76 – 1.47) 1.28 (0.87 – 1.90) 0.98 (0.70 – 1.39)
No previous cardiovascular risk factor‡ 649 4.0 1.20 (0.83 – 1.75) 1.55 (1.02 – 2.35) 1.06 (0.85 – 1.33) 1.40 (1.05 – 1.88) 0.86 (0.65 – 1.14)
Previous cardiovascular risk factor 973 4.3 1.06 (0.80 – 1.41) 1.20 (0.88 – 1.62) 0.95 (0.78 – 1.15) 1.10 (0.86 – 1.39) 0.90 (0.74 – 1.10)
No previous hyperlipidaemia 1 254 4.1 1.13 (0.87 – 1.47) 1.62 (1.23 – 2.12) 1.07 (0.92 – 1.25) 1.23 (1.00 – 1.50) 1.00 (0.85 – 1.18)
Previous hyperlipidaemia 368 4.5 1.71 (0.82 – 3.54) 1.41 (0.65 – 3.07) 1.47 (0.75 – 2.88) 1.92 (0.94 – 3.92) 1.34 (0.68 – 2.64)
No previous hypertension 857 4.1 1.27 (0.94 – 1.72) 1.31 (0.92 – 1.87) 1.14 (0.94 – 1.39) 1.53 (1.19 – 1.96) 0.96 (0.77 – 1.20)
Previous hypertension 765 4.3 0.99 (0.72 – 1.37) 1.30 (0.92 – 1.82) 0.89 (0.72 – 1.10) 0.96 (0.74 – 1.26) 0.86 (0.69 – 1.08)
No previous diabetes 1 394 4.2 1.19 (0.94 – 1.50) 1.42 (1.09 – 1.85) 1.09 (0.94 – 1.26) 1.34 (1.10 – 1.62) 0.99 (0.84 – 1.16)
Previous diabetes 228 4.1 1.11 (0.52 – 2.34) 1.14 (0.55 – 2.38) 0.90 (0.50 – 1.60) 0.92 (0.49 – 1.75) 0.88 (0.49 – 1.60)
RA, rheumatoid arthritis; IR, incidence rate (per 10 000 person-years); HR, hazard ratio; CI, confidence interval
*  Incidence rate is calculated for each recency of statin use by dividing the number of events by the person 
time within each given recency of use.
† Adjusted for confounders as shown in table 2.
‡ Cardiovascular risk factor included previous hyperlipidaemia, hypertension and diabetes.
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therapy for ≤ 1 year and >1 year. The results of the six sensitivity analyses are presented 
online (Appendix 1).
Table 3   Confounding and modifying effects of rheumatoid arthritis risk in statin users vs. non-users
adjusted HR (95% CI)†
RA IR* Past statin use Recent statin use Current statin use Current statin use Current statin use
(n) ≤ 1 year > 1 year
By age, y
40-50 131 2.6 2.17 (0.91 – 4.32) 1.60 (0.66 – 3.86) 1.31 (0.76 – 2.26) 1.07 (0.54 – 2.15) 1.41 (0.80 – 2.50)
51-60 475 4.1 1.13 (0.76 – 1.70) 1.63 (1.06 – 2.50) 0.96 (0.73 – 1.25) 1.31 (0.93 – 1.84) 0.82 (0.61 – 1.10)
61-80 938 5.1 1.09 (0.81 – 1.48) 1.21 (0.87 – 1.69) 1.02 (0.85 – 1.22) 1.23 (0.97 – 1.56) 0.95 (0.78 – 1.15)
>80 78 2.0 1.23 (0.51 – 2.94) 1.51 (0.59 – 3.88) 0.95 (0.53 – 1.71) 1.08 (0.52 – 2.25) 0.87 (0.45 – 1.69)
By sex
Women 1 021 5.4 1.21 (0.92 – 1.58) 1.71 (1.27 – 2.31) 1.19 (1.00 – 1.42) 1.51 (1.20 – 1.91) 1.08 (0.90 – 1.31)
Men 601 3.0 1.21 (0.83 – 1.74) 1.00 (0.66 – 1.52) 0.90 (0.71 – 1.14) 1.00 (0.75 – 1.33) 0.86 (0.67 – 1.10)
By any previous history of disease
No previous cardiovascular disease 1 138 3.9 1.26 (0.99 – 1.62) 1.37 (1.02 – 1.84) 1.02 (0.86 – 1.20) 1.21 (0.97 – 1.50) 0.93 (0.77 – 1.12)
Previous cardiovascular disease 484 4.8 0.96 (0.59 – 1.57) 1.33 (0.83 – 2.12) 1.06 (0.76 – 1.47) 1.28 (0.87 – 1.90) 0.98 (0.70 – 1.39)
No previous cardiovascular risk factor‡ 649 4.0 1.20 (0.83 – 1.75) 1.55 (1.02 – 2.35) 1.06 (0.85 – 1.33) 1.40 (1.05 – 1.88) 0.86 (0.65 – 1.14)
Previous cardiovascular risk factor 973 4.3 1.06 (0.80 – 1.41) 1.20 (0.88 – 1.62) 0.95 (0.78 – 1.15) 1.10 (0.86 – 1.39) 0.90 (0.74 – 1.10)
No previous hyperlipidaemia 1 254 4.1 1.13 (0.87 – 1.47) 1.62 (1.23 – 2.12) 1.07 (0.92 – 1.25) 1.23 (1.00 – 1.50) 1.00 (0.85 – 1.18)
Previous hyperlipidaemia 368 4.5 1.71 (0.82 – 3.54) 1.41 (0.65 – 3.07) 1.47 (0.75 – 2.88) 1.92 (0.94 – 3.92) 1.34 (0.68 – 2.64)
No previous hypertension 857 4.1 1.27 (0.94 – 1.72) 1.31 (0.92 – 1.87) 1.14 (0.94 – 1.39) 1.53 (1.19 – 1.96) 0.96 (0.77 – 1.20)
Previous hypertension 765 4.3 0.99 (0.72 – 1.37) 1.30 (0.92 – 1.82) 0.89 (0.72 – 1.10) 0.96 (0.74 – 1.26) 0.86 (0.69 – 1.08)
No previous diabetes 1 394 4.2 1.19 (0.94 – 1.50) 1.42 (1.09 – 1.85) 1.09 (0.94 – 1.26) 1.34 (1.10 – 1.62) 0.99 (0.84 – 1.16)
Previous diabetes 228 4.1 1.11 (0.52 – 2.34) 1.14 (0.55 – 2.38) 0.90 (0.50 – 1.60) 0.92 (0.49 – 1.75) 0.88 (0.49 – 1.60)
RA, rheumatoid arthritis; IR, incidence rate (per 10 000 person-years); HR, hazard ratio; CI, confidence interval
*  Incidence rate is calculated for each recency of statin use by dividing the number of events by the person 
time within each given recency of use.
† Adjusted for confounders as shown in table 2.
‡ Cardiovascular risk factor included previous hyperlipidaemia, hypertension and diabetes.
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DISCUSSION
This study demonstrated a 1.3-fold increased risk of developing RA during the first 
year of statin use. The risk of developing RA was increased shortly after the first 
prescription of statins and then gradually decreased to baseline level. The risk of RA 
was highest among women and restart users. In recent users, statin use was 
associated with incident RA whereas in past users no such effect was found.
Two population-based cohort studies showed no association between statin use and 
the risk of developing RA18, 19. In a nested case-control study of 313 incident RA 
patients and 1 252 matched controls, no association between current statin use and 
incident RA was found 16. The same study showed, however, in a subsample of only 
patients with hyperlipidaemia a decreased risk of developing RA in current users 16. 
We found no association between statin use and incident RA in patients with hyper-
lipidaemia. However, these conflicting results may be explained by differences in 
controlling for confounders. In addition to the matching factors, we adjusted for 
cardiovascular disease, hypertension, diabetes and smoking whereas Jick et al. 
adjusted only for smoking 16.
In a population-based cohort study of 211 627 new statin users, statin use was 
associated with a reduction in the risk of developing RA. This effect was only present 
for those who used statins for more than one year 17. In contrast, we found no 
association between statin use and incident RA in current users who continued statin 
therapy for more than one year. In a propensity score matched cohort study of 6 956 
pairs of statin users and non-users, statin use was associated with a lower risk of 
CTD20. The possible protective effect of statins was not observed in our study. The 
discrepancies may be partially explained by the difference in defining statin exposure 
and RA. We classified statin exposure by the recency of use, and modelled it as a 
time-dependent variable. Chodick et al. defined statin exposure as the mean proportion 
of follow-up days covered with statins 17, whereas Schmidt et al. defined statin use as 
receiving at least a 90-day supply at baseline 20. Our definition of RA may have been 
more specific than the one used by the other two studies 17, 20. We verified patients’ 
electronic records with at least one prescription of DMARDs after the diagnosis of 
RA. In the study by Chodick et al., patients were included when they had a diagnostic 
code for RA with or without the use of DMARDs 17, whereas Schmidt et al. included 
patients with CTD, including RA 20.  By using a more specific definition of RA, we may 
have attenuated the association between statin use and incident RA.
In our previous study 14, we found an increased risk of developing RA within six 
months of statin use, which is in line with the results of the present study. In this study, 
we found that the risk of developing RA disappeared after one year. Statins may 
accelerate the onset of RA in patients susceptible to develop RA as previously 
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demonstrated by an animal model of arthritis 15. In line with this hypothesis, the 
majority of cases of statin-associated lupus-like syndrome developed this syndrome 
within one year after starting statin therapy 11. However, in patients not prone to 
develop RA, statins are probably safe and well tolerated, even after prolonged use. 
This could also explain the difference in the risk of developing RA in ‘de novo’ and 
‘restart’ users. It may be that ‘de novo’ users were patients who can tolerate statins 
whereas ‘restart’ users were patients who were less likely to be fully adherent to 
statins because of potential discomfort or side effects. Another explanation could be 
our observed effect modification by sex: men were not at risk whereas women were 
at high risk for developing RA. It has already been shown before, that women are 
more prone to developing RA43, 45.
RA may have been present and not well documented before the start of statins. In 
both our studies, we defined the onset date of RA by the first record or specialist 
referral. Unfortunately, the onset date of symptoms is unknown in our studies. One 
study reported a median time between onset of symptoms to diagnosis of RA of 
approximately 36 weeks (range: 4 weeks to >10 years) 46. As two population-based 
studies considered a lag-time of one year between statin use and incident RA 17, 19, 
we performed an analysis where we excluded the first year following the initiation of 
statin treatment. We found no increased risk of RA in the first year after the initiation 
of statin treatment. However, the descriptive analysis showed a similar pattern of risks 
of RA during statin use but was slightly attenuated.
Importantly, cardiovascular risk factors (e.g. hyperlipidaemia) may have influenced 
the association between statin use and incident RA. Several studies have 
demonstrated an unfavourable lipid profile in patients with RA 21, 27 Hyperlipidaemia 
may induce leukocyte activation and possibly complement activation, 47–49 which 
may result in an earlier diagnosis of RA in patients prone to develop RA. When we 
conducted subgroup analyses in patients with and without these recorded 
cardiovascular risk factors, no differences in the risk of developing RA between these 
two groups were observed.
Strengths of this study include its large sample size, representativeness of the 
population, completeness of follow-up and information on matched controls, and 
detailed information on confounders, such as smoking status was available 25, 36. We 
had the opportunity to use routinely recorded medical and prescription data from 
GPs. Consequently, recall bias was minimised. 
Some drawbacks of our study should be considered. Firstly, the information about 
statin exposure was based on prescription data rather than on actual drug use, which 
could have resulted in an overestimation of statin use. 
Secondly, we may have used a relatively sensitive, but non-specific, diagnosis of RA 
as we had limited information on rheumatoid factor and anti-cyclic citrullinated 
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peptide antibodies 28. In this study, we have used the diagnostic algorithm as 
postulated by Thomas et al. 35. The proposed diagnostic algorithm resulted in a 
diagnostic specificity of 96% 35. By applying this diagnostic algorithm, we believe we 
have used a relatively accurate diagnosis of RA. Furthermore, we performed a range 
of sensitivity analyses regarding the definition of RA. All these analyses consistently 
showed similar results. 
Thirdly, no data on dietary intake, physical activity, and limited data were available on 
other examinations such as lipid, blood pressure and glucose levels, and inflammatory 
markers (e.g. C-reactive protein), which may be important confounders. Especially, in 
the subgroup analyses based on the cardiovascular risk factors, lack of clinical data 
may have affected our results. It is likely that we have included patients with high lipid, 
glucose or high blood pressure levels in the group of patients without a medical 
history of hyperlipidaemia, hypertension or diabetes. 
Fourthly, ascertainment bias may have been present in our study because patients 
starting statin therapy may have a careful follow-up, including visits to the GP and 
blood tests, thereby increasing the likelihood of detecting more abnormalities (e.g. 
RA) than non-users 18, 50. 
Fifth, the increased risk of RA in the first year after the initiation of statin therapy may 
be explained by detection bias, as some patients initiating statin therapy may 
experience myalgia or other muscle-related adverse effects;51 they may tend to visit 
their GP more often, be more likely to be referred to a rheumatologist and may have 
been more carefully examined, and therefore; these patients may be more likely to be 
diagnosed with RA.
To our knowledge, this is the first study evaluating risks of RA in current statin users 
over time. In patients who use statins, the risk of RA is substantially increased in the 
first year after initiation of statins and then diminishes to baseline. The risk of RA was 
highest among women and restart users. These findings suggest that statins can 
accelerate disease onset in patients (genetically) susceptible to develop RA. The 
alternative explanation for this increased risk of RA shortly after starting statins is 
ascertainment or detection bias with increased diagnostic monitoring around the 
time of initiation of statin therapy. Although more research is needed, this study 
supports our previous finding, showing an increased risk of developing RA shortly 
after starting statin treatment.
What is already known on this topic
· Six other studies have assessed the risk of developing RA or connective tissue 
diseases during statin treatment, and have shown conflicting results.
· It is not clear to what extent the association between statin use and the risk of 
developing RA is related to statins or to co-occurring hyperlipidaemia. 
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· None of the previous six studies described the pattern of risks of RA (hazard rates) 
with changes in statin exposure over time.
What this study adds
· The risk of developing RA is substantially increased in the first year after the start of 
statin therapy; no increased risk is found during follow-up of statin treatment. 
· The risk of RA was highest among women and restart users.
· This suggests that statins can accelerate disease onset in patients (genetically) 
susceptible to develop RA, as has been found by us in an animal model of arthritis. 
· An alternative explanation for our findings is ascertainment or detection bias with 
increased diagnostic monitoring around the time of initiation of statin therapy.
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ABSTRACT
Purpose
Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers 
(ARBs) are effective in the treatment of cardiovascular disease. Next to effects on 
hypertension and cardiac function, these drugs have anti-inflammatory and immuno-
modulating properties which may either facilitate or protect against the development 
of autoimmunity, potentially resulting in autoimmune diseases. Therefore, we determined 
in the current study the association between ACE inhibitor and ARB use and incident 
rheumatoid arthritis (RA).
Methods 
A matched case-control study was conducted among patients treated with anti- 
hypertensive drugs using the Netherlands Information Network of General Practice 
(LINH) database in 2001-2006. Cases were patients with a first-time diagnosis of RA. 
Each case was matched to five controls for age, sex, and the index date, which was 
selected one year before the first diagnosis of RA. ACE inhibitor and ARB exposure 
was considered to be any prescription issued in the period before the index date. 
Logistic regression analysis was used to estimate odds ratios (ORs) and their 95% 
confidence intervals (CI).
Results 
Our study included 211 cases and 667 matched controls. After controlling for potential 
confounders, ever use of ACE inhibitors or ARBs was not associated with incident RA 
(adjusted ORs, 0.99 (95% CI 0.55 to 1.79) and 1.02 (95% CI 0.67 to 1.56), respectively). 
The adjusted ORs for current and past use of ACE inhibitors were 1.18 (95% CI 0.75 
to 1.85) and 0.61 (95% CI 0.28 to 1.35). For current and past use of ARBs, these 
adjusted ORs were 1.40 (95% CI 0.80 to 2.45) and 0.29 (95% CI 0.05 to 1.67), 
respectively. No duration and dose-effect relationship was observed.
Conclusions 
ACE inhibitor or ARB use is not associated with incident RA.
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INTRODUCTION
Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers 
(ARBs) have been reported to reduce mortality and morbidity from cardiovascular 
events among patients with hypertension, renal, and cardiovascular diseases 1–7. 
In addition to their effects on blood pressure, cardiac function, and antiproteinuric 
effect, ACE inhibitors and ARBs have anti-inflammatory and immunomodulating 
properties 8–11. Open-label studies with rheumatoid arthritis (RA) patients and 
experimental studies in collagen-induced arthritis suggested a beneficial effect of 
ACE inhibitors and ARBs in arthritis 12–15. Similarly, ACE inhibitors and ARBs reduce 
the incidence and severity of experimental autoimmune myocarditis 16. Otherwise, it 
has been postulated that the immunomodulating effects of ACE inhibitors may 
facilitate autoimmune responses 17,18. Indeed, several case reports have suggested 
that ACE inhibitors may facilitate the development of autoantibodies 19–21 and 
autoimmune diseases such as lupus-like syndrome, vasculitis and pemphigus 22–42. 
Furthermore, one patient with ARB-associated pemphigus has been reported 43.
The proposed mechanisms by which ACE inhibitors or ARBs may facilitate and be 
protective for RA are unclear. The anti-inflammatory effects of ACE inhibitors and 
ARBs are likely due to changes in cellular immunity 8 and to inhibiting adhesion 
molecule upregulation, chemotaxis, and the release of cytokines by immune 
cells44–46. As a result, ARBs and ACE inhibitors may interfere with leukocyte- 
endothelial cell adhesion and thereby prevent the influx of inflammatory cells in the 
inflamed synovial membrane and at the cartilage-pannus junction.
Importantly, Shao et al. showed in a study with angiotensin-II-infused hypertensive 
rats elevated levels of the T helper (Th) cells 1 cytokine interferon-γ and decreased 
levels of Th2 cytokine IL-4. By administering in these rats an ARB, the imbalance of 
Th subsets was corrected 47. Furthermore, Platten et al. demonstrated in an animal 
model of experimental autoimmune encephalitis, mimicking multiple sclerosis, that 
ACE inhibitors modulate this disease by suppressing autoreactive Th1 and Th17 cells 
and promoting T-regulatory cells 8. Otherwise, Coelho dos Santos et al. found that 
ACE inhibitors increase the intensity of Trypanosoma cruzi infection of human 
monocytes and decreases the expression of the modulatory cytokine IL-10 while 
inducing Th17 cells 17 and hence may promote RA, psoriasis and psoriatic arthritis 
48–50. Finally, studies have shown that captopril blocks activation-induced apoptosis 
in T cells 18,51 and hence may interfere with clonal deletion and disturb the maintenance 
of self-tolerance, thus facilitating autoimmunity 17,18.
The objective of our study was to investigate whether the use of ACE inhibitors or 
ARBs increase or decrease incident RA in a large observational study.
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METHODS
Study population
Data for this study were obtained from the Netherlands Information Network of 
General Practice (LINH), a database derived from general practices that records data 
on morbidity, drug prescriptions and referrals on a continuous basis in electronic 
medical records. The LINH includes 350 000 patients who were registered at 85 
practices from 2001 through 2006 52. Prescription data were classified according to 
the Anatomical Therapeutic and Chemical (ATC) classification 53, and morbidity was 
coded by using the International Classification of Primary Care (ICPC) scheme 54. 
The study was carried out according to Dutch legislation on privacy. The privacy 
regulation of the study was approved by the Dutch Data Protection Authority. 
According to Dutch legislation, neither obtaining informed consent nor approval by a 
medical ethics committee is obligatory for observational studies.
Study design
We performed a nested, matched case-control study among patients treated with 
anti-hypertensive drugs. Under our definition of anti-hypertensive drugs, we included 
miscellaneous anti-hypertensive drugs (ATC code C02), thiazide diuretics (ATC code 
C03), beta blocking agents (ATC code C07), calcium channel blockers (ATC code 
C08), ACE inhibitors (ATC code C09A/C09B), and ARBs (ATC code C09C/C09D).
Case definition
All patients who were first diagnosed with RA and were registered with a general 
practitioner (GP) for at least one year at the index date were included in the study. 
Subsequent diagnoses of RA were disregarded. The date exactly one year before the 
date of first-time diagnosis of RA was subsequently used as the index date, because 
the diagnosis is usually made after the disease has been symptomatic for some 
period 55,56. When the index date was shifted one year before the first-time diagnosis 
of RA, patients still had to have a medical history of at least one year before this new 
index date. Patients were considered as having a diagnosis of RA if the first-time 
diagnosis registered by GP was verified by a referral to a rheumatologist by the use 
of at least one prescription of disease modifying anti-rheumatoid drug (DMARD) or 
two or more prescriptions of systemic corticosteroids after the index date 57.
Patients were excluded from the study if they had a medical record of ankylosing 
spondylitis (ICPC code L88.2) or received at least one prescription of DMARDs 
before the index date, if they had a diagnosis of RA by the GP with no confirmation 
according to the mentioned criteria, or if they had no registered medical history for 
one year 57.
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Control selection
Of the anti-hypertensive drug users, five controls were matched to each RA case on 
age (within five years), sex and the index date. Controls were required to be registered 
at least one year in the general practice before the index date to minimise information 
bias. The exclusion criteria used in case selection were applied to controls.
Definition of exposure
Using data on prescription dispensing date and days supplied, we determined the 
exposure to ACE inhibitors and ARBs for each patient in the study. All the patients 
were users of at least one anti-hypertensive drug. Current use was defined as 
receiving at least one prescription of ACE inhibitors and ARBs within six months 
before the index date, and past use was defined as receiving a prescription of ACE 
inhibitors and ARBs but discontinued treatment more than six months before the 
index date. Patients, who were current or past users of ACE inhibitors and ARBs 
simultaneously, were categorised as a separate group. Patients who were not users 
of ACE inhibitors or ARBs but were users of another anti-hypertensive drug such as 
thiamine diuretics, calcium antagonists and beta blockers were used as the reference 
category. The expected duration of ACE inhibitor and ARB use until the index date 
was based on treatment time and prescribed drug supply (determined by the number 
of prescribed tablets), and was divided into three categories: [1] 1-365 days, [2] 
366-1095 days, and [3] more than 1095 days. We calculated the dose of ACE 
inhibitors and ARBs according to the defined daily dose (DDD), which is the average 
daily dose of a drug for its main indication in adults 51 (1 DDD corresponds with 
captopril 50 mg, enalapril 10 mg, lisinopril 10 mg, perindopril 4 mg, ramipril 2.5 mg, 
quinapril 15 mg, fosinopril 15 mg, losartan 50 mg, valsartan 80 mg, irbesartan 0.15 g, 
candesartan 8 mg, telmisartan 40 mg and olmesartan medoxomil 20 mg). Based on 
almost equal distributions of ACE inhibitor and ARB use, ACE inhibitor exposure was 
categorised into three categories of less than 0.75 DDD per day, 0.75-1.25 DDD per 
day, and more than 1.25 DDD per day, and ARB exposure was categorised as less 
than 1.0 DDD per day and more than 1.0 DDD per day to assess a potential 
dose-response relationship.
Potential confounders
Potential confounders included prescriptions within six months preceding the index 
date for non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, proton 
pump inhibitors, statins, aspirin, antibiotics, hormone replacement therapy, anti-
depressants, calcium antagonists and thiazide diuretics, and co-morbidities including 
diabetes, hyperlipidaemia, cardiovascular disease and chronic obstructive pulmonary 
disease (COPD) 58. Patients were classified as diabetic when they had a diagnosis of 
diabetes (identified by ICPC codes T89 or T90) or when they received anti-diabetic 
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therapy before the index date. Hyperlipidaemia was considered present when the 
patient had a medical record of hyperlipidaemia (identified by ICPC code T93) or 
used lipid-lowering drugs prior to the index date. COPD and cardiovascular disease 
were identified by ICPC code R95 and ICPC codes K71, K73–K84, K89, K90, K92-K96 
and K99, respectively.
Statistical analysis
Continuous variables were expressed as mean ± standard deviation, and categorical 
variables were expressed as frequencies and percentages. For baseline characteristics, 
continuous data were analysed by Student’s t test and categorical data by Chi-square 
test or Fisher exact test when appropriate. Logistic regression conditioned on the 
matching factors was used to study the association between ACE inhibitor and ARB 
use and the risk of RA. Odds ratios and 95% confidence intervals (95% CIs) were 
estimated. We evaluated the effects of ever use, current and past use, and specific 
type, duration and DDDs of ACE inhibitor and ARB on the risk of developing RA. In 
addition to controlling for age, sex and calendar time by matching, estimates were 
adjusted for the mentioned confounders. Furthermore, we evaluated the confounding 
effects of aspirin, statins, antibiotics, hormone replacement therapy, corticosteroids, 
antidepressants and thiazide diuretics, and diabetes, hyperlipidaemia and COPD, 
but we did not include these covariates in the regression models because we did not 
observe more than 10% change in the estimate of the exposure-outcome association 
by adding each time one of these variables into the model 59. A p value of ≤0.05 was 
considered statistically significant. We used SAS version 9.2 (SAS Institute, Cary, 
North Carolina, USA) to analyse the data. 
We performed a sensitivity analysis where we investigated the influence of thiazide 
diuretics on the association between ACE inhibitors/ARB and RA because several 
studies have demonstrated the association between thiazide diuretics and 
autoimmune reactions 60,61. To explore the influence of inclusion of prevalent cases 
in the study, we performed two sensitivity analyses where we shifted the index date 
exactly two and three years before the first-time diagnosis of RA. Two sensitivity 
analyses were performed to examine the effect of misclassification of patients by 
changing the definition of the outcome (RA). First, we varied the definition of the 
outcome (RA), specified as first-time diagnosis of RA and a referral to a rheumatologist 
and a prescription of DMARDs after the index date (irrespective of the use of cortico-
steroids), a definition used in another study 62. Second, we investigated the influence 
of the inclusion of patients with psoriatic arthritis and performed an analysis that 
excluded patients with a medical record for psoriasis.
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RESULTS
The study population consisted of 57 457 patients who used at least one prescription 
of anti-hypertensive drugs during the study period from 2001 through 2006. Of those, 
877 patients had a first-time diagnosis of RA. Of these RA patients, 72 patients were 
excluded because they used at least one prescription of DMARDs before the index 
date and 269 patients because they had no minimum registered medical history of 
one year. In addition, 325 patients were excluded from the study because the first-time 
diagnosis of RA by the GP was not confirmed according to the predefined criteria. 
After these exclusions, we identified 211 eligible RA patients that were matched to 
667 controls. 
Characteristics of the study population at the index date are described in Table 1. The 
average age of the study population was 65 years, and approximately 67% were 
women. RA patients used more often corticosteroids, NSAIDs, antidepressants and 
proton pump inhibitors, and were more often diagnosed with COPD than were 
controls. The duration of registration with the GP was approximately 11.2 years in RA 
patients and 10.5 years in controls. 
Table 1   Characteristics of study population at the index date
 
Characteristics Case
 (n = 211)
Control
 (n = 667)
p value*
Mean Age in years (SD) 69.6 ± 11.2 68.3 ± 11.8 NS
Sex (%)
 Male 66 (31.3) 195 (29.2) NS
 Female 145 (68.7) 472 (70.8) NS
Duration registration at general practice in years (%)†
1 – 5.99 53 (25.1) 197 (29.5) NS
6 – 11.99 93 (44.1) 286 (42.9) NS
≥ 12 65 (30.8) 184 (27.6) NS
Disease history before the index date (%)
Hypertension 134 (63.5) 421 (63.1) NS
Diabetes 31 (14.7) 125 (18.7) NS
Cardiovascular disease 95 (45.0) 219 (32.8) 0.001
Hyperlipidaemia 58 (27.5) 165 (24.7) NS
Hepatic disease 6 (2.8) 14 (2.1) NS
Renal disease 4 (1.9) 8 (1.2) NS
COPD 31 (14.7) 27 (4.1) <0.001
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Table 2 shows that ACE inhibitor use or ARB use prior to the index date was not 
associated with incident RA (adjusted odds ratios (ORs), 1.02 (95% CI 0.59 to 1.78)) 
and (adjusted OR, 1.02 (95% CI 0.69 to 1.51)), respectively. The adjusted ORs of 
Table 1   Characteristics of study population at the index date
 
Characteristics Case
 (n = 211)
Control
 (n = 667)
p value*
Disease history before the index date (%)
Cancer 9 (4.3) 33 (5.0) NS
Inflammatory bowel syndrome 2 (0.3) 2 (1.0) NS
Drug use 6 months before the index date (%)
Corticosteroids 34 (16.1) 16 (2.4) <0.001
NSAIDs 71 (33.7) 48 (7.2) <0.001
Anti-hypertensive drugs
Miscellaneous anti-hypertensive drugs 0 (0.0) 8 (1.2) NS
Thiazide diuretics 95 (45.0) 277 (41.5) NS
Beta blockers 95 (45.0) 292 (43.8) NS
Calcium channel blockers 48 (22.8) 109 (16.3) NS
ACE inhibitors 52 (24.6) 155 (23.2) NS
ARBs 32 (15.2) 76 (11.4) NS
Aspirin 28 (13.3) 87 (13.0) NS
Anti-diabetics 23 (10.9) 85 (12.7) NS
Lipid-lowering agents 50 (23.7) 132 (19.8) NS
HRT 7 (3.3) 20 (3.0) NS
Antibiotics 40 (19.0) 83 (12.4) 0.02
Anti-psychotics 1 (0.5) 6 (0.9) NS
Antidepressants 23 (10.9) 33 (5.0) 0.002
PPI 47 (22.3) 52 (7.8) <0.001
NS = not significant; 
SD = standard deviation; 
ACE = angiotensin-converting enzyme; 
ARBs = angiotensin II receptor blockers; 
COPD = chronic obstructive pulmonary disease; 
NSAIDs = non-steroidal anti-inflammatory drugs; 
HRT = hormone replacement therapy; 
PPI = proton pump inhibitors
*  Chi-square test or Fisher’s Exact test for comparison of proportions and Student’s t test for 
comparisons of means between cases and controls. 
†   Duration of registration with a general practitioner was defined by the date of registry at a general 
practice or the first medical record of the patient.
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incident RA associated with current and past use of ACE inhibitors were 1.15 (95% CI 
0.76 to 1.74) and 0.70 (95% CI 0.34 to1.47), respectively. Current and past use of ARBs 
were not associated with incident RA (adjusted ORs, 1.39 (95% CI 0.82 to 2.33) and 
0.29 (95% CI 0.06 to 1.96), respectively). In addition, current use and past use of the 
combination therapy of ACE inhibitors and ARBs were not associated with incident RA. 
No relation between the duration and intensity of use of ACE inhibitors or ARBs, 
expressed as days of use and numbers of DDD, and the risk of developing RA was 
observed (Table 3). Stratifying results according to the type of ACE inhibitor and ARB 
use showed no risk differences between ACE inhibitor or ARB users and non-users 
(data not shown).
Table 2   Association between use of angiotensin-converting enzyme inhibitors 
and angiotensin II receptor blockers and the risk of rheumatoid arthritis
Cases
(n = 211)
Controls
(n = 667)
Crude OR  
(95% CI)
Adjusted OR§  
(95% CI)
Other anti-hypertensive drugs* 113 373 1.00 (reference) 1.00 (reference)
Ever use
ACE inhibitors 61 195 1.10 (0.66 – 1.82) 1.02 (0.59 – 1.78)
ARBs 24 74 1.07 (0.75 – 1.54) 1.02 (0.69 – 1.51)
ACE inhibitors/ ARBs 13 25 1.87 (0.91– 3.82) 1.62 (0.74 – 3.52)
Current use†
ACE inhibitors 50 150 1.12 (0.76 – 1.65) 1.15 (0.76 – 1.74)
ARBs 30 71 1.44 (0.89 – 2.32) 1.39 (0.82 – 2.33)
ACE inhibitors/ARBs 2 5 1.29 (0.24 – 6.80) 0.95 (0.17 – 5.45)
Past use‡
ACE inhibitors 13 47 1.00 (0.52 – 1.94) 0.70 (0.34 – 1.47)
ARBs 2 15 0.46 (0.10  – 2.04) 0.29 (0.06 – 1.96)
ACE inhibitors/ARBs 1 6 0.63 (0.07 – 5.35) 0.33 (0.03 – 3.55)
ACE = angiotensin-converting enzyme; 
ARBs = angiotensin II receptor blockers; 
OR =odds ratio; 
CI = confidence interval
*  Other anti-hypertensive drugs include calcium channel blockers, beta blockers, thiazide diuretics, 
and miscellaneous anti-hypertensive drugs
†   Current users were patients who had received a prescription of ACE inhibitors and ARBs within six 
months prior to the index date. 
‡   Past users were patients who received at least one prescription of ACE inhibitors and ARBs but 
discontinued treatment more than six months before the index date.
§   adjusted for age, sex, calendar year and history of  cardiovascular diseases, and the use of NSAIDs, 
proton pump inhibitors and calcium channel blockers.
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Sensitivity analyses
The risk of RA associated with ACE inhibitors or ARBs was similar for subjects using 
thiazide diuretics and subjects not using thiazide diuretics. When we shifted the index 
date two and three years before the first-time diagnosis of RA, we found no association 
between ACE inhibitor and ARB use and incident RA (data not shown), and no 
difference in the distribution of NSAID and corticosteroid use between cases and 
controls was observed. When the analysis was restricted to RA patients referred to a 
rheumatologist or received at least one prescription of a DMARD after the index date, 
Table 3   Use of different dosages of angiotensin-converting enzyme inhibitors 
and the risk of rheumatoid arthritis
Cases
(n = 211)
Controls
(n = 667)
Crude OR  
(95% CI)
Adjusted OR†  
(95% CI)
Other antihypertensive drugs* 113 373 1.00 (reference) 1.00 (reference)
Use of ACE inhibitors, days
1 – 365 19 61 1.04 (0.59 – 1.81) 0.90 (0.50 – 1.62)
366 – 1 095 19 69 0.89 (0.51 – 1.56) 0.84 (0.47 – 1.50)
> 1 095 23 65 1.27 (0.74 – 2.16) 1.24 (0.72 – 2.16)
Use of ARBs, days
1 – 365 8 33 0.85 (0.38 – 1.90) 0.80 (0.35 – 1.84)
366 – 1 095 10 29 1.12 (0.53 – 2.36) 0.93 (0.42 – 2.05)
> 1 095 6 12 1.82 (0.66 – 5.06) 1.64 (0.57 – 4.69)
Use of ACE inhibitors, DDD
≤ 0.75 17 64 0.90 (0.50 – 1.62) 0.83 (0.44 – 1.58)
0.75 – 1.25 27 70 1.34 (0.82 – 2.21) 1.28 (0.75 – 2.21)
> 1.25 17 61 0.94 (0.52 – 1.67) 0.96 (0.52 – 1.78)
Use of ARBs, DDD
≤ 1 17 61 0.96 (0.53 – 1.72) 0.84 (0.44 – 1.59)
> 1 7 13 1.71 (0.66 – 4.43) 2.03 (0.72 – 5.76)
ACE = angiotensin-converting enzyme; 
ARBs = angiotensin II receptor blockers; 
OR =odds ratio; 
CI = confidence interval; 
DDD = defined daily dose
*  Other anti-hypertensive drugs include calcium channel blockers, beta blockers, thiazide diuretics, 
and miscellaneous anti-hypertensive drugs
†   adjusted for age, sex, calendar year and history of  cardiovascular diseases, and the use of NSAIDs, 
proton pump inhibitors and calcium channel blockers.
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the adjusted ORs for ACE inhibitor and ARB use and the risk of developing RA were 
0.92 (95% CI 0.45 to 1.87) and 0.89 (95% CI 0.36 to 1.79), respectively. To exclude 
possible bias by accidental inclusion of patients with psoriatic arthritis among RA 
patients, we repeated the analysis after removing the patients who had a recorded 
diagnosis of psoriasis. Results were consistent with all other analyses (adjusted OR 
ACE inhibitor, 1.03 (95% CI 0.61 to 1.85), adjusted OR ARB, 1.06 (95% CI 0.68 to 1.53) 
and adjusted OR ACE inhibitor and ARB, 1.63(95% CI 0.74 to 3.57)).
DISCUSSION
The present study did not demonstrate an association between ACE inhibitor and 
ARB use and the risk of developing RA. The effect was consistent when we defined 
the exposure to ACE inhibitors and ARBs as current and past use and duration of use. 
Furthermore, no dose-response effect was observed. Thus, our data do not support 
the hypothesis that ACE inhibitors and ARBs either facilitate or protect against RA.
To our knowledge, this is the first observational study investigating the influence of 
ACE inhibitor and ARB use and incident RA. Evidence for the association between 
ACE inhibitor and/or ARB use and the occurrence of autoimmune diseases was 
derived from case reports of lupus-like disease, vasculitis and pemphigus 22–43. In 
these case reports, the commonly prescribed ACE inhibitors such as captopril and 
enalapril were often reported as a suspected drug for the occurrence of these 
autoimmune diseases. In our study, however, we observed no difference in the risk 
estimates of individual ACE inhibitors and the risk of developing RA.
Several studies have shown the beneficial effects of ARB and ACE inhibitor use in 
animal models of induced arthritis 13,14,63,64. Furthermore, in an open study of patients 
with active RA treated with captopril, reductions in joint symptoms, the number of 
swollen joints and reduced levels of C-reactive protein (CRP) were found 12. In 
addition, in an open study using pentopril, no clinical improvement in patients with RA 
was observed, although CRP levels decreased 65. Furthermore, ARB use in RA 
patients was found to be associated with a significant reduction in erythrocyte 
sedimentation rate 15. The findings are, however, inconclusive 15,66.
Several limitations of our study should be considered in the interpretation of these 
results. First, the definition of RA in our study was based on GPs’ diagnosis, a referral 
to a rheumatologist, or prescriptions of DMARDs and/or corticosteroids after the 
index date. We may have used a relatively sensitive, but nonspecific, diagnosis of RA 
because no specific ICPC codes were available for other rheumatic diseases, e.g., 
psoriatic arthritis. Furthermore, no data on examinations such as the presence of 
anti-cyclic citrullinated peptide antibodies or X-ray of hands and feet were available 
for making a diagnosis of RA. Therefore, false positives, meaning that not all cases 
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were true cases of RA, may have diluted the results of our study, and we may have 
underestimated the OR of RA. However, our results remained unchanged when 
analyses were restricted to RA patients referred to a rheumatologist or those who 
received DMARDs after their first-time diagnosis, or when we excluded patients with 
a diagnosis for psoriasis, or when we modified the index date exactly two and three 
years before the first-time diagnosis of RA. Because of limited power of our study 
population, we used an index date exactly one year before the first-time diagnosis of 
RA. When the analysis was restricted to RA patients referred to a rheumatologist and 
received at least one prescription of a DMARD after the index date, the results were 
consisted with all other analyses. Our findings indicate no association between ACE 
inhibitor and ARB use and incident RA when we used other criteria for defining RA in 
our study.
Second, our study was observational, and patients were not randomly assigned to 
anti-hypertensive therapy. Physicians and patients selected anti-hypertensive drug 
therapies, and this may have introduced bias. We believe, however, that it is unlikely 
that this bias has influenced our results because no differences between cases and 
controls in the prescriptions of other anti-hypertensive drugs were observed. 
Third, misclassification of ACE inhibitor and ARB use may be a concern in this study 
because we used computerised prescription data from the GP. Patients may have 
been non-adherent to the treatment of ACE inhibitors or ARBs and therefore could 
have used less ACE inhibitors or ARBs than prescribed. However, this misclassifica-
tion is likely to be non-differential between cases and controls and may have resulted 
in an underestimation of the association between use of ACE inhibitors and/or ARBs 
and RA. 
Fourth, selection bias may have been introduced in this study because GPs could 
have paid more attention to co-morbidities of RA patients. Yet, the average duration 
in the registry is almost equal between RA and controls, and therefore; the patients in 
our study had similar opportunities to have been prescribed an ACE inhibitor or ARB. 
Further limitations include the lack of information on dietary intake, physical activity 
and smoking, and limited data on other examinations (e.g. blood pressure, lipid 
levels) 67–69. 
From the approximately 57 457 eligible patients who were taking anti-hypertensive 
medication, we ultimately included 211 RA patients in our study. Due to several 
exclusions, our results may not necessarily be extrapolated to all treated hypertensive 
patients. In addition, the group of users of ACE inhibitors and ARBs in our study was 
relatively small.
Strengths of our study include the use of different classes of anti-hypertensive drugs 
and the use of a computerised database, allowing us to use routinely recorded 
medical and prescription data from GPs. Consequently, recall bias was minimised. 
Another strength of our study is its inclusion of patients who were prescribed an an-
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ti-hypertensive drug. By including only these patients, we have ensured that 
prognostic factors such as cardiovascular risk factors (e.g. hypertension) were almost 
evenly distributed between the RA patients and controls 70.
Furthermore, because hypertension may be considered as an immune-mediated 
disease71,72 hypertension-related immunological abnormalities relevant for the 
development of RA were probably also equally distributed between both groups. 
Nonetheless, hypertension is more prevalent in RA patients than in the general 
population 73, and theoretically, in view of their immunomodulating capacities, the 
use of ACE inhibitors and/or ARBs might prevent the development of RA.
In conclusion, this study suggests that there is no association between incident RA 
and ACE inhibitor or ARB use. Our results indicate that the beneficial effects of ACE 
inhibitors and ARBs studied in patients with RA were not observed among 
hypertensive patients without clinically manifest RA. Furthermore, our study does not 
underline findings from individual case reports suggesting that ACE inhibitors and 
ARBs may facilitate the development of autoimmune diseases. Based on these 
findings, we believe that both ACE inhibitors and ARBs are considered to be safe for 
patients with a risk of developing RA. Further research using larger sample size and 
a prospective study design are needed to confirm our findings. It is of interest to 
replicate the design of this study to assess the association with psoriasis and psoriatic 
arthritis.
Key points
· Use of ACE inhibitors or ARBs is not associated with incident RA.
· In contrast to the beneficial effects of ACE inhibitors and ARBs studied in patients 
with RA, we did not observe effects on the incidence of RA among patients initially 
free of RA.
· This study does not underline findings from individual case reports, suggesting 
that ACE inhibitors or ARBs may not facilitate the development of autoantibodies 
and/or autoimmune disease.
· Based on our findings, both ACE inhibitors and ARBs are considered to be safe for 
patients with a risk of developing RA.
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CHAPTER 4.1
ABSTRACT
Introduction
It has been suggested that statins can both stimulate and suppress the immune 
system, and thereby, may influence autoimmune diseases. Therefore, we studied 
effects of statins on innate and adaptive immunity, and self-tolerance by measuring 
serological levels of C-reactive protein (CRP), neopterin, immunoglobulin E (IgE) 
antibodies and the presence of autoantibodies (antinuclear antibodies (ANA) and 
IgM rheumatoid factor (RF)) in the general population. 
Methods 
We conducted a nested case-control study within the population-based Doetinchem 
cohort. Data from health questionnaires, serological measurements and information on 
medication from linkage to pharmacy-dispensing records were available. We selected 
332 statin users (cases) and 331 non-users (controls), matched by age, sex, date of 
serum collection, history of cardiovascular diseases, diabetes mellitus type II and 
stroke. Multivariate regression analyses were performed to estimate effect of statins 
on the immune system. 
Results
The median level of CRP in statin users (1.28 mg/L, interquartile range (IQR): 0.59-2.79) 
was lower than in non-users (1.62 mg/L, IQR: 0.79-3.35), which after adjustment was 
estimated to be a 28% lower level. We observed an inverse association between 
duration of statin use and CRP levels. Elevated levels of IgE (>100 IU/mL) were more 
prevalent in statin users compared to non-users. A trend towards increased levels of 
IgE antibodies in statin users was observed, whereas no associations were found 
between statin use and levels of neopterin or the presence of autoantibodies. 
Conclusions 
In this general population sub-sample, we observed an anti-inflammatory effect of 
statin use and a trend towards an increase of IgE levels, an surrogate marker for 
T helper (Th) 2 responses without a decrease in neopterin levels, a surrogate marker 
for Th1 response and/or self-tolerance. We postulate that the observed decreased 
inflammatory response during statin therapy may be important but is insufficient to 
induce loss of self-tolerance. 
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INTRODUCTION
Numerous clinical trials have demonstrated that statins, or anti-3-hydroxy-3-methyl-
glutaryl coenzyme A reductase (HMG-CoA or HMGCR) inhibitors, are effective in the 
primary and secondary prevention of cardiovascular diseases 1–3. In addition to 
lowering cholesterol, statins have anti-inflammatory and immunomodulatory 
properties which also may contribute to the beneficial effects of these drugs 4,5. 
Several studies of patients with rheumatoid arthritis (RA) and experimental studies in 
collagen-induced arthritis suggested beneficial effects of statins in arthritis 6–12. 
Similarly, in studies of antiphospholipid syndrome, vasculitis, systemic sclerosis, and 
systemic lupus erythematosus (SLE) patients and murine lupus models, attenuation 
of lupus activity has been ascribed to statins 13–20. On the other hand, it has been 
postulated that statins may facilitate the loss of self-tolerance that could potentially 
result in autoimmune diseases. Indeed, several case-reports and reviews have linked 
statin use with autoimmune disorders, such as lupus-like syndrome, vasculitis, poly- 
and dermatomyositis, and necrotising autoimmune myositis 21–25. Furthermore, we 
recently demonstrated that statins are associated with an increased risk of developing 
RA, SLE and polymyalgia rheumatica 26–29.
The proposed mechanisms by which statins may facilitate and/or be protective for 
the development of autoimmune diseases are unclear. As described in various 
studies, statins seem to affect the functions of immune cells, including natural killer 
cells, monocytes, macrophages and T cells 30. Statins have been shown reduce 
pro-inflammatory cytokines, including tumor necrosis factor (TNF)-α, interleukin 
(IL)-6 and IL-8, and the levels of C-reactive protein (CRP), a marker of the innate 
immune system reflecting underlying systemic inflammation 31–35. Statins may also 
block stimulation of T cells and inhibit interferon (IFN)-gamma induced macrophage 
activation 30, resulting in suppressed secretion of neopterin 36. In a murine model 
mimicking multiple sclerosis, atorvastatin promoted the differentiation of T helper (Th) 
0 into Th2 cells, resulting in the systemic production of Th2 cytokines (IL-4, IL-5, 
IL-10, and transforming growth factor beta (TGF-β) 37. IL-4 is a cytokine that induces 
differentiation of naive helper T cells (Th0 cells) to Th2 cells. Upon activation by IL-4, 
Th2 cells subsequently produce additional IL-4 which is responsible for the induction 
of immunoglobulin E (IgE) synthesis by B cells. Levels of circulating IgE antibodies 
are representative for Th2 immune responses 38,39, whereas neopterin is considered 
to be a marker of Th1 responses 36.  It has been suggested that statins may induce a 
shift in the Th1/Th2 balance by their direct effect on T cells. A shift in the Th1/Th2 
balance may dysregulate the immune homeostasis and can lead to the breakdown 
of self-tolerance, precipitating autoimmunity 24,37,40. To study the relationship between 
statin use and different aspects of the immune system, we assessed whether statins 
influenced the immune responses, by measuring CRP, neopterin levels, IgE antibodies 
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and some prevalent autoantibodies (IgM rheumatoid factor (RF) and antinuclear anti- 
bodies (ANA)) in subjects from the general population who were either statin user or 
non-user. 
MATERIALS AND METHODS
Study setting
Subjects from the Dutch Doetinchem Cohort Study were linked to the PHARMO 
Record Linkage System (PHARMO-RLS), using information on sex, and date of birth 
and postal code in order to obtain information on the use of statins to study markers 
representative of the immune status.
The Doetinchem Cohort Study is a population-based longitudinal study among 
inhabitants of the Dutch town Doetinchem. The main objective of this ongoing cohort 
study is to investigate the impact of (changes in) lifestyle and biological risk factors 
on the incidence of chronic diseases. A total of 12 405 men and women aged 20-59 
years at baseline were examined in the years 1987-1991 (round 1) and a two-third 
random sample of these participants has been invited for (re-)examinations at 5-year 
intervals, during 1993-1997 (round 2), 1998-2002 (round 3) and 2003-2007 (round 4). 
Details on the Doetinchem Cohort Study have been previously described 41. We used 
data from all four examination rounds of the Doetinchem Cohort Study. At every 
examination round demographic, lifestyle and health characteristics were collected 
using a self-administered questionnaire, including items regarding smoking and 
alcohol habits, educational level and physical activity. Additionally, participants 
underwent physical examination which included anthropometric and blood pressure 
measurements, and collection of blood samples. The Doetinchem Cohort Study was 
approved according to the guidelines of the Helsinki Declaration by the external 
Ethics Committee of the Dutch TNO Research Institute. Linkage between the 
Doetinchem Cohort Study and PHARMO-RLS has been conducted for subjects with 
an agreement in their informed consent 41.
PHARMO-RLS is a population-based database, comprising pharmacy-dispensing 
and hospital admission data of approximately 2.3 million community-dwelling 
inhabitants of 48 geographically defined areas in the Netherlands from 1985 onwards. 
With regard to prescription drugs, pharmacy records are virtually complete since 
the majority of Dutch inhabitants are registered with a single community pharmacy. 
For this study, we used drug-dispensing and hospitalisation data. The pharmacy 
dispensing records include information on the type of drug dispensed, dispensing 
date, amount dispensed and prescribed dosage regimen. Hospitalisation data 
include detailed information on the primary and secondary discharge diagnoses, 
and dates of hospital admission and discharge. Drugs were coded according to the 
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Anatomical Therapeutic Chemical (ATC) classification, and hospital diagnoses were 
coded according to the ICD-9-Cm codes 42,43. Within these linked datasets, each 
subject was followed from the date of the first prescription of statins until collection of 
serum during examination.
Study population
Linkage between the Doetinchem Cohort Study and PHARMO-RLS has been 
conducted for 9 179 subjects. Of these subjects, 1 779 were statin users. Clinical 
examination data were available for 778 statin users. For each statin user, one non- 
user of statins was randomly selected and matched for age (+/- five years), sex, date 
of examination, and history of cardiovascular diseases, diabetes mellitus type II and 
stroke. After matching on these factors, 1 016 subjects were included in the analysis. 
For the purpose of the study, subjects who used corticosteroids (n = 22) one month 
before the date of examination, or who ever used disease modifying anti-rheumatic 
drugs (DMARD) (n = 29), or had a diagnosis of an autoimmune disease before the 
date of examination were excluded, as were subjects who did not have a registered 
medical history for at least one year (n = 73) at entrance of the linked data from the 
Doetinchem Cohort Study and PHARMO-RLS. Of these 892 subjects, 229 blood 
samples could not be retrieved. A total of 663 subjects (332 users and 331 non-users 
of statins) remained for the first analysis. For the second analysis, we selected from 
these 663 subjects, 192 subjects for whom blood samples were available from 
multiple rounds of examination.  The study design is depicted in Figure 1. 
Exposure definition
Exposure to statins was defined as the use of at least one prescription of any approved 
and commercially available statin (pravastatin, simvastatin, rosuvastatin, atorvastatin, 
fluvastatin) in the Netherlands before each date of examination. Cerivastatin was 
also included in this study, although cerivastatin was withdrawn from the market in 
the year 2001. Cumulative duration and daily dose of statins until examination was 
assessed, as well as the sum of prescriptions, defined daily doses (DDD) and 
adherence to statins 26. Adherence to statin use was calculated by dividing the sum 
of the days’ supply by the total number of days between the first prescription and 
the last prescription of statins in the year before the date of examination, multiplied 
by 100%. To determine adherence to statin use, we excluded subjects who received 
one prescription of statins, and who used no statin in the year before the date of 
examination. Subjects who received one prescription of statins before the date of 
examination were not excluded from other analyses. The potency of statins was 
determined by taking type and dose of statins into account, in order to control for the 
fact that different types and doses of statins differ with respect to the percentage 
reduction in low-density lipoprotein (LDL) cholesterol 44.
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Figure 1   Study design.
1. Cross sectional study; 2. Longitudinal study.
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Outcome definition
Non-fasting venous blood samples were drawn in each examination round. Blood 
samples were then centrifuged and separated sera were stored in 0.5 mL aliquots at 
-20˚C until analyses. High sensitivity CRP was determined on a clinical autoanalyser 
(LX20-Pro, Beckman Coulter, Mijdrecht, the Netherlands), using standard kits. Data 
are expressed as mg/L. CRP levels lower than 2 mg/L are considered as normal 45. 
Serum concentration of neopterin was measured by commercially available enzyme- 
linked immunosorbent assay (ELISA) kits (IBL, Hamburg, Germany, distributed via 
Mediphos, Renkum, the Netherlands) according to manufacturer’s instructions 46. 
Data are expressed as ng/mL.  Neopterin levels lower than 2.5 ng/mL were considered 
as normal (manufacturer’s recommendation). Levels of IgE antibodies were measured 
by using an Immunocap 250 (Phadia, Uppsala, Sweden), following manufacturer’s 
instructions. Data are expressed as IU/mL. Total IgE levels below 100 IU/mL were 
considered normal 47.  Sera were diluted 1:80 with phosphate buffered saline (PBS), 
and were screened for ANA by indirect immunofluorescence assay on HEp-2000 
cells (ImmunoConcepts, Sacramento, CA, distributed via BMD, Antwerpen, Belgium) 48. 
IgM RF was determined with an ELISA (Sanquin Reagents, Amsterdam, the Netherlands), 
using a previously described protocol 49. Serum levels above 12.5 IU/mL were 
considered positive based on measurements in a group of normal healthy blood 
donors in the Netherlands (n = 665), which yielded IgM RF values below 12.5 IU/mL in 
96% of the cases according to manufacturer’s instructions 49. The intra-assay and 
interassay variability were less than 10% for all test systems. To eliminate inter- assay 
variability, all samples from one patient were tested in a single assay. 
Potential confounding variables
The following variables were considered as potential confounders: body mass index 
(BMI), educational level, smoking and drinking behaviour, physical activity level, 
parental history of myocardial infarction (MI), levels of total cholesterol and 
high-density lipoprotein (HDL) cholesterol, hypertension and asthma,  and the use of 
non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, proton pump 
inhibitors (PPIs), aspirin, anti-hypertensive and anti-diabetic drugs, antibiotics, anti-
depressants and hormone replacement therapy in the six months prior to the date of 
examination 50. Parental history of MI was divided into two variables: 1) father with a 
history of MI and 2) mother with a history of MI, both with an age onset of <60 years. 
Hypertension was considered present when the subject had a systolic blood pressure 
of 140 mmHg or higher, a diastolic blood pressure of 90 mmHg or higher and/or used 
anti-hypertensive drugs. The matching factors age, sex, date of serum collection, and 
a history of cardiovascular diseases, diabetes mellitus type II and stroke were 
included in all models. In addition, all other covariables that changed the regression 
coefficient for statin use by ≥10% were entered into the model 51.
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Statistical analysis
Baseline characteristics were reported as mean (SD) for continuous variables and 
proportion (percentage) for categorical variables. At baseline, comparisons between 
the non-users and users of statins were analysed using independent Student’s t and 
Mann-Whitney tests for continuous variables, and Chi-square and Fisher exact tests 
for categorical variables. Skewed data were transformed logarithmically to approximate 
normal distribution. Distribution of levels of neopterin, IgE antibodies and CRP were 
positively skewed, and are presented as median with interquartile ranges (IQR). 
The associations between statin use and CRP and neopterin levels were studied in a 
linear regression model with adjustment for age, sex, date of examination, history of 
cardiovascular diseases, diabetes mellitus type II  and stroke (model 1). In the second 
model lifestyle factors and cardiovascular disease risk factors were added, namely 
smoking status, anti-hypertensive drugs and total cholesterol levels. Similarly, the 
association of statin use with IgE levels was analysed with additional adjustment for 
asthma. Log-transformed markers CRP, neopterin and IgE antibodies were back 
transformed for presentation and the associations are expressed as slope (β) with 
confidence intervals (CIs), representing the expected percentage change in the 
outcome 52. Associations between statin use and the presence of elevated levels of 
CRP, neopterin and IgE, and ANA and IgM RF were calculated using logistic regression 
models, analyses were adjusted for the same variables, as listed previously. The 
associations are expressed as odds ratio (OR) with CIs. We evaluated effects of 
cumulative duration and daily dose, DDDs, number of prescriptions, adherence and 
potency of statins on the immune status. To test P for trend of the associations across 
increasing quartiles of cumulative duration and daily dose, DDDs, number of prescriptions, 
adherence or potency of statins, the median values of these different exposure aspects 
of statin use were assigned to each quartile and used as a continuous variable in the 
linear regression model. 
Because of a potential modifying effect due to the presence of cardiovascular 
diseases, the analysis was stratified according to history of cardiovascular diseases. 
Changes in the immune system with aging and sex differences have been reported. 
Therefore, age- (<50, ≥50 years) and sex-stratified analyses for the evaluation of 
effect modification were carried out 53,54.   
To study the relationship between statin use and the levels of CRP and IgE antibodies 
during follow-up, we used linear mixed-effects models for the analysis of repeated 
measurements with adjustment for the matching and baseline covariables, as described 
above. The model deals with the correlation between repeated measurements in a 
subject, and allows subjects to have unequal gaps and numbers of observations. 
Only subjects with at least two serological measurements were included in the model. 
The random effects of the model include a random intercept and/or slope of time. 
In the model where we only included a random intercept, specification of a random 
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slope did not change the results in a relevant way. Data are presented as β’s with CIs 
and denotes the adjusted percentage change in the levels of CRP and IgE antibodies 
compared between and within statin users and non-users. P<0.05 was considered 
statistically significant using a 2-tailed test. Data were missing on several variables as 
listed in table 1. The missing values were imputed by the multiple imputation method 
by using the Markov Chain Monte Carlo Method 55. All original outcome and 
covariables presented in table 1 were included in the imputation model. Twenty 
imputation sets were created, analysed and pooled by the MIANALYZE procedure. 
Baseline measurements of complete and imputed cases were compared based on 
the means and frequencies. Results from the complete case and multiple imputation 
analyses were compared and multiple imputation analyses are presented. All 
analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC).
RESULTS
Baseline characteristics
Baseline characteristics of the study population are presented in table 1. The study 
comprised 332 statin users of whom 196 (59%) were men with a mean age of 59.5 
(SD 8.0) years and 331 non-users of whom 194 (59%) were men with a mean age of 
59.3 (SD 8.0) years.  In statin users, total cholesterol levels and BMI were higher and 
the level of HDL cholesterol was lower than in non-users. Hypertension and cardio- 
vascular disease were more frequently reported among statin users than non-users. 
As a result of these differences, anti-hypertensive drugs, aspirin and PPIs were more 
used among statin users. 
Inflammation
Measurements of immune parameters are presented in Table 2. The median (IQR) 
level of CRP was significantly lower for statin users, 1.28 (0.59 – 2.79) mg/L, than for 
non-users 1.62 (0.79 – 3.35) mg/L. After controlling for the matching variables, anti- 
hypertensive drugs, total cholesterol levels and smoking status, a lower CRP level 
was observed in statin users compared with non-users (difference of -28% for statin 
use vs. non-use, P<0.01). When we used a cut-off value of less than 2 mg/L to 
discriminate between normal and increased levels of CRP, statin use was associated 
with the presence of low levels of CRP (OR: 0.67; 95% CI: 0.45 to 0.99). 
Immunomodulation
We found no difference in levels of neopterin or the prevalence of low levels of 
neopterin (<2.5 ng/mL) between statin users and non-users. The median IgE level in 
statin users was 28.6 IU/mL compared to 25.3 IU/mL in non-users. The prevalence of 
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elevated levels of IgE antibodies (>100 IU/mL) was higher in statin users compared 
to non-users. A trend towards higher levels of IgE antibodies was observed in statin 
users compared with non-users, although this difference did not meet the criteria for 
significance.
Table 1   Baseline characteristics of the study population
Statin 
users
N
Statin 
users 
(n = 332)
Non- 
users
N
Non- 
users
(n = 331)
p value
Men, %
Mean age in years (SD)
Mean BMI in kg/m2(SD)*
Low education level, %
History myocardial infarction father, %
Current smoking, %
Regular alcohol consumption, %
Physical active, %
Mean total cholesterol in mmol/L (SD)
Mean HDL cholesterol in mmol/L (SD)†
332
332
316
253
316
252
299
236
316
316
196 (59)
59.5 ± 8.0
26.8 ± 3.4
136 (54)
41 (13)
74 (29)
193 (65)
188 (80)
6.82 ± 1.18
1.19 ± 0.32
331
331
292
236
292
236
271
216
291
291
194 (59)
59.3 ± 8.0
26.1 ± 3.6
131 (56)
26 (9)
57 (24)
186 (69)
156 (72)
5.68 ± 1.01
1.30 ± 0.35
-
-
0.02
0.72
0.11
0.10
0.61
0.06
<0.0001
<0.0001
Disease history before date  
of examination, %
Diabetes
Hypertension
Cardiovascular disease
Stroke 
Asthma
Cancer 
Drug use six months before date  
of examination (%)
Corticosteroids 
NSAIDs‡ 
Fibrates
Anti-hypertensive drugs
Anti-diabetic drugs
Aspirin 
HRT§
Antibiotics 
Antidepressants 
PPIsⅡ
266
332
332
315
261
332
332
332
332
332
332
332
332
332
332
332
67 (25)
147 (47)
87 (26)
11 (3)
5 (2)
16 (5)
3 (1)
44 (13)
1 (0)
135 (41)
29 (9)
78 (24)
12 (4)
32 (10)
17 (5)
26 (8)
249
331
331
290
245
331
331
331
331
331
331
331
331
331
331
331
50 (20)
99 (34)
25 (8)
9 (3)
10 (4)
15 (5)
3 (1)
53 (16)
0 (0)
53 (16)
23 (7)
15 (5)
10 (3)
26 (8)
18 (5)
14 (4)
-
0.002
<0.0001
-
0.15
0.86
1.00
0.31
1.00
<0.0001
0.39
<0.0001
0.67
0.42
0.85
0.05
* BMI, Body mass index
† HDL, High-density lipoprotein
‡ NSAIDs, Nonsteroidal anti-inflammatory drugs
§ HRT, Hormone replacement therapy
Ⅱ PPIs, Proton pump inhibitors
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Self-tolerance
No associations were observed between statin use and the presence of the auto-
antibodies, ANA and IgM RF.
CRP and IgE levels and different aspects of exposure to statins
As we observed associations between statin use and levels of CRP and IgE anti- 
bodies, we studied these associations in detail in statin users by the different aspects 
of exposure to statins. We present in table 3 the regression coefficients for the different 
aspects of exposure to statins in relation to CRP and IgE levels, adjusted for confounders. 
Regarding the number of prescriptions, cumulative duration and daily dose, DDDs, 
potency and adherence to statins, associations with CRP levels were inverse, although 
none of them were statistically significant. In addition, an association between increasing 
number of days of statin use and decreased levels of CRP was observed (Ptrend=0.02). 
For IgE levels, the fully adjusted associations with different aspects of exposure to 
statins were positive, but no association was statistically significant. 
CRP and IgE levels and different groups of age, sex and history  
of cardiovascular diseases
The associations between statin use and levels of CRP did not differ between strata 
of sex, age and history of cardiovascular diseases (data not shown). However, levels 
of IgE antibodies were higher in statin users versus non-users who were older than 60 
years and had a history of cardiovascular disease (data not shown). 
Development of CRP and IgE levels over time
Cross-sectional analyses did not show differences in the levels of neopterin, and the 
presence of ANA and IgM RF between statin users and non-users. Therefore, we only 
studied the change in CRP and IgE levels over time between statin users and 
non-users (table 4). After controlling for the matching variables, anti-hypertensive 
drugs, total cholesterol levels and smoking status, the change over time in mean CRP 
level was lower in statin users compared to non-users, by on average 29% (p=0.04). 
No difference in the change over time in mean levels of IgE antibodies between statin 
users and non-users was observed. We found no effect modification between time 
and statin treatment between users and non-users of statins, indicating that the 
difference in CRP levels remained constant over time.
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DISCUSSION
In the present study, we observed that statins suppress the innate immune response, 
by decreasing the levels of CRP, both cross-sectionally and over time. A more detailed 
analysis on different aspects of exposure to statins, showed an inverse association 
between duration of statin use and levels of CRP. Furthermore, we observed a trend 
towards higher levels of IgE antibodies in statin users, which infers that it did not meet 
the pre-specified criteria for significance. Neopterin levels were not affected. Finally, 
ANA and IgM RF were not different between statin users and non-users suggesting 
that the use of statins was not associated with a loss of self-tolerance. 
Importantly, our study consistently showed that the use of statins is associated 
with decreased levels of CRP in the general population, as previously described in 
population-based studies and clinical trials 33,56–60. Essentially, by confirming this 
well-known association between statin use and decreased levels of CRP, it demonstrates 
that we have used appropriate methods for patient selection. This strengthens the 
conclusions of our study.
Apart from the anti-inflammatory effects, it has been suggested that statins may have 
a direct immunomodulating effect on T cells and may promote a shift from Th1 to Th2 
immune responses, possibly leading to a dysregulation in the immune homeostasis 
24,30,37. Cherfan et al. reported that statins did not affect Th1 cells but suppressed Th2 
Table 4   Regression coefficients‡ for the change in CRP* and IgE† levels over  
time between statin users and non-users.
Crude β(95% CI) §,Ⅱ Adjusted β(95% CI)¶ p value††
CRP (mg/l) ‡ ‡ 0.81 (0.98 – 1.07) 0.71 (0.51 – 0.98) 0.04
IgE (IE/ml) ** 0.87 (0.84 – 1.41) 0.97 (0.84 – 1.13) 0.70
*  CRP, C-reactive protein
†  IgE, Immunoglobulin E
‡  Regression coefficients denote the adjusted percentage change in the levels of CRP and IgE 
antibodies compared between and within statin users and non-users (reference group).
§  Differences of the geometric means were reported for CRP and IgE levels as these variables were 
non-normally distributed and the natural logarithm was used in the analyses.
Ⅱ  Adjusted for the matching covariables age, sex, date of examination, cardiovascular diseases, 
diabetes mellitus type II and stroke (model 1).
¶  Adjusted for the matching covariables from model 1 and anti-hypertensive drugs, smoking and total 
cholesterol levels (model 2).
**  Adjusted for the covariables from model 1 and 2, and asthma 
†† P<0.05 after adjustment for confounding factors.  
‡ ‡ The random-effects portion of the model consists only of a random intercept.
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responses 58. In contrast, other studies suggested that statins promote a Th2 bias 
61,62. In our study, we observed a trend towards increased levels of IgE antibodies, 
representative of Th2 responses, but this was not accompanied by a decrease in 
neopterin levels, a marker for Th1 cell activity. This is in agreement with two other 
studies showing that treatment with statins had no effect on the levels of neopterin 
63,64. However, two studies including patients with cardiovascular diseases showed 
that neopterin levels declined during statin treatment 36,65, indicating a suppressive 
effect on Th1 cells. We found no association between statin use and the presence of 
the most prevalent autoantibodies, ANA and IgM RF 66,67, suggesting maintenance 
of self-tolerance. So far, an indication for an association between statin use and the 
presence of ANA was shown in case reports of lupus-like syndrome, poly- and 
 dermatomyositis 24. To date, no study has been performed on statin use and the 
presence of RF in the general population. The study of Chodick et al. actually showed 
a decreased risk of RA in persistent statin users 7. In this study, persistent statin users 
were compared to non-persistent statin users and were followed until the study 
outcome (RA). In our study, we compared statin users with non-users. The outcome 
variable autoimmune disease, i.e., RA, was not part of our study. We measured 
incidence of IgM RF, in combination with ANA, merely as markers for loss of self-
tolerance. However, when the risk of RA was compared between statin users and 
non-users, three population-based studies demonstrated no association between 
statin use and the risk of developing RA 9,68,69.
Recently, Mammen et al. identified the presence of anti-HMGCR antibodies in sta-
tin-associated autoimmune myopathy 70. The same authors screened a large 
population of statin exposed patients without myopathy and found no anti-HMGCR 
antibodies in these subjects 71. As our observations showed that statins were not 
related to the development of autoantibodies in the general population, we 
hypothesise that statins do not themselves cause autoimmunity but that they may 
promote a pre-existing autoimmune-prone condition to progress towards clinically 
manifest diseases. Several studies demonstrated that statins may exacerbate or 
trigger cellular apoptosis 24,72,73, which may lead to increased levels of apoptotic 
cells and blebs, resulting in increased amounts of autoantigens in the circulation 74,75. 
As patients treated with statins may be less efficient in clearing apoptotic cells, they 
may be more susceptible to autoimmune diseases. Furthermore, statins may be able 
to amplify autoimmunity in genetically susceptible individuals, thereby increasing the 
risk of developing autoimmune diseases 76. It is known that statins not only interfere 
with the mevalonate or cholesterol synthesis pathway but also inhibit the prenylation 
of Rho GTPases, including Rac-1 77,78. Rac-1 is directly implicated in the activation of 
caspase-1 79, which is crucial for processing and secretion of the proinflammatory 
cytokines IL-1β and IL-18, promoting autoimmunity 80,81. However, patients with 
mutations in the mevalonate kinase gene (e.g. hyper-IgD syndrome) may respond 
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differently to the treatment with statins 82, although the prevalence rate of this immune 
disorder is very low. To prove our hypothesis, a much larger cohort study (probably 
more than 40 000 subjects 83) should be performed. 
One of the strengths of this study is the linkage between a large population-based 
cohort study and a registry of pharmacy and hospital discharge records, enabling us 
to assess data on statin use and sera from subjects in Doetinchem. Another strong 
feature of our study is the prospective and longitudinal design with a relatively long 
follow-up (>15 y). Moreover, as sera were collected at several time points, our subjects 
were compared not only cross-sectionally but also longitudinally. Using a computerised 
database, PHARMO-RLS, we were allowed to use routinely recorded dispensing 
data from pharmacies. Consequently, recall and non-response bias were minimised. 
Furthermore, detailed information on confounders, including smoking status was 
available.
Some limitations of our study should be acknowledged. First, we selected a restricted 
number of immune markers in our study as statins may have influenced other 
T-cell-mediated responses. It has been suggested that statins block the differentia-
tion of the pro-inflammatory Th17 cells and have a direct effect on regulatory T cells 
(Treg) in atherosclerotic plaques in mice and peripheral circulation of coronary 
patients 84–86. Regrettably, to date, no valid markers for detecting Th17 and Treg cells 
in human sera are available. Furthermore, the long-term storage of our samples 
limited us in the selection of immune markers as our samples were stored from 2 up 
to 20 years (depending on the round of examination). Long-term storage of the sera 
samples may have affected the levels of various immune markers, such as antibodies, 
chemokines, cytokines and other soluble markers of immune activation. However, 
several studies have shown that prolonged storage did not affect CRP 87, neopterin 
88 and IgE antibodies 89. Since statin users and non-users were matched on date of 
examination in order to maintain an equally distributed duration of sample storage, 
we do not expect that long-term storage influenced our associations between statin 
use and the levels of CRP, neopterin and IgE antibodies. Second, despite our best 
efforts, matching on cardiovascular diseases was only partially achieved as the 
majority of the subjects with cardiovascular diseases were treated with statins. 
However, when we stratified for cardiovascular diseases, no differences in the 
association between statin use and immune markers were observed. Third, statin 
users or non-users may have visited a pharmacy, not participating in our computerised 
database to collect their prescription, possibly resulting in an underestimation of the 
actual statin use. However, a recent study showed that the majority of Dutch patients 
are loyal to their pharmacy, i.e., approximately only 11% of patients visited two or more 
pharmacies in 2001 90. When patients visited another pharmacy, it would most likely 
be a pharmacy in the same region. Since we had data from all pharmacies in the 
Doetinchem region, we could assess the complete medication history from a single 
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statin user or non-user across these pharmacies. Therefore, we do not expect that 
this would have affected our findings.
Fourth, the linkage of the Doetinchem Cohort Study and the PHARMO-RLS database 
yielded 663 subjects who had at least one serum sample in one of the examination 
rounds. This restricted number of subjects may have raised concerns about the 
 generalisability of our findings. It is conceivable that this may have affected the estimates 
of the baseline characteristics, but we believe to a lesser extent on the magnitude of 
the associations between statin use and the serological markers of (auto) immunity. 
Finally, it should be acknowledged that this is an observational study which may have 
been subject to residual confounding due to potential unmeasured differences in 
cardiovascular risk profile and subjects’ characteristics between statin users and 
non-users. However, we have matched the statin users and non-users on several 
factors; we believe we have reduced residual confounding as much as possible.
CONCLUSIONS
In the present study, we have demonstrated that statins exert anti-inflammatory 
effects as shown by a decrease in levels of CRP. However, no effects on the levels of 
neopterin and the presence of the autoantibodies, ANA and RF, were shown. These 
findings suggest that this population-based study does not provide evidence that 
statins exert immunomodulatory effects on a Th1 response and/or loss of self-
tolerance. An immunomodulatory effect on Th2 response, however, cannot be 
excluded as we observed a slight increase in IgE levels. Further research is warranted 
to investigate the immunomodulatory effects of statins in peripheral blood of healthy 
individuals from a large population-based cohort study.
Key points
· Statins suppress the innate immune response, by decreasing the levels of CRP.
· Statins do not exert immunomodulatory effects on Th1 response and/or loss of 
self-tolerance.
· An immunomodulatory effect on Th2 response, however, cannot be excluded.
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ABSTRACT
Introduction
Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are effective 
in reducing the risk of cardiovascular morbidity and mortality in patients with hyper-
lipidaemia, hypertension, or diabetes mellitus type II. Next to their cholesterol-lowering 
activity, statins have immunomodulatory properties. Based on these properties, we 
hypothesised that statin use may eventually lead to dysregulation of immune responses, 
possibly resulting in autoimmunity. We have recently shown in an observational study 
that statin use was associated with an increased risk of developing rheumatoid arthritis. 
Our objective was to investigate whether a causal relationship could be established 
for this finding.
Methods
The mouse collagen type II (CII)-induced arthritis (CIA) model was used, with immunisation, 
challenge and euthanasia at days 0, 21 and 42, respectively. Statins were given orally 
before (day -28 until day 21) or after (day 21 until day 42) CIA induction. Atorvastatin 
(0.2 mg/day) or pravastatin (0.8 mg/day) was administered. Arthritis was recorded 
three times a week. Serum anti-CII autoantibodies and cytokines in supernatants 
from Concanavalin-A-stimulated lymph node cells and CII-stimulated spleen cells 
were measured.
Results
Statin administration accelerated arthritis onset and resulted in 100% arthritic animals, 
whereas only seven out of twelve non-statin animals (controls) developed arthritis. 
Atorvastatin administration after CIA induction resulted in earlier onset than atorvastatin 
administration before induction, or than pravastatin administration before or after 
induction. The arthritic score of animals given pravastatin before CIA induction was 
similar to that of the non-statin controls, whereas the other groups that received 
statins showed higher arthritic scores. Atorvastatin administration, especially before 
CIA induction, increased anti-CII autoantibody production. Interleukin (IL)-2 and IL-17 
production by lymph node and spleen cells was higher in CIA animals than in Phosphate 
buffered saline (PBS) controls, but was not affected by statin administration. While 
interferon-γ (IFN-γ) production was not affected by CIA induction, atorvastatin 
administration before CIA induction increased the production of this cytokine.
Conclusion
These data support previous results from our observational studies, indicating a role 
for statins in the induction of autoimmunity.
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INTRODUCTION
Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) have been 
shown to be effective in reducing the risk of cardiovascular morbidity and mortality in 
patients with hyperlipidaemia, hypertension, or diabetes mellitus type II 1–4. In addition 
to their cholesterol-lowering activity, several studies have shown that statins have 
anti-inflammatory and immunomodulatory properties 5–8. We hypothesised that 
because of these immunomodulatory properties statin use may eventually lead to 
dysregulation of immune responses, possibly resulting in autoimmunity. In line with 
this hypothesis, we have recently shown in an observational study that statin use was 
associated with an increased risk of developing rheumatoid arthritis (RA) 9. Moreover, 
based on individual case reports we found a positive association between statin use 
and the occurrence of lupus-like syndrome 10. This latter association was recently 
confirmed by another research group 11. To investigate whether a causal relationship 
can be established for these observations, we evaluated the effects of statin 
administration on arthritis in the collagen type II (CII)-induced arthritis (CIA) mouse 
model. In this model for RA, mice are immunised with CII mixed with Freund’s 
complete adjuvant, and are challenged three weeks later with CII alone. Arthritis is 
scored from the time of challenge onwards 12. Several studies have shown beneficial 
effects of statin administration on joint inflammation in the mouse CIA model 13–16. 
However, these studies did not specifically address the effects of statin administration 
before arthritis induction, an issue that follows from our observational study 9. 
Nonetheless, to relate our results to the animal studies indicated above 13–16, we also 
evaluated effects of statin administration after arthritis induction. Here we show that 
statin administration accelerated arthritis onset and resulted in 100% arthritic animals, 
whereas only seven out of twelve non-statin animals (controls) developed arthritis. 
Atorvastatin administration after CIA induction resulted in earlier onset than 
atorvastatin administration before induction, or than pravastatin administration before 
or after induction. The arthritic score of animals given pravastatin before CIA induction 
was similar to that of the non-statin controls, whereas the other groups that received 
statins showed higher arthritic scores. Atorvastatin administration, especially before 
CIA induction, increased anti-CII autoantibody production. Interleukin (IL)-2 and IL-17 
production by lymph node (LN) and spleen cells was not affected by statin 
administration. Atorvastatin administration before CIA induction increased interferon-γ 
(IFN-γ) production.
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MATERIALS AND METHODS
Induction and assessment of collagen-induced arthritis
Male DBA/1OlaHsd mice were obtained from Harlan (Horst, the Netherlands). At the 
age of 10 to 12 weeks the animals were injected intradermally at the base of the tail 
with 100 μl of an emulsion of bovine CII (Chondrex, Redmond, WA, USA) and Freund’s 
complete adjuvant (Chondrex) on day 0 (final concentrations of CII and Freund’s 
complete adjuvant, 1 mg/ml). Mice were challenged by intra-peritoneal injection of 
100 μl CII (concentration 1 mg/ml) on day 21. Body weight and arthritis severity were 
assessed three times per week in a blinded manner, using a semi-quantitative scoring 
system (with scores ranging from 0 to 4 for each paw) until mice were euthanized on 
day 42 12. Arthritis scoring was performed by two individuals, alternating between 
days; there were no visible systematic differences in the way they scored. Mice were 
anesthetised with ketamine, rompun and atropine, and blood was collected from the 
orbital plexus. Inguinal LNs of the hind paws and the spleens were excised. The 
animal experiments were approved prior to their commencement by an independent 
ethical committee, in accordance with national legislation.
Statin administration
Atorvastatin (calcium salt) was a kind gift from Pfizer (Groton, CT, USA). Pravastatin 
(sodium salt) was obtained from Teva (Debrecen, Hungary). Atorvastatin (1 mg/ml) 
and pravastatin (4 mg/ml) were administered daily by oral gavages (0.2 ml). The 
atorvastatin dose approximates 10 mg/kg body weight 17. The cholesterol-lowering 
and low-density lipoprotein-lowering efficacy of pravastatin is four times lower than that 
of atorvastatin 18, and pravastatin was thus given at a four times higher concentration 
than atorvastatin. Atorvastatin and pravastatin were given either before challenge 
(day -28 until day 20) or after challenge (day 22 until day 42; see Figure 1). Phosphate 
buffered saline (PBS) (0.2 ml) was given as a control on days when statins were not 
administered. One control group received only PBS, and a second control group 
(negative control) received only PBS and arthritis was not induced. These groups 
received 0.2 ml PBS by oral gavages daily throughout the experiment. There were 12 
mice per group.
Measurement of autoantibodies
Anti-bovine CII immunoglobulin G (IgG) antibodies were measured using an ELISA 
(mouse anti-bovine CII IgG assay kit; Chondrex) according to the manufacturer’s 
instructions. Briefly, after incubation with blocking buffer, a serial dilution of the 
standard as well as a 20 000-fold dilution of serum samples was incubated. After 
incubation with peroxidase-conjugated goat anti-mouse IgG, O-phenylenediamine 
dihydrochloride was added, the reaction was stopped, and the optical density was 
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measured at 490 nm. The plates were washed before and between all incubation 
steps.
Cell culture
The culture medium used was RPMI-1640 (Gibco, Grand Island, NY, USA) 
supplemented with 10% FCS, 100 μg/ml streptomycin and 100 IU/ml penicillin. Cell 
suspensions were made by pressing the LNs and spleens through a cell strainer 
(Falcon, Franklin Lakes, NJ, USA). Cells were counted using a Coulter Counter 
(Coulter Electronics, Luton, UK). LN cell suspensions were cultured at 106 cells/ml 
culture medium with 5 μg/ml Concanavalin A (MP Biomedicals, Irvine, CA, USA) in 
96-well tissue culture plates (Nunc, Roskilde, Denmark) for 24 hours. Spleen cell 
suspensions were cultured at 106 cells/ml culture medium with 50 μg/ml CII or 5 μg/
ml Concanavalin A in 96-well tissue culture plates (Nunc) for 72 hours. Culture 
conditions were 37°C in a humidified atmosphere containing 5% carbon dioxide. 
Cytokine measurements
A 10-plex panel containing beads for mouse IL-1β, IL-2, IL-4, IL-6, IL-10, IL-12p70, IL-17, 
granulocyte-macrophage colony-stimulating factor, IFN-γ and TNF-α (Bio-Rad, 
Hercules, CA, USA) was used. After incubation and washing steps 19, the beads were 
measured on a Bio-Plex (Bio-Rad).
Statistical analysis of arthritis induction
We analysed the fraction of animals with arthritis as a function of time, by fitting time- 
response models to our data. We used PROAST, a general program for dose-response 
modelling 20,21. These models apply directly by regarding time rather than dose as 
the independent variable - that is, the time of onset of arthritis defined as the median 
Figure 1   Scheme of CIA induction and statin administration. 
Mice were immunised at day 0 (IMM) and challenged at day 21 (CHA), after which arthritis was scored 3 times 
a week until day 42. Atorvastatin (A) or pravastatin (P) were given daily, either before (day -28 until day 20) or 
after CIA induction (day 22 until day 42). Mice were euthanized at day 42.
-28 20 21 22 42
IMM CHA arthritis
day0
A after CIA induction
P before CIA induction
A before CIA induction
P after CIA induction
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time when 50% of the animals develop arthritis (ET50). The fitted model was the 
log-logistic model:
y = a + (1 − a) / {1 + exp [c ln (b/x)]}
where y is the fraction of animals showing arthritis and x is the time (a, b and c are 
constants). First, the model was fitted to the data from all (five) experimental groups 
combined - that is, the same ET50 value was estimated for all treatment groups. The 
same model was then fitted but now by estimating a treatment-specific ET50 value. 
When the associated fit of the model (as reflected by the value of the log-likelihood) 
is significantly improved (likelihood ratio test), this indicates a significant treatment 
effect on the ET50 value.
The analysis of the fraction of animals with arthritis over time as described above is 
statistically invalid because the observations over time relate to the same animals 
(that is, the assumption of independent observations does not hold). As a result, 
p values and confidence intervals of the means will be too optimistic. We therefore 
performed an additional analysis as follows. The arthritis severity scores were analysed 
as a function of time using a so-called latent-variable model. In this model the latent 
variable reflects the arthritis severity as a continuously increasing value with time, 
while the observed scores are imagined to arise from consecutive cut-off values on 
that underlying continuous severity scale. These cut-off values are estimated while 
fitting the time-response model to the scores 22.
The latent-variable model:
y = a exp (b × d)
where y is the latent variable and x is time (a, b and d are constants), was fitted to the 
observed scores for all individuals combined, by including the factor individual animal 
as a covariate. Individuals were found to significantly differ in the time-response curve 
regarding parameter b, but parameters a and d were not found to differ significantly. 
Hence, we fitted the model with only parameter b dependent on the individual animal. 
The resulting estimates for b were then analysed in a one-way analysis of variance to 
compare the treatments. In this analysis the estimates for b are statistically 
independent. Because the results of statin treatments on arthritis induction using the 
latent variable model were similar to the results using the log-likelihood model, we 
have chosen to show the results of the latter model.
General statistical analysis
The effect of arthritis induction on body weight, autoantibody production and cytokine 
production was assessed using an independent samples t test (SPSS Inc., Chicago, 
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Illinois, USA). The effect of statin treatments on body weight, autoantibody production 
and cytokine production was assessed using one-way analysis of variance, followed 
by the Bonferroni post hoc test (SPSS Inc.).
RESULTS
Body weight
Induction of CIA resulted in a lower body weight compared with negative control 
animals (Figure 2). This difference was statistically significant (p<0.05) from day 33 
after immunisation onwards. Atorvastatin administration before CIA induction resulted 
in a lower body weight compared with CIA control animals (Figure 2). This difference 
was statistically significant (p<0.05) from day 37 after immunisation onwards. 
Atorvastatin administration after CIA induction, or pravastatin administration before or 
after CIA induction, did not significantly alter body weight compared with CIA control 
animals.
Figure 2   Effect of CIA induction and statin treatment on body weight. 
Mice were immunised at day 0, challenged at day 21, and weighed 3 times a week until euthanasia at day 
42. Statins were given daily. Black circles connected by dotted line: atorvastatin before CIA induction. Black 
squares connected by dotted line: atorvastatin after CIA induction. Black triangles connected by dotted line: 
pravastatin before CIA induction. Black upside-down triangles connected by dotted line: pravastatin after 
CIA induction. Black diamonds connected by dotted line: CIA control. Black circles connected by continuous 
line: negative control. N = 12 per group. The effect of arthritis induction was assessed using an independent 
samples t-test; the effect of statin treatments was assessed using one-way ANOVA, followed by the 
Bonferroni post-hoc test.
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Arthritis
Statin administration (both atorvastatin and pravastatin, both before and after CIA 
induction) resulted in 100% arthritic animals at the time of euthanasia, whereas only 
seven out of twelve non-statin animals (controls) had developed arthritis at that time 
point (Figure 3A). Statin administration resulted in earlier arthritis onset, expressed as 
the day after immunisation in which 50% of the animals show arthritis (Figure 4). 
Figure 3   Effect of statin treatment on arthritis incidence and score. 
(A) Number of arthritic animals per group vs. time after immunisation. 
(B) Summed arthritis score per group of animals vs. time after immunisation. Mice were immunised at day 
0 and challenged at day 21, after which arthritis was scored 3 times a week until day 42. Statins were given 
daily. Black circles connected by dotted line: atorvastatin before CIA induction, Black squares connected by 
dotted line: atorvastatin after CIA induction, Black triangles connected by dotted line: pravastatin before CIA 
induction, Black upside-down triangles connected by dotted line: pravastatin after CIA induction. Black 
diamonds connected by continuous line: CIA control. N = 12 per group.
21 23 26 28 30 33 35 37 41
0
20
40
60
80
100
day after induction
di
se
as
e 
in
ci
de
nc
e 
(%
)
21 23 26 28 30 33 35 37 41
0
10
20
30
40
50
day after induction
su
m
m
ed
 a
rt
hr
iti
s 
sc
or
e
A
B
177
STATINS ACCELERATE THE ONSET OF COLLAGEN TYPE II-INDUCED ARTHRITIS IN MICE 
5
Figure 4   Statin administration accelerates arthritis onset (fraction of arthritic 
animals vs. time). 
Mice were immunised at day 0 and challenged at day 21, after which arthritis was scored 3 times a week until 
day 42. (A) Mice were given atorvastatin before challenge (days -28 until day 20; pre-A; cross sign, grey line) 
or after challenge (days 22 until 42; post-A; open triangle, dark grey line), or they were given pravastatin 
before challenge (pre-P; plus sign, dashed line) or after challenge (post-P; open circle, black line). Control 
mice (open diamond, dotted line) did not receive statins. The grey and black lines are overlapping. 
(B) The ET50 values (mean and 90% confidence intervals) calculated from Fig.4A are depicted. (*) 
significantly different (p<0.05) from control mice; (+) significantly different (p<0.05) from pre-A, pre-P, and 
post-P treated mice. N = 12 per group. The ET50 values (mean and 90% confidence intervals) were 
calculated using the PROAST program. One-way ANOVA followed by the Bonferroni post-hoc test.
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Atorvastatin administration after CIA induction resulted in earlier onset than atorvastatin 
administration before CIA induction, or than pravastatin administration before or after 
CIA induction (Figure 4). 
The arthritic score summed per group of animals showed a similar score for the 
animals that received pravastatin before CIA induction and non-statin controls, 
whereas the other groups of statin-administered animals showed higher scores 
(Figure 3B). Only seven out of twelve non-statin controls became arthritic, so the 
mean arthritic score for animals that received pravastatin before CIA induction was 
lower than for the non-statin controls (data not shown).
Autoantibody production
Induction of CIA resulted in the presence of anti-CII antibodies (log IgG level = 5.17; 
p<0.001 compared with the negative controls). Atorvastatin administration resulted in 
higher anti-CII antibody production compared with pravastatin administration and the CIA 
control (p=0.005 and p=0.013, respectively). In addition, atorvastatin administration 
before CIA induction increased the anti-CII antibody production compared with the 
CIA control (p<0.05; Figure 5).
Cytokine production
Induction of CIA resulted in increased IL-2 production by Concanavalin-A-stimulated 
LN cells and increased IL-2 and IL-17 production by CII-stimulated spleen cells 
(p<0.05; Figure 6). For none of the other cytokines tested was a significant effect due 
to CIA induction found.
Figure 5   Anti-collagen type II IgG levels. 
Mice were immunised at day 0 and challenged at day 21. Atorvastatin (A) or pravastatin (P) were given daily, 
either before (day -28 until day 20) or after (day 22 until day 42) CIA induction. Mice were euthanized at day 
42. Control mice (C) did not receive statins. Anti-CII IgG was measured in serum by ELISA. N = 12. (*) 
Significantly different (p<0.05) from C. N = 12 per group. One-way ANOVA followed by the Bonferroni 
post-hoc test.
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Atorvastatin administration after CIA induction increased IFN-γ production by 
CII-stimulated spleen cells (p<0.05; Figure 6). Combining the results of both statins, 
administration after but not before CIA induction resulted in increased production 
(p<0.01). Combining the results of both time points, both atorvastatin and pravastatin 
increased IFN-γ production (P<0.05). For none of the other cytokines tested was a 
significant effect due to statin administration found.
Figure 6   Cytokine productions by LN and spleen cells. 
(A) IL-2 production by Con A-stimulated inguinal LN cells. (B) IL-2 production by collagen type II-stimulated 
spleen cells. (C) IL-17 production by collagen type II-stimulated spleen cells. (D) IFN- production by collagen 
type II-stimulated spleen cells. Mice were immunised at day 0 and challenged at day 21. Atorvastatin (A) or 
pravastatin (P) were given daily, either before (day -28 until day 20) or after (day 22 until day 42) CIA induction. 
Mice were euthanized at day 42. Control mice (C) did not receive statins. In negative mice (N) arthritis was 
not induced and these mice did not receive statins. Inguinal LN were excised and LN cells were cultured in 
the presence of Con A for 24 hours. Spleens were excised and spleen cells were cultured in the presence of 
CII for 72 hours. Cytokine content was measured in the supernatants. N = 12. (*) Significantly different 
(p<0.05) from negative mice (N). (+) Significantly different (p<0.05) from control mice (C). N = 12 per 
group. The effect of arthritis induction was assessed using an independent samples t test; the effect of statin 
treatments was assessed using one-way ANOVA, followed by the Bonferroni post-hoc test.
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DISCUSSION
Here we have shown that statin administration results in 100% arthritic animals, 
whereas only seven out of twelve non-statin animals (controls) developed arthritis. 
Moreover, statin administration accelerated arthritis onset. This accelerated onset 
was seen when statin administration was started either before or after CIA induction. 
Accelerated onset resulting from statin administration before CIA induction is in line 
with our hypothesis of statin-induced immune deviation resulting in autoimmunity 9,10. 
In addition, we observed that atorvastatin administration after CIA induction resulted 
in earlier arthritis induction than administration with the same statin before CIA 
induction. Overall, atorvastatin had a somewhat stronger effect on accelerating onset 
than pravastatin. Atorvastatin administration before or after CIA induction, or 
pravastatin administration after CIA induction, resulted in a similar mean arthritic 
score compared with the non-statin control, while pravastatin administration before 
CIA induction resulted in a lower mean arthritic score. In this latter pravastatin group 
the acceleration of arthritis onset was five days, while that in the other cases was 
seven or nine days. This lower mean arthritic score may suggest a beneficial effect of 
pravastatin. This dosing regime, however, also results in accelerated arthritis onset 
and an increased number of arthritic animals (mice).
Other studies using the mouse CIA model have shown beneficial effects of statin 
administration on joint inflammation 13–16. To establish whether statin type, dose, 
route of administration, or timing of administration relative to CIA induction influenced 
the clinical outcome, the results of the abovementioned studies, as well as our data, 
are compared in Table 1. Suppression of arthritis development was seen after oral 
administration of 10 mg/kg atorvastatin (the same exposure route and dose as we 
used in our study) during (almost) the whole period from immunisation to euthanasia 
13. This finding contrasts our results that show accelerated onset when 10 mg/kg 
atorvastatin was given orally either before or after CII challenge. This issue needs to 
be resolved in future studies. Suppression of arthritis development was also found 
after intraperitoneal administration of 100 mg/kg pravastatin 14 or 40 mg/kg simvastatin 
15,16. Using other statins, lower doses, or other exposure routes failed to show an 
effect on arthritis. An accelerated onset of arthritis was only found in our study.
Atorvastatin administration before CIA induction resulted in increased anti-CII 
antibody production, whereas atorvastatin administration after CIA induction resulted 
in a non-significant increase in production of this antibody. Pravastatin administration 
before and after CIA induction, however, did not affect anti-CII IgG antibody production.
Atorvastatin administration before CIA induction resulted in accelerated arthritis onset 
and increased autoantibody production. This observation may suggest that increased 
autoantibody production plays a role in accelerated arthritis onset. Our observational 
study showed that statin use is associated with an increased risk of developing RA 9. 
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In humans, IgM rheumatoid factor and anti-cyclic citrullinated peptide antibodies 
have been found years before RA becomes clinically apparent 23. For RA patients 
that used statins before developing clinically manifest disease, therefore, statin use 
may have coincided with autoantibody development. Statins may be speculated to 
increase autoantibody production, thereby facilitating RA development.
CIA induction resulted in increased IL-2 production by Concanavalin-A-stimulated LN 
cells, probably reflecting the stronger activation or higher frequency of T cells in the 
LN draining the inflamed joints. Production of this cytokine was not significantly 
affected by statin administration. Similarly, CIA induction resulted in increased IL-2 
production by CII-stimulated spleen cells, and production of IL-2 was not significantly 
affected by statin administration.
Table 1  Comparison of statin effects on murine collagen-induced arthritis
Study Statin Dose  
(mg/kg)
Exposure  
route
Timing 
(days)
Effect on 
arthritis
This study A* 10 Oral -28 till 20 ΔET50 -7 daysⅡ
This study A 10 Oral 22 till 42 ΔET50 -9 days
This study P† 40 Oral -28 till 20 ΔET50 -5 days
This study P 40 Oral 22 till 42 ΔET50 -7 days
Ho and colleagues.13 A 10 Oral 2 till 49 suppression
Yamagata and colleagues.14 P 100 intraperitoneal 0 till 35 suppression
Leung and colleagues.15 S‡ 40 intraperitoneal 21 till 40 suppression
Leung and colleagues.15 S 20 intraperitoneal 21 till 40 no effect
Leung and colleagues.15 S 10 intraperitoneal 21 till 40 no effect
Palmer and colleagues.16 A 100 Oral 0 till 48 no effect
Palmer and colleagues.16 A 1 Oral 0 till 48 no effect
Palmer and colleagues.16 R 2 subcutaneous 0 till 48 no effect
Palmer and colleagues.16 R§ 0.2 subcutaneous 0 till 48 no effect
Palmer and colleagues.16 R 40 intraperitoneal 21 till 35 no effect
Palmer and colleagues.16 S 40 intraperitoneal 21 till 35 suppression
Palmer and colleagues.16 S 40 Oral 21 till 35 no effect
* A, atorvastatin
† P, pravastatin
‡ S, simvastatin
§ R, rosuvastatin. 
Ⅱ  ΔET50: number of days between the ET50 of the statin treated animals and the ET50 of the control 
animals (ET50 is the time where 50% of the animals developed arthritis)
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Furthermore, CIA induction resulted in increased IL-17 production by CII-stimulated 
spleen cells. Since IL-23-deficient mice that lack IL-17-producing CD4+ cells (T helper 
(Th) 17 cells) are resistant to CIA induction 24, Th17 cells are assumed to play an 
essential role in CIA. The activation or frequency of Th17 cells in the spleen is probably 
increased in arthritic mice, in line with previous studies 24–27. Importantly, IL-17 
production was not significantly affected by statin administration.
In addition, CIA induction resulted in decreased IFN-γ production by LN cells 
(0.75-fold) and CII-stimulated spleen cells (0.71-fold), albeit not statistically 
significantly (data not shown). Since IFN-γ acts as a disease-limiting factor in CIA 28, 
reduced levels of this cytokine may possibly be characteristic for CIA. Since 
atorvastatin was shown to inhibit IFN-γ production 29, and absence of IFN-γ signalling 
resulted in accelerated arthritis onset 30,31, reduced production of this cytokine may 
be a possible mechanism underlying accelerated arthritis onset due to atorvastatin 
treatment. We did not, however, observe altered IFN-γ production due to statin 
administration. Taking together the IL-17 and IFN-γ data, the increased IL-17 and 
decreased IFN-γ production upon CIA induction fits the selective induction of Th17 
and not Th1 cells in CIA 24.
Another possible mechanism by which statins may affect arthritis is through their 
induction of caspase-1, IL-1β and IL-18 in monocytes, resulting in increased IFN-γ 
production by T cells 32. Interestingly, this increased IFN-γ production occurred only 
at low statin concentrations. Caspase-1 activation results in cleavage of pro-IL-1β and 
pro-IL-18 to their mature (active) forms. Caspase-1, IL-1β and IL-18 are all implicated in 
CIA. The pharmacologic caspase-1 inhibitor VX-765 reduced paw inflammation when 
given prophylactically and therapeutically in mice 33. IL-1β administration accelerated 
arthritis 34, while anti-IL-1β treatment markedly suppressed established arthritis 35. 
IL-18 administration resulted in higher arthritis incidence and severity 36,37 , while 
IL-18-deficient mice showed reduced arthritis incidence and severity 38. This 
observation may suggest that statins aggravate arthritis by activating caspase-1, 
thereby inducing IL-1β and IL-18. Increased IFN-γ production may, on the contrary, 
reduce arthritis. Taking the two possible mechanisms together, caspase-1 activation 
by statins may aggravate arthritis by inducing IL-1β and IL-18. The resulting IFN-γ 
induction that in itself reduces arthritis may be counteracted by the Th2 skewing 
effect of statins. Clearly, disease outcome results from a complicated interplay 
between various effects of statins. In our hands, statin exposure resulted in accelerated 
arthritis onset. 
In summary, the anti-CII antibody, IL-2, IL-17 and IFN-γ data do not provide a possible 
mechanism for the accelerated arthritis observed in this study. It should be noted, 
however, that establishing such a mechanism was not the aim of our study. We aimed 
to investigate whether a causal relationship could be established for the association 
between statin use and an increased risk of developing RA.
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The CIA model was chosen because our observational study has shown that statin 
use was associated with an increased risk of developing RA9; because it is a model 
for RA, recapitulating many aspects of the disease 39–42; because an induced model 
is preferred to a spontaneous model, since that is the only model where the effects of 
statin use prior to expression of arthritis can be tested; and because the mouse CIA 
model is both B-cell and T-cell mediated and is therefore more similar to human RA 
than models such as the rat adjuvant arthritis model, which is (only) T-cell mediated.
CONCLUSIONS
Here we have shown that administration of atorvastatin and pravastatin resulted in 
accelerated arthritis onset in a mouse CIA model. Atorvastatin administration after 
CIA induction resulted in earlier onset than atorvastatin administration before CIA 
induction, or than pravastatin administration before or after CIA induction. Atorvastatin 
administration, especially before CIA induction, resulted in increased autoantibody 
production. Importantly, our data provide a causal relationship for previous results 
obtained from observational studies 9,10.
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1. INTRODUCTION
In recent decades, it has been recognised that the development of autoimmunity is a 
multi-factorial process in which both genetic and environmental features interfere and 
contribute to the aetiology and progression of the disease. Despite many years of 
intensive research, exact mechanisms of initiation of autoimmunity remain unclear. 
Several studies have demonstrated that environmental components play a major role 
in this process of autoimmunity 1–5 and may be responsible for the increased 
prevalence of autoimmune disorders in highly industrialised countries 6. Many drugs 
are associated with the development of certain autoimmune disorders, e.g., lupus-like 
syndrome and vasculitis 7–19. 
Statins, angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor 
blockers (ARBs) are widely prescribed to reduce the risk of cardiovascular morbidity 
and mortality in patients with or at risk for coronary heart disease 20–25. In addition to 
their cholesterol and blood pressure lowering effects, several studies have shown 
that these drugs also have anti-inflammatory and immunomodulatory properties 26–43, 
and are thereby also effective in the treatment of certain autoimmune disorders. The 
beneficial effects of these drugs are well described, but interestingly, such immuno-
modulating effects may, on the other hand, adversely influence immune regulation. 
Therefore, a hypothesis may be put forward that statins, ACE inhibitors and ARBs 
facilitate the development of autoimmunity, potentially resulting in autoimmune disorders. 
At the time of marketing authorisation of a drug, not all is known about the safety of a 
drug. The full safety profile of a drug may not be known until many years after its market 
launch. This knowledge gap may be due to limitations in clinical trials, including 
homogeneous populations, small sample size, limited duration and the inability to 
predict the real world 44. Post-marketing collected safety data offers a valuable and 
necessary addition to clinical trials 44, as is shown in this thesis. Currently, a more 
pro-active approach towards the identification and quantification of safety data has 
been anticipated 45,46. Actually, among regulators and pharmaceutical industries 
there is an agreement that safety data should be continuously collected throughout 
its market life 47. This agreement has been implemented in several guidelines for risk 
management programs 48,49. Not only the pro-active approach by pharmaceutical 
industries and regulatory authorities, but also the routine approaches in pharma-
covigilance, such as spontaneous reporting of adverse drug reactions (ADRs) by 
healthcare professionals, patients, regulatory authorities and pharmaceutical industries 
are of importance in the detection of new, rare and/or serious ADRs 50. In clinical 
practice, it is a challenge to detect autoimmune disorder-associated ADRs as they 
are relatively uncommon, appear after long-term use and may not disappear after 
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withdrawal of these drugs 51–53. This thesis aims to explore whether there is an 
association between the use of cardiovascular drugs (statins, ACE inhibitors and 
ARBs) and the incidence of autoimmune disorders. In this chapter, we summarise 
and discuss our main findings and immune-mediated mechanisms of statin-associated 
immune disorders, consider several methodological issues, address the practical 
and clinical implications, and present important areas for future research. 
2. SUMMARY OF THE MAIN FINDINGS
Signal detection for statin-associated autoimmune disorders in 
spontaneous reporting databases
Since the introduction of statins to the market in the late eighties 54, increasing numbers 
of cases of statin-associated lupus-like syndrome, vasculitis and polymyalgia 
rheumatica (PMR) have been reported in the literature 55–61. Based on these case 
reports, we assessed whether there was an association between statin use and the 
occurrence of lupus-like syndrome (chapter 2.1), and PMR (chapter 2.2), respectively. 
In the first study, using a spontaneous reporting database (VigiBase), we found that 
statin use was more often reported in patients with lupus-like syndrome than in 
patients who experienced other ADRs (chapter 2.1). In accordance with our finding, 
Moulis et al. observed an association between statin use and reporting lupus 
erythematosus in the French PharmacoVigilance database 62. Our second study showed 
a strong association between statin use and reporting of PMR in a spontaneous 
reporting database (chapter 2.2). Furthermore, in this study, six individual case safety 
reports (ICRs) had records of recurrence of PMR after re-exposure to statins, which 
strengthened the suspicion regarding the drug’s causal involvement in these patients. 
The results of both studies lend support to previous anecdotal case reports in the 
literature 57–59, suggesting a pharmacovigilance signal of statin-associated lupus-like 
syndrome and PMR. 
To strengthen our findings of statin-associated PMR, we described a patient in more 
detail to illustrate the possible causality of statin-associated PMR/giant cell arteritis 
(GCA). In this case report, we describe the disappearance of PMR after withdrawal of 
statins and recurrence of PMR/GCA after resumption of treatment with a statin, which 
is strongly suggestive of statin-induced PMR/GCA (chapter 2.3). 
Testing the association between cardiovascular drug use and  
the incidence of autoimmune disorders in electronic health record 
databases
As the spontaneous reporting database is primarily used for signal detection (hypothesis 
strengthening) and hypothesis generation purposes, and not for hypothesis testing, 
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we tested our hypothesis in electronic health record databases. As described in 
chapter 3, we performed two studies to determine whether statin use was associated 
with an increased risk of developing RA. In the first study, statin use and incident RA 
were derived from data on drug prescriptions, morbidity and referrals of the 
Netherlands Information Network of General Practice (LINH). By performing a case- 
control study, we found an increased risk of developing RA within six months of statin 
use (chapter 3.1). A consistent trend of increasing risk of developing RA with increased 
duration, defined daily doses and number of prescriptions, was not observed, nor 
with adherence to statin treatment. However, we observed a small trend between 
increasing potencies of statin treatment and the risk of RA. To deal with the limitations 
of a case-control study 63, we performed a second study where we addressed the 
same research question by using a time-dependent analysis. We have confirmed 
and extended our findings by describing the patterns of risks of RA (hazard rates) 
with changes in statin exposure over time in a large retrospective cohort study, the 
United Kingdom (UK) Clinical Practice Research Datalink (CPRD). In this second 
study, statin use and incident RA were derived from data on prescriptions, diagnoses 
and referrals to specialist care. For the second time, we found that statin use was 
associated with an increased risk of developing RA (chapter 3.2). The risk of RA was 
substantially increased in the first year after the start of exposure to statins and then 
diminished to baseline. The risk of RA was highest among women and restart users. 
Since the risk of developing RA was increased shortly after statin initiation, it is 
possible that statins can accelerate RA onset in patients susceptible to developing 
RA, as was demonstrated by our in vivo study which is discussed later in this chapter. 
In a systematic review of case reports of statin-associated lupus-like syndrome, it 
was shown that the majority of these cases also had a time to onset of less than a 
year 60.  However, the use of statins for a prolonged time is probably safe and well 
tolerated in patients not prone to develop RA. This could also explain the difference 
in the risk of developing RA in ‘de novo’ and ‘restart’ users. It may be that ‘de novo’ 
users were patients who can tolerate statins whereas ‘restart’ users were patients 
who were less likely to be fully adherent to statins because of potential discomfort or 
side effects. Another explanation could be our observed effect modification by sex: 
men were not at risk whereas women were at high risk for developing RA. Accordingly, 
it has been shown that women are more prone to developing RA64,65.  To date, five 
other studies have assessed the risk of incident RA after statin treatment, and have 
shown conflicting results 66–70. None of these studies found an increased risk of 
developing RA with statin use. Three population-based cohort studies reported that 
statins may exert a protective effect on the development of RA 66,67,70 whereas two 
other population-based cohort studies did not observe an effect 68,69. These findings 
conflict with our studies which may be explained by considering a lag-time between 
exposure to statins and incident RA 68,69, using different definitions of RA 67–70 or 
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exposure to statins 66–70, comparing to a control group of non-persistent statin users 
instead of non-users 67, controlling for other confounders 66–70, shifting the date of the 
first event of RA 66, conducting separate analyses in patients with or without a medical 
history of cardiovascular risk factors 66, or propensity score matching on baseline 
characteristics 70 (Table 1). This latter method was originally proposed by Rosenbaum 
and Rubin in 1983 71. With this method, a subject’s propensity score is defined as the 
conditional probability of receiving a certain treatment (versus another), given a 
collection of observed confounders. In general, this probability is unknown, but is 
usually estimated from the data using logistic regression, modelling exposure status 
(e.g. exposed or non-exposed to statins) as the dependent variable and the potential 
confounders as the independent variables. It has been shown that two subjects with 
the same propensity score have an equal estimated probability of exposure. After 
matching on the propensity score, the group of subjects who are exposed or 
non-exposed to statins tend to have the same distribution of potential confounding 
factors. Balance of the potential confounders across exposed and non-exposed 
groups can be quantified as proposed by Belitser et al. 72. 
As we have shown an increased risk of developing RA within a year after statin 
initiation, a plausible explanation for the discrepancy between our findings and the 
other five observational studies 66–70, may be that our study did not take a lag-time 
for developing RA into consideration. Although we used two different study designs 
and databases to study whether statin use was associated with RA, the distribution 
of cardiovascular diseases and related risk factors (e.g. hyperlipidaemia) were not 
balanced at baseline in both studies, and may have influenced our results. 
We further tested our main hypothesis by performing a study where we investigated 
whether the use of ACE inhibitors or ARBs is associated with incident RA. In this 
case-control study, we included only users of ACE inhibitors or ARBs or other anti- 
hypertensive drugs (the reference group) (chapter 3.3). Within the Dutch general 
practice database (LINH), we did not observe an association between ACE inhibitor 
or ARB use and the risk of developing RA. The effect was consistent when we defined 
the exposure to ACE inhibitors and ARBs as current and past use, duration, or dosage 
of use. These results do not support the hypothesis that ACE inhibitors or ARBs 
either facilitate or protect against RA. To our knowledge, apart from our study, no 
observational study has investigated the influence of ACE inhibitor or ARB use and 
incident RA. Evidence for the association between ACE inhibitor or ARB use and the 
occurrence of autoimmune disorders was derived from case reports, animal models 
and patients. These findings were, however, inconclusive. Case reports suggested 
ACE inhibitor or ARB-associated lupus-like syndrome, vasculitis and pemphigus 73–94, 
whereas in animal models of induced arthritis, beneficial effects of ACE inhibitor and 
ARB use were demonstrated 95–98. Conflicting results were presented in open-label 
193
SUMMARY AND GENERAL DISCUSSION
6
studies with patients with RA treated with ACE inhibitors or ARBs. Two open-label 
studies showed that patients with RA treated with these drugs had reductions in 
clinical symptoms and inflammation markers 32,33, whereas in two other studies no 
clinical improvements were observed 99,100. These latter two studies are in line with 
our findings. However, these studies were conducted in patients in whom RA had 
already been diagnosed. In our study, we evaluated the risk of developing RA among 
patients initially free from RA who were treated with ACE inhibitors or ARBs. 
Nevertheless, hypertension may be considered as an immune-mediated disease 101 
and is more prevalent in patients with RA than in the general population 102. With 
regard to their immunomodulatory abilities and the high occurrence of hypertension 
in patients with RA, ACE inhibitors and ARBs are effective in treating hypertension, 
and may be beneficial in the treatment of RA.
Statin use and autoimmunity
In the introduction of this chapter, we postulate that statins may facilitate the 
development of autoimmunity. It has been suggested that statins, apart from their 
anti-inflammatory effects, may have a direct immunomodulating effect on T cells and 
may promote a shift from T helper (Th) 1 to Th2 immune responses, possibly leading 
to a dysregulation in the immune homeostasis 36,60,103. In the studies above, we were 
not able to evaluate this hypothesis, but by using serum samples from the Doetinchem 
Cohort Study which was linked to PHARMO Record Linkage System (PHARMO-RLS), 
a database comprising pharmacy-dispending records on statin use, we could study 
the association between statin use and markers of (auto) immunity. We studied the 
effects of statin use on markers of innate and adaptive immunity, and self-tolerance 
by measuring serum levels of C-reactive protein (CRP), neopterin, immunoglobulin E 
(IgE) antibodies and the presence of autoantibodies (antinuclear antibodies (ANA) 
and IgM rheumatoid factor (RF)) in subjects from the general population who were 
either statin user or non-user (chapter 4). As also observed in population-based 
studies and clinical trials 104–109, levels of CRP were found to be lower in the statin 
users than in non-users. By confirming this well-known association between statin 
use and decreased levels of CRP, we have shown that we have used appropriate 
methods for patient selection in our study. In addition, we found in statin users a 
trend towards higher levels of IgE antibodies, a surrogate marker for Th2 response. 
No differences were observed in the levels of neopterin, a surrogate marker for Th1 
response, and/or the presence or absence of autoantibodies between statin users 
and non-users. These findings suggest that statins exert anti-inflammatory effects 
but do not provide evidence that statins exert immunomodulatory effects on a Th1 
response and/or loss of self-tolerance. However, an immunomodulatory effect on 
Th2 response cannot be excluded. This latter finding should be investigated in 
peripheral blood of healthy individuals instead of sera. Our finding on Th2 response 
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Table 1   All observational studies showing the risk of developing rheumatoid  
arthritis with statin use
Observational studies 
of statin-associated RA
Smeeth et al., 2008 69 Jick et al., 2009 66 Hippisley-Cox et al., 2010 68 Chodick et al., 2010 67 Schmidt et al., 2013 70
Data source UK Health Improvement Network 
Database (THIN)
General Practice Research 
Database (GPRD)
QResearch Database Maccabi Healthcare Service 
(MHS)
San Antonio area military health 
care system
Study design Retrospective cohort Nested case-control Prospective cohort Retrospective cohort Retrospective cohort
Study population · All patients registered with a GP 
between Jan 1995 - Dec 2006 
· Comprising EMR for 5.5 million 
patients derived from 303 
practices
· All patients registered with a GP 
between Jan 1, 1992 – Dec 31, 
2001
· Since 1987, ≥ 5 million residents in 
the UK have been enrolled
· All practices in England and 
Wales using the computer 
based Egton Medical 
Information System (EMIS)
· All patients registered with the 
practices between Jan 1, 2002 – 
June 30, 2008
· All patients who were 
continuously enrolled in the 
Israel Health Maintenance 
Organisation (HMO) from 
1995-1998 were included in 
the cohort (Jan 1, 1998 – July 1 
2007)
· Comprising 1.8 million people in 
the HMO
· All patients who were enrolled 
as Tricare Prime or Tricare Plus 
in the San Antonio are military 
health care system between Oct 
1, 2003- Mar 5, 2010
· Study period was divided into 
baseline period (Oct 1, 2003-
Sept 30, 2005) for describing 
the baseline characteristics 
and follow-up period (Oct 1, 
2005-Mar 5, 2010) for identifying 
connective tissue diseases
Exposure to statins · All patients aged 40-80 years who 
received their first prescription for 
a statin on or after Jan 1, 1995 
· Date of the first prescription of 
statins is defined as index date
· All patients aged 40-89 years with 
at least 1 prescription for a statin 
at any time
· Current statin use was defined as 
receipt of at least two prescriptions 
within 1 year preceding the first-
time diagnosis of RA
· All other receipt of statins was 
considered past use
· All new users of statins aged 
30-84 years during the study 
period 
· All patients aged ≥18 years 
who had at least 1 dispensed 
prescription of statins during the 
study period 
· Date of the first dispensed statin 
is defined as index date
· All patients aged 30-85 
years who received a statin 
prescription of at least 90-day 
supply between Oct 1, 2004-
Sept 30, 2005
Control group · Up to 5 non-users of statins were 
matched to each user on sex and 
age within 5 years
· Randomly selected up to 4 
controls, i.e. people without a 
diagnosis of RA 
· Matched by age (within 1 year), 
sex, calendar time (using the 
same date as first-time diagnosis 
of RA), practice and number of 
years of previous recorded history
· Non-use of statins during the 
study period
· <20% proportion of days 
covered with statins
· Did not receive a statin at any 
time during the study
Medical history · At least one year before start statin 
treatment
- · At least one year registered with 
the general practice when the 
date of the study started
· Patients who did not receive a 
statin prescription at least 3 year 
prior to the index date
· At least one year before start 
statin treatment (start date 
baseline period Oct 1, 2003  
and start date statin prescription 
Oct 1, 2004)
Definition RA · First time diagnosis of RA  · First time diagnosis of RA 
· Included cases with a stated 
diagnosis of RA and/or a referral 
to outpatient specialist or inpatient 
hospitalization and use of 
DMARDs
· First time diagnosis of RA · First time diagnosis of RA · The occurrence of 3 separate 
codes for connective tissue 
disorder, including RA, SLE, 
dermatomyositis, polymyositis, 
polymyalgia rheumatica, sicca 
syndrome, keratoconjuctivitis 
sicca, Sjögren’s disease and 
connective tissue disorder 
(unspecified) during the follow-
up period
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Table 1   Continued
Observational studies 
of statin-associated RA
Smeeth et al., 2008 69 Jick et al., 2009 66 Hippisley-Cox et al., 2010 68 Chodick et al., 2010 67 Schmidt et al., 2013 70
Shifting the date of the 
first diagnosis of RA
- · Exactly one year prior to the date of 
the first RA diagnosis (index date)
- - -
Considering a lag-time · Cases of RA in the first year after 
statin initiation were excluded
- - · Cases of RA in the first year after 
statin initiation were excluded
-
Time-dependent 
analysis
- - · To determine the risk of RA within 
1 year, 1-3 years, 3-5 years  
and ≥5 years of taking statins
- -
Confounders · Propensity score* at index date, 
year initiation of statin treatment, 
first diagnosis of the following 
post-index date: diabetes, 
cerebrovascular disease, 
coronary heart disease, peripheral 
vascular disease, other atheroma, 
atrial fibrillation, heart failure, 
hyperlipidaemia, hypertension, 
other circulatory disease, cancer, 
dementia, first use of the following 
post-index date: aspririn, nitrates, 
fibrates, β-blockers, CCB, 
potassium channel activators, 
diuretics, positive inotropes, 
anticoagulants, anti-hypertensive 
drugs, or other cardiovascular 
drugs
· Smoking before index date · Age, BMI, ethnicity, smoking, 
hypothyroidism at start study
· Age, sex, socioeconomic level, 
utilization of healthcare services 
in the year before the index date
· In the propensity score matched 
cohort: no correction for 
confounders
· In the unmatched cohort: 
adjusted for all covariates which 
were included in the propensity 
score model 
Propensity score · Adjusted for propensity score*
· Propensity score is based on 
factors that may influence statin 
prescribing
- - - · Matching on propensity score**
Subgroup analysis - · Hyperlipidaemia, type of statins · Sex, type of statins · Age categories, sex, baseline 
LDL levels and efficacy of initial 
statin therapy
-
RA, rheumatoid arthritis; GP, general practitioner; EMR, electronical medical records; UK, United Kingdom; 
DMARDs, disease-modifying anti-rheumatoid drugs; BMI, body mass index; CCB, calcium channel blockers; 
LDL, low-density lipoprotein
*included covariates in the propensity score model: body mass index, socioeconomic status, consultation 
rate, prescribing rate, smoking status, drinking habits, diabetes, coronary heart disease, cerebrovascular 
disease, peripheral vascular disease, other atheroma, other circulatory disease, dementia, cancer, atrial 
fibrillation, heart failure, recent hepatic disease, recent renal disease, thyroid disease, hyperlipidaemia, 
hypertension, recent use of hormone replacement therapy, anti-psychotics, antidepressants, steroids 
(oral or inhaled), fibrates, cytochrome P450 3A4 inhibitors, any prior use of non-statin or fibrate 
lipid-lowering medication, nitrates, aspirin, β-blockers, calcium channel blockers, potassium channel 
activators, diuretics, positive inotropes, anticoagulants, anti-hypertensive drugs, or other cardiovascular 
drugs.
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Table 1   Continued
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confounders
· In the unmatched cohort: 
adjusted for all covariates which 
were included in the propensity 
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Propensity score · Adjusted for propensity score*
· Propensity score is based on 
factors that may influence statin 
prescribing
- - - · Matching on propensity score**
Subgroup analysis - · Hyperlipidaemia, type of statins · Sex, type of statins · Age categories, sex, baseline 
LDL levels and efficacy of initial 
statin therapy
-
**included covariates in the propensity score model: age, sex, acute myocardial infarction, congestive heart 
failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic obstructive pulmonary 
diseases, rheumatologic diseases, peptic ulcer disease, mild liver disease, diabetes mellitus, diabetes mellitus 
complications, hemiplegia/paraplegia, renal disease, malignancy, liver disease (moderate/severe), metastatic 
neoplasm, HIV, illicit drug use, alcohol abuse/dependence, smoker, total Charlson co-morbidity index, 
number of outpatient medical encounters and inpatient admissions during each of the baseline period 
and the follow-up period, and the use of β-blockers, calcium channel blockers, diuretics, non-statin lipid- 
lowering drugs, angiotensin receptor blockers/ angiotensin converting enzyme inhibitors, oral 
hypoglycemic, cytochrome P450, aspirin, non-steroidal anti-inflammatory drugs, selective serotonin 
reuptake inhibitors, systemic corticosteroids, anti-psychotics, sedatives, tricyclic antidepressants. 
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is in line with the results of two other studies which suggested that statins promote a 
Th2 bias of the immune response 110,111. In contrast to this finding, Cherfan et al. 
reported that statins suppress Th2 response 107. As for the findings on Th1 response, 
our findings are in agreement with three other studies that found no effect on the 
levels of neopterin after treatment with statins 107,112,113, whereas in two other studies 
neopterin levels declined during statin treatment 114,115. To date, no studies have 
compared the presence of autoantibodies between statin users and non-users in the 
general population. As we did not observe an effect of statin use on the presence of 
autoantibodies in the general population, it seems that statins do not themselves 
cause a breakdown of self-tolerance, but may promote a pre-existing autoim-
mune-prone condition to develop towards a clinically manifest disease. However, in 
our animal study only administration of a specific type of statin, atorvastatin, before 
induction of collagen-induced arthritis has resulted in an increased autoantibody 
production (chapter 5). 
Causal relationship between statin use and autoimmune disorders
Based on the findings presented in chapter 3, it has been proposed that statin use is 
associated with an increased risk of developing RA. Yet, other observational studies 
found that statins have a protective effect, or no effect on developing RA 66–70. To 
date, our findings have not been corroborated by other studies. To further evaluate 
the association between statin use and the risk of developing RA, we performed an 
in vivo study, in a murine experimental model for RA, to investigate whether a causal 
relationship between statin use and the risk of developing RA could be established 
(chapter 5). In this study, we used the murine collagen type II (CII)-induced arthritis 
(CIA) model which is a well-known animal model for RA. In this animal model, mice 
are immunised by an injection of an emulsion of bovine CII mixed and Freund’s 
complete adjuvant, and are challenged three weeks later with CII alone, producing an 
immune response to connective tissues. Arthritis is scored from the time of challenge 
onwards 116. The CIA mice were orally administered with pravastatin, atorvastatin or 
phosphate buffered saline (PBS) daily for four to six weeks, either before (day -28 until 
day 20) or after (day 22 until day 42) CIA induction (n = 12 per group). In addition, we 
included unchallenged mice that only received PBS. We found that treatment with 
both 40 mg/kg pravastatin and 10 mg/kg atorvastation, either before or after CIA 
induction resulted in earlier arthritis onset compared to no treatment. Moreover, we 
observed that atorvastatin and pravastatin administration after CIA induction resulted 
in earlier arthritis onset than administration with the same statins before CIA induction. 
The observation of earlier arthritis onset after treatment with statins before CIA 
induction supports the results from chapter 3.1 and chapter 3.2. Four other animal 
studies, using the CIA murine model, have shown beneficial effects or no effects of 
statin treatment on arthritis onset 40,117–119. All of these of studies used different types, 
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routes, doses per body weight (mg/kg), initiation and duration of statin exposure. This 
substantial heterogeneity in approach and methodology between these studies, 
including ours, makes it difficult to compare the results from all these studies. 
Nevertheless, our study supports a causal relationship between statin use and the 
risk of developing RA. The murine model we have used in this study, however, seems 
to be an appropriate model for testing statin exposure prior to expression of arthritis. 
3.  IMMUNE-MEDIATED MECHANISMS OF STATIN-
ASSOCIATED IMMUNE DISORDERS
In this thesis we have assessed a causal relationship between statin use and the risk 
of developing RA. However, our data did not provide a possible mechanism for the 
statin-associated RA, nor did we reveal the mechanism of statin-associated lupus-like 
syndrome or PMR. 
It has been suggested that statins may promote a shift in Th1/Th2 balance 36,60, 
affect regulatory T cells 120–122, or lead to unstable regulatory T cells in the periphery. 
All of these mechanisms may promote autoimmunity 123,124. In addition, statins may 
exacerbate or trigger cellular apoptosis 60,125,126, which may result in increased 
amounts of autoantigens in the circulation 127,128 due to less efficient clearing of 
apoptotic cells. Also, statins may induce neo-antigens as a result of muscle damage 
which are subsequently presented to the immune system, as observed in statin-as-
sociated necrotising myopathy 129,130. A similar mechanism may be operative in sta-
tin-associated PMR. Furthermore, statins may inhibit the prenylation of Rho GTPases, 
including Rac-1 131,132. Rac-1 is directly implicated in the activation of caspase-1 133, 
which is crucial for processing and secretion of the pro-inflammatory cytokines 
interleukin (IL)-1β and IL-18 and to a lesser extent of IL-12, an inducer of IL-18, thereby 
promoting autoimmunity 134–136. Statins may be able to amplify autoimmunity in 
genetically susceptible individuals, thereby increasing the risk of developing 
autoimmune disorders 137. Another possible hypothesis is that the self-tolerance is 
lost due to persistence of infectious agents in individuals who were treated with 
statins. Since statins may reduce Th1 responses 42, infectious agents may not be 
cleared as efficiently as under normal circumstances 138, or statins themselves may 
increase the risk of herpes zoster 139,140 or the commonly encountered infections (e.g. 
sepsis) 141. As a consequence, these individuals may become immunocompro-
mised. Individuals who are immunocompromised may not have the ability to respond 
normally to infections due to an impaired or weakened immune system, possibly 
resulting in a loss of self-tolerance.
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4. METHODOLOGICAL CONSIDERATIONS
Type of study design
Different types of study design have been used in chapters 2, 3, 4 and 5 to address 
the association between prolonged use of cardiovascular drugs, statins, ACE 
inhibitors and ARBs, and the incidence of autoimmunity/autoimmune disorders. The 
differences in study design have been depicted in Figure 1. In this section, we will 
discuss the rationale for using different study designs and their strengths and 
limitations.
Descriptions of statin-induced autoimmune disorders are sparsely found in the 
literature. To date, only case reports have been reported and reviewed. Case reports 
provide a first opportunity to discover and explore potential associations 142. 
Qualitative signal detection on possible causal relations between an adverse event 
and a drug can then be detected through case assessment 143,144 as was performed 
by Moulis et al. using the French PharmacoVigilance database 62. For causality 
assessment, several decision algorithms have been introduced 145 which require 
positive dechallenge (disappearance of the adverse reaction after withdrawal of the 
drug) or positive rechallenge (recurrence of the adverse event after re-exposure) to 
fulfil the criteria of ‘certain causality’ 143. In chapter 2.3 we describe a case with a 
positive rechallenge of statin-associated PMR. 
When substantial numbers of case reports are available as in the spontaneous 
reporting system from the WHO collaborating Centre for International Drug Monitoring, 
comparing the proportion of these reports of adverse events with a specific type of 
drug may provide strong hypothesis-generating signals. The studies described in 
chapter 2.1 and 2.2 were conducted as a first essential step to strengthen our 
hypothesis of an association between statin use and the incidence of autoimmune 
disorders. Data from spontaneous reporting systems offer the opportunity to monitor 
all drugs after marketing. In addition, studies using these data may generate alerts 
and are not limit to the monitoring of specific patient groups. On the other hand, these 
ICRs have been submitted by governmental pharmacovigilance centres around the 
world and are heterogeneous in their source, documentation and relationship 
likelihood 146. A registry of this kind is not complete and reporting bias may occur as 
a result of differential underreporting 147–149. By including reports in which lupus-like 
syndrome or PMR were related to the suspected or concomitant drug (statins), we 
have tried to reduce the problem of selective reporting. The advantage of this analysis 
is that, the case/ non-case selection is neutral for exposure to statins 149. Nonetheless, 
case-by-case analysis is a valuable tool in pharmacovigilance and drug safety 
research 147.
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CHAPTER 6
As we detected a signal as reported in chapter 2, we tested our hypothesis in 
observational studies. The results from observational studies on the risk of 
autoimmune disorders associated with statins are scarce and lack consistency. 
Observational studies play an important role in establishing the safety profile of statin 
use in the post-marketing phase. Observational studies are valuable to test 
hypotheses and quantify the size of the effect of statins (chapters 3.1 and 3.2), ACE 
inhibitors, or ARBs (chapter 3.3) on the risk of developing RA. With regard to selecting 
a study design for assessing the associations between cardiovascular drugs and the 
risk of developing RA, no paradigm method exists. A case-control approach enables 
us to study the rare, potentially adverse events with a delayed outcome (e.g. RA) 
(chapters 3.1 and 3.3), while follow-up studies in electronic health databases with 
sufficient power are a good alternative (chapter 3.2). 
To test our hypotheses, we used data from GPs in the Netherlands and the UK as 
these two datasets provide medical information from patients in a real-life setting. 
Since the data in the GP datasets have already been collected, observational studies 
can be carried out relatively easily and rapidly compared with randomised controlled 
trials (RCTs) or animal studies. Furthermore, if exposure data are linked to the 
outcome of the study, the study can be performed without requiring additional 
information from patients or physicians. 
In the Netherlands and the UK, the vast majority of the population is registered with a 
GP who acts as a gatekeeper for access to specialised care. The GP is, in general, 
the first professional to be consulted for diagnoses of health problems or prescription 
of treatments 150,151. The data that was continuously recorded in both databases 
included demographic information, diagnoses, prescription details and details of 
referrals to specialist care 152,153. However, no data were available on dietary intake 
and physical activity. In the UK CPRD only limited data were available on smoking 
and other clinical examinations (e.g. lipid levels, inflammatory and immunomodulato-
ry markers (e.g. CRP, ANA, anti-citrullinated protein antibodies (anti-CCP)), blood 
pressure, BMI and glucose levels), all of which may be important confounders. When 
the GP databases are linked and extended with other types of data we may obtain a 
complete medical history of the patient, thereby improving the quality and quantity of 
confounding factors. By eliminating confounding as much as possible within each 
study, the higher its internal validity will be.
We did not have medical information from these patients that were referred to a 
rheumatologist, such as which treatment the patients were advised to start. However, 
Dutch guidelines for optimising GP–medical specialist communication instruct 
medical specialists to inform GPs of the results of the diagnostic tests and treatment 
advice given to the referred patient 154,155. 
Since potential unmeasured differences in the cardiovascular risk profile and other 
individuals’ characteristics between RA and controls, or statin users and non-users 
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may have been present, all three observational studies that we performed may have 
been subject to residual confounding (i.e. the distortion that remains after controlling 
for confounding factors in the design and/or analysis of the study) 156.  
It has been suggested that statins may dysregulate immune homeostasis and this 
can result in breakdown of self-tolerance, and induction of autoimmunity. To test this 
hypothesis (chapter 4), we performed a study using serum samples from the ongoing 
Dutch Doetinchem Cohort study linked to automated pharmacy-dispending records. 
With these serum samples, we measured surrogate markers for Th1 and Th2 
responses and for loss of self-tolerance, and the well-known marker for inflammation, 
CRP. To date, in the Doetinchem Cohort study, participants have been re-invited three 
times for examinations at 5-year intervals. At every examination round, serum was 
collected from participants, which allows us to study the association between statin 
use and autoimmunity not only cross-sectionally but also longitudinally. Not only 
serum, but also anthropometric and blood pressure measurements, and 
demographic, lifestyle and health characteristics were collected using a self-admin-
istered questionnaire. Using these data, we have a detailed description of the 
participants in a real-life setting. 
As described earlier, the observational Doetinchem Cohort study may be subject to 
residual confounding. However, we have matched the statin users and non-users on 
several factors; we believe we have reduced residual confounding as much as 
possible.
All of these observational studies (chapters 3.1, 3.2, 3.3 and 4) have been shown to 
be useful in testing our hypothesis. 
The in vivo study described in chapter 5, was conducted to confirm our findings 
presented in chapters 3.1 and 3.2. The results from this in vivo study may be 
considered as an important step towards establishing causality between statin use 
and the risk of developing RA. Besides establishing the causality of the relationship 
between statin exposure and autoimmune disorders, experimental studies in mouse 
models have the advantage of allowing us to study the adverse effects of statins, 
such as statin-induced RA. Moreover, controlling for all factors related to statin 
exposure and the development of RA in human intervention studies is complicated 
because of practical and ethical reasons. Uncertainties in relation to extrapolation of 
data from animal studies to humans are, however, a main disadvantage of 
experimental animal studies. Causality can also be illustrated by RCTs 157. However, 
RCTs are inefficient to detect rare adverse events or adverse events with a delayed 
outcome (e.g. autoimmune disorders). Furthermore, RCTs may be less generalisable 
due to, for instance, selection of patients without co-morbidities or co-medication, or 
patients’ non-adherence to the drug therapy (e.g. statins) 44. 
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Assessment of statin use
For the observational studies described in chapters 3.1, 3.2 and 3.3 of this thesis, 
routinely recorded prescription data from GPs were used. An advantage of using a 
computerised database is that we do not have to rely on patients’ recall of statin, ACE 
inhibitor, or ARB use, thereby eliminating recall bias. In addition, accurate data on the 
prescribed drugs over a long period of time are available. However, using 
computerised prescription data from the GP may introduce an overestimation of 
actual statin, ACE inhibitor, or ARB use. 
In chapter 4 pharmacy-dispensing data were obtained from PHARMO-RLS which 
was linked to the Doetinchem Cohort Study. Practically, all inhabitants are registered 
with a single community pharmacy, independent of the prescriber. Pharmacy-dis-
pensing data have similar advantages to prescription data from GPs. Pharmacy-dis-
pending records; however, have the advantage over prescription records of including 
information about whether statins, ACE inhibitors, or ARBs were actually obtained 
from the pharmacist in addition to being only prescribed by the GP. In a study where 
the differences between prescribed and dispensed medications were examined, it 
was demonstrated that approximately 13% of the drugs prescribed in general practice 
are not dispensed. However, patients eligible for governments’ reimbursement, as in 
the Netherlands, were more likely to have their prescriptions filled than patients 
without financial support 158. 
In a validation study of pharmacy records, it has been shown that such records are a 
reliable reflection of drug exposure as determined by a home inventory 159. However, 
it is still not clear whether statins, ACE inhibitors, or ARBs were actually being taken 
according to physician’s prescribed regimen. Furthermore, no information regarding 
the adherence to or discontinuation of therapy is available in electronic health record 
databases. 
Assessment of autoimmune disorders
In the studies presented in chapters 2 and 3 of this thesis, autoimmune disorders 
were assessed by spontaneous case reports and routinely recorded morbidity data 
from GPs. Despite the fact that we have reports or electronic records from specific 
autoimmune disorders, we may have used a relatively sensitive, but non-specific, 
definition of lupus-like syndrome, PMR and RA. In chapters 2.1 and 2.2, the definition 
of lupus-like syndrome and PMR was based on ADR terms used in the ICSRs 
submitted by physicians, manufacturers and consumers. Regrettably, in these ADR 
reports no detailed description such as elevation of inflammatory markers (erythrocyte 
sedimentation rate (ESR) and CRP), or response to therapeutics and disease course, 
for diagnosing PMR or lupus-like syndrome were available. As a consequence, we 
were not able to recognise possible diagnostic misclassification 160,161. However, in 
at least one of the ADR reports, we were able to collect clinical data from the reporter 
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which gave us the opportunity to describe the clinical course of a patient with sta-
tin-associated PMR/GCA in more detail (chapter 2.3).  Furthermore, in a small number 
of ADR reports of lupus-like syndrome the presence of ANA was listed. Since the 
inception of the WHO Global ICSR database in the late 1960s 162, lupus erythematosus 
(LE) cells could also have been listed in ADR reports of lupus-like syndrome. LE cell 
testing was once performed to diagnose lupus-like syndrome but has been replaced 
by testing for ANA and anti-double stranded DNA. To minimise possible misclassifi-
cation of lupus-like syndrome, we conducted a sensitivity analysis where we only 
included ADR reports of lupus-like syndrome in which the presence of ANA and/or LE 
cells was listed. Another approach to minimise misclassification of lupus-like 
syndrome or PMR involved limiting the heterogeneity of the ADR reports by conducting 
a sensitivity analysis where we only included ADRs from physicians. All of the 
sensitivity analyses have shown the same results, indicating that possible misclassi-
fication of lupus-like syndrome or PMR did not have a substantial impact on the 
results.
In chapters 3.1, 3.2 and 3.3 we defined RA based on routinely recorded morbidity 
data from GPs. In both GP databases, we had sufficient numbers of cases of RA to 
perform a case-control study or cohort study. Furthermore, both databases 
comprised robust data on morbidities of the patients. Again, we could not assess a 
complete description of the patient, and therefore we may have used a relatively 
sensitive, but non-specific, definition of RA. To deal with potential misclassification of 
RA, the first-time diagnosis registered by a GP was verified by the use of disease-mod-
ifying anti-rheumatoid drugs (DMARDs), or corticosteroids, or referrals to a 
rheumatologist. In chapter 3.2, we defined RA based on a diagnostic algorithm as 
postulated by Thomas et al. 163. The proposed diagnostic algorithm classified 
patients as having RA when they received at least one prescription of DMARDs after 
their first-time diagnosis, resulting in a relatively accurate diagnosis of RA 163. In 
chapters 3.1 and 3.3, we used a definition of patients with RA as those who received 
at least one prescription of DMARDs (as described in chapter 3.2), or at least two 
prescriptions of corticosteroids, or were referred to a rheumatologist. This increased 
the sample size of our cases of RA. By using stringent criteria for defining RA, we 
ultimately included a small number of patients with RA in our studies. Our restricted 
sample of patients with RA may have hampered the external validity of the studies.
We evaluated the impact of changing definitions of RA in several sensitivity analyses. 
Our results remained unchanged when we changed the definition of RA. As 
mentioned previously, GP databases lack medical information from the rheumatolo-
gists. For instance, when DMARDs or corticosteroids were prescribed by the 
rheumatologist, the prescription of the patient may not always appear in these 
datasets, resulting in a possible underestimation of patients with RA. Otherwise, 
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patients with other forms of arthritis, e.g., psoriatic arthritis may have appeared in 
these datasets. As a consequence, we may have introduced information bias that 
may produce an under- or over-estimation of the associations. Again, by assessing a 
complete medical history of the patient through data linkage, we may overcome the 
hurdle of possible misclassification of RA by using more specific markers for RA: RF 
and/or anti-CCP.
Other methodological considerations
Some additional methodological issues need to be considered when examining the 
associations between statin use and the risk of developing systemic autoimmune 
disorders. In our observational studies with RA, we could define the date of onset of 
RA by the first record of the GP for RA, but the date of onset of the RA symptoms is 
unknown 164. Chan et al. reported that the median time between the onset of 
symptoms and the diagnosis of RA was approximately 36 weeks 165. When there is a 
lag-time from the first symptoms and start of statin treatment before actual diagnosis 
of RA, protopathic bias may have occurred 166. In two previous population-based 
studies, it was considered that in the first year following initiation of statin treatment 
the development of RA may not be attributable to statins 67,69. To prevent this possible 
type of bias (protopathic bias) of defining the date of onset, we performed several 
sensitivity analyses where we shifted the date of the first-time diagnosis of RA to an 
earlier date (chapters 3.1, 3.2 and 3.3) and found similar, although somewhat more 
attenuated findings. In chapter 3.2 we performed an extra sensitivity analysis where 
we excluded the first year following the initiation of statin treatment from the follow-up 
time and found that the association between statin use and the risk of developing RA 
disappeared. Despite the results of our sensitivity analyses, we cannot exclude the 
possibility of protopathic bias. In addition, ascertainment or detection bias may have 
accounted to some degree for the increased risk of RA shortly after starting statin 
use. Patients who are treated with statins or patients who may experience myalgia or 
other muscle-related adverse effects due to statins; 167 tended to have more diagnostic 
testing or visits to their GP, or were more likely to be referred to a rheumatologist than 
the untreated patients, around the time of initiation of statin therapy; and may lead to 
an increased likelihood of being diagnosed with RA 68,168. 
Furthermore, differences in diagnoses and prescribing regimens by general practice 
could have biased the results of our studies. In our two case-control studies (chapters 
3.1 and 3.3), the average duration of registration with the GP is almost equal between 
patients with RA and controls, indicating that the patients in our studies had similar 
opportunities to have been prescribed a statin, or ACE inhibitor, or ARB. Because of 
the small number of patients with RA per GP, we could not control for general practice 
effects in our analyses.
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Another methodological consideration within observational studies is the phenomenon 
of ‘confounding by indication’ 169,170, which may occur when the prognosis of patients 
varies according to the exposure. By definition, characteristics differ inherently 
between those who were taking a given drug, and those who were not taking the 
drug, because they are taking the drug for a reason. Physicians have a reason to 
prescribe (‘indication’) drugs to patients, and tend to ‘channel’ certain drugs, or 
certain dosing regimens to specific patients. When these characteristics are related 
to the occurrence of the outcome, the association between exposure and outcome 
may be confounded. Importantly, cardiovascular risk factors (e.g. hyperlipidaemia) 
could have influenced the association between statin use and incident RA. In patients 
with RA, the systemic proinflammatory cytokines such as IL-1, IL-6 and tumor necrosis 
factor alpha (TNF-α) produced in synovial tissue of the joints, may promote the 
development of both traditional (e.g. hyperlipidaemia, hypertension, insulin 
resistance) and non-traditional (e.g. oxidative stress) systemic cardiovascular risk 
factors, thereby increasing the development of cardiovascular diseases (e.g. athero-
sclerosis) 171. Several studies have demonstrated an unfavourable lipid profile in 
patients with RA172,173. Hyperlipidaemia may induce leukocyte activation and possibly 
complement activation, 174–176 which may result in an earlier diagnosis of RA in 
patients prone to develop RA. When we conducted subgroup analyses in patients 
with and without these recorded cardiovascular risk factors, no differences in the risk 
of developing RA between these two groups were observed. Acknowledgement of 
the proinflammatory mechanisms in RA, atherosclerosis and hyperlipidaemia may 
lead to better recognition of cardiovascular co-morbidities in patients with RA 171. 
However, it is still difficult to determine the onset of the cardiovascular co-morbidities. 
Since several studies have demonstrated an unfavourable lipid profile and 
hypertension in RA patients, or in patients who later develop RA 172,173, statin, ACE 
inhibitor, or ARB use could be a proxy for hyperlipidaemia or hypertension which may 
be responsible for the increased risk of developing RA in our studies. Taking the 
baseline characteristics from our studies into account, cardiovascular diseases and 
cardiovascular risk factors (e.g. hyperlipidaemia, hypertension) may have influenced 
our results. An approach to deal with confounding by indication involves restricting 
the study population to patients with a similar indication. Within cohort studies with a 
follow-up, this can either be achieved by comparing the incidence of events of interest 
between patients using comparative drugs, or to compare incidence rates within a 
single group of patients between the time when they used the drug and the time 
when they did not use the drug of interest 177,178. In order to limit confounding 
by indication in the case-control study, presented in chapter 3.3, we selected only 
patients who were prescribed anti-hypertensive drugs for the same indication 179. 
By including these patients only, we have ensured that prognostic factors such as 
cardiovascular risk factors (e.g. hypertension, diabetes, hyperlipidaemia) were almost 
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equally distributed between the RA patients and controls 179. Regrettably, this strategy 
is not applicable in studies where the effects of statin use on the risk of developing 
autoimmune disorders will be evaluated. Since statins are the first choice agents in 
the treatment for patients with hyperlipidaemia, other lipid-lowering agents are less 
frequently prescribed. Due to the small sample size, it was not feasible to use other 
lipid-lowering medication users as an appropriate control group. 
Another approach for limiting confounding by indication in observational studies is to 
match by characteristics (e.g. age, sex, cardiovascular disease, diabetes) that are 
related to both the risk of the future outcome (e.g. RA) 180,181 and the choice of drug 
therapy (statins) 182,183, to ensure similar intervention groups with respect to important 
prognostic factors. We have used this technique in chapters 3 and 4. However, in our 
cohort studies, the distribution of, e.g., the cardiovascular risk factors among the 
statin users and non-users remained unbalanced. Additionally, we conducted 
subgroup analyses in patients with the same indication (with or without cardiovascular 
diseases and cardiovascular related risk factors) as described in chapters 3.1, 3.2 
and 4. Another method to minimise confounding by indication is to estimate 
propensity scores and analyse the data within homogenous levels of propensity 
scores. By using stratification or matching, for instance, by the propensity score a 
balance of covariates between the statin users and non-users may be achieved 179.
Finally, adjustment for confounding factors or inclusion of a single propensity score 
value (as a covariate) in the analyses by using multivariable regression analysis may 
minimise confounding by indication. The propensity score technique usually does 
not result in substantially different treatment effect estimates compared with the 
conventional regression methods 184,185. The conventional regression and propensity 
score techniques, however, are similar in that they can only adjust for known and 
measured potential confounders 186. We used multiple imputation methods (chapter 
4) or a missing indicator method (missing data in the variables were treated as a 
separate category in the analysis) (chapter 3.2) to account for missing data. In order 
to deal with unmeasured confounding such as smoking status, we performed several 
simulation models with potential effects of smoking, thereby estimating the impact of 
smoking on the association between statin use and the risk of developing RA187 
(chapter 3.1). Another approach that is used to reduce unmeasured confounding is 
by data linkage. An example is the Doetinchem cohort study, which is already linked 
to pharmacy-dispensing and hospital admission data from PHARMO-RLS; this may 
be extended with morbidity data from general practitioners, clinical and laboratory 
data, in- and outpatient medication use from hospitals, and samples and data from 
biobanks. One of the health care data linkage possibilities for the Doetinchem cohort 
study may be to link to the electronic patient file (in Dutch: Elektronisch Patiënten 
Dossier (EPD)) which would provide data covering all healthcare services in the 
Netherlands. Yet, ethical dilemmas play a major role in accessing the EPD system 188, 
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and data from this system would not be in an automated database format 188. To deal 
with the ethical dilemmas of linking data, linkage of these individual databases could 
be professionally conducted by a trusted third party, as has been carried out in the 
Mondriaan project and LINH. The Mondriaan project and ZorgTTP (the trusted third 
party for LINH) facilitate linkage of several individual databases from health care 
providers and research projects of linked data research institutes in the Netherlands. 
By using a trusted third party, medical and research data can be separated from the 
name, address and postal code (encrypted). Through their settlement agreement, 
the Mondriaan project and LINH only receives medical and research data with 
certified anonymity, thereby guaranteeing patients’ privacy 189,190.
Another possibility of linking data can involve encrypting patients’ identification into a 
unique personal identification number, as in Denmark. In Denmark, each person is 
issued with a unique personal identification number upon birth or immigration. This 
unique personal identification number encodes, among other information, date of 
birth and sex, and by that means, information on a given subject can be linked to 
multiple data sources 191,192.
5. PRACTICAL AND CLINICAL IMPLICATIONS
Based on the findings reported in this thesis and the literature we would like to make 
several recommendations for clinical practice.
Reporting adverse drug reactions
Despite the pro-active and routine approaches used in pharmacovigilance, 
underreporting of the ADRs is extremely high and expected to be approximately 90% 
50. Additionally, selective underreporting may have occurred since the reporter may 
not always be alert on the ADR, and therefore; the assessment of an association 
between drug intake and an adverse event remains a challenge. However, collection 
of ADRs is warranted for signal detection (hypothesis strengthening) and hypothesis 
generation. In this thesis, we have shown that two decades after approval for 
marketing, reporting of lupus-like syndrome and PMR occurred more often with 
statins than with other drugs.
We urge physicians, pharmacists and other healthcare providers, and above all, 
patients to report potential side effects to pharmacovigilance centres. Patients have 
been invited to report ADRs directly in the US, Canada and New Zealand 193. Since 
the European Parliament legislative resolution on pharmacovigilance of medicinal 
products for human use (Regulation [EC] No 726/2004) which was launched in July 
2012 194, patients from all European member states are allowed to report concerns 
regarding drugs, directly to the competent authorities by web-based structured forms 
195,196. At the Dutch pharmacovigilance centre, Lareb, every ADR from patients is 
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stored in a database and compared with previous national and international ADRs. 
All potential ADR signals are sent to the Dutch regulatory authority and European 
Medicines Agency 197.
The information reported by patients and healthcare professionals is generally 
comparable, although patients’ reports on ADRs tend to provide more information on 
the impact of the reported ADRs whereas reports from healthcare professionals focus 
on diagnosis related information. Both types of information are valuable to pharma-
covigilance centres 198,199. In studies using databases containing spontaneously 
reported ADRs, we have shown that excluding ADRs submitted by patients did not 
change our findings (chapters 2.1 and 2.2), indicating that ADRs submitted by 
patients are useful for signal detection and hypothesis generation.
Inform physicians and pharmacists of statin-associated 
autoimmune disorders
In general, statins are considered to be safe although the market withdrawal of 
cerivastatin has demonstrated that some serious adverse effects are not always 
detected in clinical trials. The most commonly reported side effects of statins are 
marked elevation of liver enzymes and muscular abnormalities 200. Our findings raise 
awareness about the possibility of developing lupus-like syndrome, PMR or RA in 
patients treated with statins. For instance, when a patient on statin therapy presents 
with myalgia of hip and shoulder region in combination with morning stiffness, one 
should consider the possibility of PMR. Physicians and pharmacists should be 
informed about these possible statin-associated autoimmune disorders.
Prescribing statins in low cardiovascular risk patients
According to several guidelines, patients with a high risk of cardiovascular disease 
should be treated with statins 182,183,201–205. For instance, according to the European 
guideline on cardiovascular disease prevention in clinical practice, patients with a 
10-year risk of cardiovascular disease death of ≥5% (based on the Systematic 
Coronary Risk Evaluation Project (SCORE) chart) should be on statin treatment 182. 
In patients with a low cardiovascular risk (SCORE level of ≤ 5%), statin therapy may 
be considered when lifestyle modification such as smoking cessation, regular 
physical activity and/or dietary changes is not sufficient 182. However, the findings in 
this thesis shed new light on the benefit-risk ratio of statins. We found that statin use 
was associated with an increased occurrence or risk of developing lupus-like 
syndrome, PMR or RA. Our findings may slightly alter the ‘risk’ component of the 
benefit-risk ratio. However, others have not corroborated these findings 66–70, and 
therefore; more definitive studies in healthy (low-risk) subjects are needed. Until this 
question is resolved, one should be conservative in prescribing statins to individuals 
with a low cardiovascular risk.
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Update drug labels
In daily clinical practice, drug labels can play a pivotal role in signalling the risk of rare 
autoimmune disorders. Drug labels inform healthcare professionals on the safe and 
effective use of a specific drug. According to the guideline for the summary of product 
characteristics 206, a list of all adverse reactions with their respective frequency and 
the source of the safety database (e.g. from clinical trials, post-authorisation safety 
studies or spontaneous reporting) should be enclosed. So far, data on statin-associ-
ated immune-mediated disorders has only been based on case reports. In this thesis, 
we have conducted several studies with different designs (e.g. observational, 
experimental, case history) and data sources (e.g. spontaneous reporting, electronic 
health records, laboratory and in vivo), and all of them showed an increased 
occurrence or risk of developing autoimmune disorders when individuals were 
treated with statins. Based on this information, we suggest that it is time to update the 
information on the label.
Develop a validated risk tool to predict statin-associated 
autoimmune disorders 
Despite the increase in statin use in last two decades, only a small number of patients 
who were treated with these drugs over a prolonged period of time developed a 
systemic statin-induced syndrome 8. While the absolute number of patients is low, 
statin-associated autoimmune disorders may potentially impose a heavy burden on 
public health, since these disorders can be chronic, with long-term morbidity and 
may account for high healthcare costs, loss of quality of life and loss of productivity. 
Therefore, careful risk assessment should be considered. Patients who are susceptible 
to autoimmune disorders may have a high risk of developing these disorders when 
treated with a statin. A validated risk prediction tool, such as developing biomarkers 
may therefore be useful to predict statin-associated autoimmune disorders. Recently, 
autoantibodies, that recognise 3-hydroxy-3-methylglutaryl-coenzyme A reductase 
(HMGCR) have been identified in patients with statin-associated autoimmune 
myopathy 207, whereas in a large population of statin exposed patients without 
myopathy no anti-HMGCR antibodies were found 208. Although to date, no validated 
biomarkers are available for predicting statin-associated autoimmune disorders, we 
propose that such risk prediction tools could potentially help healthcare professionals 
to categorise patients based on risk profiles.
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6. RECOMMENDATIONS FOR FUTURE RESEARCH
After studying the effects on the development of autoimmune disorders of the 
commonly prescribed drugs such as statins, ACE inhibitors and ARBs, some 
research questions remained unanswered and/or new questions have been triggered. 
· Although both ACE inhibitors and ARBs can be considered to be safe and well 
tolerated with regard to RA risk, even after prolonged use, further research using a 
larger sample size and other electronic health care databases (e.g. health 
administrative databases), and taking other autoimmune disorders related events 
into account are needed to confirm our findings as presented in chapter 3.3.
· Since we are the first to observe an association between statin use and an increased 
risk of autoimmune disorders, our findings should be replicated by additional 
observational studies, including a large post-approval study following more than 
40 000 patients for at least 10 years after initiation of statin treatment.  
· We have detected potential signals for statin-associated lupus-like syndrome and 
PMR, and these findings should be further confirmed and the risk should be 
quantified by large retrospective cohort studies. 
· In the future, more databases such as data from registries and biobanks should be 
linked and extended with other types of data, to investigate the association between 
statin use and autoimmunity/immune disorders in detail, and to address the 
methodological challenges, as outlined in this chapter. 
· To understand the findings presented in this thesis, the mechanisms that have 
been proposed in this chapter should be further unravelled in experimental and 
clinical studies. 
· As statin, ACE inhibitor or ARB use might be considered as a proxy for hyperlipi-
daemia or hypertension, more clinical and experimental studies should be 
conducted to elucidate whether, hyperlipidaemia or hypertension, or the immuno-
modulatory properties of statins, ACE inhibitors or ARBs is primarily responsible for 
the increased risk of developing autoimmune disorders.
· To address our hypothesis that statins may promote a pre-existing autoim-
mune-prone condition to develop into a clinically manifest disease. Patient data, 
e.g., genotyped and structurally screened risk factors, co-morbidities and 
co-medication, should be available and stored in a large database, as has been 
carried out by researchers in the Rainbow-projects of the Dutch Biobanking and 
Biomolecular Resource Research Infrastructure (BBMRI-NL) 209. 
· When cohort studies are not feasible for practical and economic reasons, the use 
of a nested case-control study is a reasonable and valid alternative for studying 
associations between statin use and autoimmune disorders since the person time 
of every individual is also taken into account. A nested case-control study is a 
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special type of case-control study in which ‘cases’ of an autoimmune disorder that 
arise during the follow-up period are selected from the same cohort (population of 
people) as the controls (who are at risk for developing an autoimmune disorder at 
the case’s date of first diagnosis) to whom they are compared. This study is thus 
said to be ‘nested’ within the cohort study 210. 
· When cohort studies are feasible, we recommend the use of time-dependent 
exposure classification (chapter 3.2), whenever applicable, in order to determine 
the absolute risk estimates and minimise immortal time bias. Immortal time bias 
refers to a period of cohort follow-up during which, by design, the event (e.g. RA or 
death) cannot occur 211. 
· When taking a time-dependent cohort methodology into consideration, we strongly 
encourage using hazard pattern analyses when the relative risks are not constant 
over time and to detect the period when drug users are sensitive to developing 
drug-induced autoimmune disorders.
· More studies focussing on the development of autoimmune disorders in the first 
year after initiation of statins, in particular in a selective group of patients prone to 
autoimmune disorders are needed to disentangle whether the genetic susceptibility 
to an autoimmune disorder, or ascertainment bias, or detection bias is mainly 
responsible for the increased risk of developing autoimmune disorders
· Data mining studies that combine clinical, laboratory, experimental and pharma-
coepidemiology methods have shown promising results when investigating the 
relationships between the cardiovascular drugs and the risk of developing auto- 
immune disorders. Therefore, multidisciplinary research should be encouraged. 
7. CONCLUSION
In conclusion, this thesis shows that use of statins may be associated with an 
increased risk of developing autoimmune disorders. Current evidence shows that 
statins are associated with an increased occurrence or risk of developing lupus-like 
syndrome, PMR or RA. The risk of developing RA is apparent in the first year of statin 
use. Moreover, we have demonstrated causality between statin use and the risk of 
developing autoimmune disorders. On the other hand, in healthy subjects statin use 
was not associated with a loss of self-tolerance. In contrast to statins, we demonstrated 
that both ACE inhibitors and ARBs can be considered as safe and well tolerated with 
regard to RA, even after prolonged use. 
The findings of this thesis add pieces to the puzzle of the cardiovascular drug-associated 
autoimmune disorder hypothesis, however, a number of issues remain unsolved. 
Firstly, statins may not cause autoimmunity by themselves but may promote a pre- 
existing autoimmune-prone condition to progress towards clinically manifest diseases. 
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Linkage of biobank data to population health data and pharmacy-dispensing records 
would be helpful in this respect. Research is needed to study this hypothesis in detail. 
Secondly, one can argue whether we have used the most relevant outcome definitions 
and confounders. By assessing a complete medical history of the patient through 
linkage of datasets, it may be possible to minimise misclassification of lupus-like 
syndrome, PMR or RA, or protopathic bias, or to improve the quality and quantity of 
confounding factors. 
Thirdly, statin, ACE inhibitor or ARB use could serve as a proxy for hyperlipidaemia or 
hypertension. More research should be conducted to elucidate whether hyper-
lipidaemia or hypertension, or the immunomodulatory properties of statins, ACE inhibitors 
or ARBs is primarily responsible for the increased risk of developing autoimmune 
disorders.
Since our findings have not been corroborated by others, multidisciplinary research 
designed to confirm, explain in detail, and establish causality of the association 
between the use of cardiovascular drugs, particularly statins, ACE inhibitors and 
ARBs, and the incidence of autoimmune disorders is of the utmost importance. 
215
SUMMARY AND GENERAL DISCUSSION
6
REFERENCES 
1. Molina V, Shoenfeld Y. Infection, vaccines and other environmental triggers of autoimmunity. 
Autoimmunity 2005; 38(3): 235-45. 
2. Marrack P, Kappler J, Kotzin BL. Autoimmune disease: why and where it occurs. Nat Med 2001; 7(8): 
899-905.  
3. Klareskog L, Malmström V, Lundberg K, Padyukov L, Alfredsson L. Smoking, citrullination and genetic 
variability in the immunopathogenesis of rheumatoid arthritis. Semin Immunol 2011; 23(2): 92-8.  
4. Singh N, Singh U, Singh B, Price R, Nagarkatti M, Nagarkatti P. Activation of aryl hydrocarbon receptor 
(AhR) leads to reciprocal epigenetic regulation of FoxP3 and IL-17 expression and amelioration of 
experimental colitis. PLoS ONE 2011; 6(8): e23522.  
5. Todd J. D’oh! genes and environment cause Crohn’s disease. Cell 2010; 141(7): 1114-6.  
6. WHO Collaborating Centre for Immunotoxicology and Allergic Hypersensitivity. Principles and methods 
for assessing autoimmunity associated with exposure to chemicals: Environmental Health Criteria. 
Bilthoven, The Netherlands: World Health Organisation, 2006.  
7. Wiik A. Drug-induced vasculitis. Curr Opin Rheumatol 2008; 20(1): 35-9.  
8. Vasoo S. Drug-induced lupus: an update. Lupus 2006; 15(11): 757-61.  
9. Vedove CD, Del Giglio M, Schena D, Girolomoni G. Drug-induced lupus erythematosus. Arch Dermatol 
Res 2009; 301(1): 99-105.  
10. Olsen N. Drug-induced autoimmunity. Best Pract Res Clin Rheumatol 2004; 18(5): 677-88.  
11. Mor A, Pillinger M, Wortmann R, Mitnick H. Drug-induced arthritic and connective tissue disorders. 
Semin Arthritis Rheum 2008; 38(3): 249-64.  
12. Mongey A, Hess E. Drug insight: autoimmune effects of medications-what’s new? Nat Clin Pract 
Rheumatol 2008; 4(3): 136-44.  
13. Borchers AT, Keen CL, Gershwin ME. Drug-induced lupus. Ann N Y Acad Sci 2007; 1108: 166-82.  
14. Choi HK, Merkel PA, Walker AM, Niles JL. Drug-associated antineutrophil cytoplasmic antibody-positive 
vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis 
rheumatism 2000; 43(2): 405-13.  
15. Dolman KM, Gans RO, Vervaat TJ, et al. Vasculitis and antineutrophil cytoplasmic autoantibodies 
associated with propylthiouracil therapy. Lancet 1993; 342(8872): 651-2. 
16. Hess E. Drug-related lupus. N Engl J Med 1988; 318(22): 1460-2. 
17. Marzano AV, Vezzoli P, Crosti C. Drug-induced lupus: an update on its dermatologic aspects. Lupus 
2009; 18(11): 935-40.  
18. Rubin RL. Drug-induced lupus. Toxicology 2005; 209(2): 135-47. 
19. Uetrecht J. Current trends in drug-induced autoimmunity. Autoimmun Rev 2005; 4(5): 309-14.  
20. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, 
ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326(7404): 1423. 
21. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering 
regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 
358(9287): 1033-41.  
22. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, 
Prolonged differences in blood pressure: prospective observational studies corrected for the regression 
dilution bias. Lancet 1990; 335(8692): 765-74.  
23. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, 
Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological 
context. Lancet 1990; 335(8693): 827-38.  
24. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy--I: 
Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various 
categories of patients. BMJ 1994; 308(6921): 81-106.  
25. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet 
therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 
324(7329): 71-86.  
216
CHAPTER 6
26. Platten M, Youssef S, Hur EM, et al. Blocking angiotensin-converting enzyme induces potent regulatory 
T cells and modulates TH1- and TH17-mediated autoimmunity. Proc Natl Acad Sci U S A 2009; 106(35): 
14948-53.  
27. Sukumaran V, Watanabe K, Veeraveedu PT, et al. Olmesartan, an AT1 antagonist, attenuates oxidative 
stress, endoplasmic reticulum stress and cardiac inflammatory mediators in rats with heart failure 
induced by experimental autoimmune myocarditis. Int J Biol Sci 2011; 7(2): 154-67.  
28. Ruiz-Ortega M, Bustos C, Hernández-Presa MA, Lorenzo O, Plaza JJ, Egido J. Angiotensin II participates 
in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa 
B activation and monocyte chemoattractant protein-1 synthesis. J Immunol 1998; 161(1): 430-9.  
29. Schindler R, Dinarello CA, Koch KM. Angiotensin-converting-enzyme inhibitors suppress synthesis of 
tumour necrosis factor and interleukin 1 by human peripheral blood mononuclear cells. Cytokine 1995; 
7(6): 526-33.  
30. Fukuzawa M, Satoh J, Sagara M, et al. Angiotensin converting enzyme inhibitors suppress production of 
tumor necrosis factor-alpha in vitro and in vivo. Immunopharmacology 1997; 36(1): 49-55.  
31. Constantinescu CS, Goodman DB, Ventura ES. Captopril and lisinopril suppress production of 
interleukin-12 by human peripheral blood mononuclear cells. Immunol Lett 1998; 62(1): 25-31.  
32. Martin MF, Surrall KE, McKenna F, Dixon JS, Bird HA, Wright V. Captopril: a new treatment for rheumatoid 
arthritis? Lancet 1984; 1(8390): 1325-8.  
33. Perry ME, Chee MM, Ferrell WR, Lockhart JC, Sturrock RD. Angiotensin receptor blockers reduce 
erythrocyte sedimentation rate levels in patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67(11): 
1646-7.  
34. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and 
cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 
2009; 373(9670): 1175-82.  
35. Weitz Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function 
antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7(6): 687-92.  
36. Youssef S, Stüve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 
bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420(6911): 
78-84. 
37. Vollmer T, Key L, Durkalski V, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. 
Lancet 2004; 363(9421): 1607-8.  
38. Neuhaus O, Stüve O, Zamvil SS, Hartung HP. Are statins a treatment option for multiple sclerosis? Lancet 
Neurol 2004; 3(6): 369-71.  
39. McCarey DW, McInnes IB, Madhok R, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): 
double-blind, randomised placebo-controlled trial. Lancet 2004; 363(9426): 2015-21.  
40. Leung BP, Sattar N, Crilly A, et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. 
J Immunol 2003; 170(3): 1524-30.  
41. Kwak BR, Mulhaupt F, Mach F. Atherosclerosis: anti-inflammatory and immunomodulatory activities of 
statins. Autoimmun Rev 2003; 2(6): 332-8. 
42. Arnaud C, Braunersreuther V, Mach F. Toward immunomodulatory and anti-inflammatory properties of 
statins. Trends Cardiovasc Med 2005; 15(6): 202-6.  
43. López-Pedrera C, Aguirre MÃ, Barbarroja N, Cuadrado MJ. Accelerated atherosclerosis in systemic 
lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches. J Biomed 
Biotechnol 2010; 2010: pii:607084.  
44. Stricker BH, Psaty BM. Detection, verification, and quantification of adverse drug reactions. BMJ 2004; 
329(7456): 44-7.  
45. Poluzzi E, Raschi E, Koci A, et al. Antipsychotics and torsadogenic risk: signals emerging from the US 
FDA Adverse Event Reporting System database. Drug Saf 2013; 36(6): 467-79.  
46. Hoffman KB, Kraus C, Dimbil M, Golomb BA. A survey of the FDA’s AERS database regarding muscle 
and tendon adverse events linked to the statin drug class. PLoS One 2012; 7(8): e42866.  
47. Eichler HG, Pignatti F, Flamion B, Leufkens H, Breckenridge A. Balancing early market access to new 
drugs with the need for benefit/risk data: a mounting dilemma. Nat Rev Drug Discov 2008; 7(10): 818-26. 
217
SUMMARY AND GENERAL DISCUSSION
6
48. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuti-
cals for Human Use. ICH Harmonised Tripartite Guideline Pharmacovigilance Planning E2E. November 
2004. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/
E2E/Step4/E2E_Guideline.pdf [accessed 23 December 2013]. 
49. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuti-
cals for Human Use. ICH Harmonised Tripartite Guideline Immunotoxicity Studies for Human Pharma-
ceuticals S8. September 2005; Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_
Products/Guidelines/Safety/S8/Step4/S8_Guideline.pdf [accessed 23 December 2013].  
50. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006; 
29(5): 385-96.  
51.    Noël B. Statins and lupus erythematosus. Rheumatology 2004; 43(3): 397-8.  
52. Noël B, Panizzon R. Lupus-like syndrome associated with statin therapy. Dermatology 2004; 208(3): 276-7.  
53. Noël B. Risks and benefits of statins in lupus erythematosus. Arch Intern Med 2004; 164(1): 107-8.  
54. Krukemyer JJ, Talbert RL. Lovastatin: a new cholesterol-lowering agent. Pharmacotherapy 1987; 7(6): 
198-210.  
55. Haroon M, Devlin J. A case of ANCA-associated systemic vasculitis induced by atorvastatin. Clin 
Rheumatol 2008; 27 Suppl 2: S75-7. 
56. Sen D, Rosenstein E, Kramer N. ANCA-positive vasculitis associated with simvastatin/ezetimibe: 
expanding the spectrum of statin-induced autoimmunity? Int J Rheum Dis 2010; 13(3): e29-31.  
57. Goëb V, Guillemant N, Vittecoq O, Le Loët X. Cerivastatin-induced polymyalgia rheumatica-like illness. 
Clin Rheumatol 2004; 23(2): 179.  
58. Kay J, Finn D, Stone J. Case records of the Massachusetts General Hospital. Case 4-2006. A 79-year-old 
woman with myalgias, fatigue, and shortness of breath. N Engl J Med 2006; 354(6): 623-30.  
59. Rudski L, Rabinovitch MA, Danoff D. Systemic immune reactions to HMG-CoA reductase inhibitors. 
Report of 4 cases and review of the literature. Medicine 1998; 77(6): 378-83.
60. Noël B. Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic 
review. J Eur Acad Dermatol and Venereol 2007; 21(1): 17-24.  
61. Golomb BA, Evans MA. Statin adverse effects : a review of the literature and evidence for a mitochondrial 
mechanism. Am J Cardiovasc Drugs 2008; 8(6): 373-418. 
62. Moulis G, Béné J, Sommet A, Sailler L, Lapeyre-Mestre M, Montastruc JL, French Association of Phar-
macoVigilance Centres. Statin-induced lupus: a case/non-case study in a nationwide pharmacovigi-
lance database. Lupus 2012; 21(8): 885-9. 
63. Lewallen S, Courtright P. Epidemiology in practice: case-control studies. Community Eye Health 1998; 
11(28): 57-8.  
64. Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of rheumatoid 
arthritis rising?: results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum 2010; 62(6): 
1576-82. 
65. Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 2005; 4(3): 130-6. 
66. Jick SS, Choi H, Li L, McInnes IB, Sattar N. Hyperlipidaemia, statin use and the risk of developing 
rheumatoid arthritis. Ann Rheum Dis 2009; 68(4): 546-51.  
67. Chodick G, Amital H, Shalem Y, Kokia E, Heymann AD, Porath A, Shalev V. Persistence with statins and 
onset of rheumatoid arthritis: a population-based cohort study. PLoS Med 2010; 7(9): e1000336.  
68. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: 
population based cohort study using the QResearch database. BMJ 2010; 340: c2197.  
69. Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S. Effect of statins on a wide range of health outcomes: 
a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol 2009; 67(1): 99-109. 
70. Schmidt T, Battafarano DF, Mortensen EM, Frei CR, Mansi I. Frequency of development of connective 
tissue disease in statin-users versus nonusers. Am J Cardiol 2013; 112(6): 883-8.  
71. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal 
effects. Biometrika 1983; 70: 41-55.  
72. Belitser SV, Martens EP, Pestman WR, Groenwold RH, de Boer A, Klungel OH. Measuring balance and 
model selection in propensity score methods. Pharmacoepidemiol Drug Saf 2011; 20(11): 1115-29. 
218
CHAPTER 6
73. Patri P, Nigro A, Rebora A. Lupus erythematosus-like eruption from captopril. Acta Derm Venereol 1985; 
65(5): 447-8.  
74. Sieber C, Grimm E, Follath F. Captopril and systemic lupus erythematosus syndrome. BMJ 1990; 
301(6753): 669.  
75. Bertin P, Kamdem J, Bonnet C, Arnaud M, Treves R. Captopril-induced lupus. Clin Exp Rheumatol 1993; 
11(6): 695.  
76. Pelayo M, Vargas V, Gonzales A, Vallano A, Esteban R, Guardia J. Drug-induced lupus-like reaction and 
captopril. Ann Pharmacother 1993; 27(12): 1541-2.  
77. Fernández-Diaz ML, Herranz P, Suárez-Marrero MC, Borbujo J, Manzano R, Casado M. Subacute 
cutaneous lupus erythematosus associated with cilazapril. Lancet 1995; 345(8946): 398.  
78. Ratliff NB 3rd. Captopril induced lupus. J Rheumatol 2002; 29(8): 1807-8.  
79. Disdier P, Harle JR, Verrot D, Jouglard J, Weiller PJ. Adult Schönlein-Henoch purpura after lisinopril. 
Lancet 1992; 340(8825): 985.  
80. Moots RJ, Keeling PJ, Morgan SH. Adult Schönlein-Henoch purpura after enalapril. Lancet 1992; 
340(8814): 304-5.  
81. Gonçalves R, Cortez Pinto H, Serejo F, Ramalho F. Adult Schönlein-Henoch purpura after enalapril. J 
Intern Med 1998; 244(4): 356-7.
82. Gupta S, Gandhi NM, Ferguson J. Cutaneous vasculitis secondary to ramipril. J Drugs Dermatol 2004; 
3(1): 81-2. 
83. Pinto GM, Lamarao P, Vale T. Captopril-induced pemphigus vegetans with Charcot-Leyden crystals. J 
Am Acad Dermatol 1992; 27(2 Pt 2): 281-4. 
84. Kaplan RP, Potter TS, Fox JN. Drug-induced pemphigus related to angiotensin-converting enzyme 
inhibitors. J Am Acad Dermatol 1992; 26(2 Pt 2): 364-6.
85. Ruocco V, Satriano RA, Guerrera V. “Two-step” pemphigus induction by ACE-inhibitors. Int J Dermatol 
1992; 31(1): 33-6.  
86. Kuechle MK, Hutton KP, Muller SA. Angiotensin-converting enzyme inhibitor-induced pemphigus: three 
case reports and literature review. Mayo Clin Proc 1994; 69(12): 1166-71. 
87. Bastiaens MT, Zwan NV, Verschueren GL, Stoof TJ, Nieboer C. Three cases of pemphigus vegetans: 
induction by enalapril--association with internal malignancy. Int J Dermatol 1994; 33(3): 168-71. 
88. Butt A, Burge SM. Pemphigus vulgaris induced by captopril. Br J Dermatol 1995; 132(2): 315-6.  
89. Vignes S, Paul C, Flageul B, Dubertret L. Ramipril-induced superficial pemphigus. Br J Dermatol 1996; 
135(4): 657-8.
90. Buzón E, Perez-Bernal AM, De la Peğa F, Ríos JJ, Camacho F. Pemphigus foliaceus associated with 
cilazapril. Acta Derm Venereol 1998; 78(3): 227.  
91. Ong CS, Cook N, Lee S. Drug-related pemphigus and angiotensin converting enzyme inhibitors. 
Australas J Dermatol 2000; 41(4): 242-6. 
92. Parodi A, Cozzani E, Milesi G, Drosera M, Rebora A. Fosinopril as a possible pemphigus-inducing drug. 
Dermatology 2002; 204(2): 139-41. 
93. Patterson CR, Davies MG. Pemphigus foliaceus: an adverse reaction to lisinopril. J Dermatolog Treat 
2004; 15(1): 60-2. 
94. Bae YI, Yun SJ, Lee SC, Park GT, Lee JB. Pemphigus foliaceus induced by an angiotensin II receptor 
blocker. Clin Exp Dermatol 2008; 33(6): 721-3.  
95. Sagawa K, Nagatani K, Komagata Y, Yamamoto K. Angiotensin receptor blockers suppress antigen-spe-
cific T cell responses and ameliorate collagen-induced arthritis in mice. Arthritis Rheum 2005; 52(6): 1920-8. 
96. Dalbeth N, Edwards J, Fairchild S, Callan M, Hall FC. The non-thiol angiotensin-converting enzyme 
inhibitor quinapril suppresses inflammatory arthritis. Rheumatology (Oxford) 2005; 44(1): 24-31. 
97. Sakuta T, Morita Y, Satoh M, Fox DA, Kashihara N. Involvement of the renin-angiotensin system in the 
development of vascular damage in a rat model of arthritis: effect of angiotensin receptor blockers. 
Arthritis Rheum 2010; 62(5): 1319-28. 
98. Price A, Lockhart JC, Ferrell WR, Gsell W, McLean S, Sturrock RD. Angiotensin II type 1 receptor as a 
novel therapeutic target in rheumatoid arthritis: in vivo analyses in rodent models of arthritis and ex vivo 
analyses in human inflammatory synovitis. Arthritis Rheum 2007; 56(2): 441-7. 
219
SUMMARY AND GENERAL DISCUSSION
6
99. Bird HA, Le Gallez P, Dixon JS, et al. A clinical and biochemical assessment of a nonthiol ACE inhibitor 
(pentopril; CGS-13945) in active rheumatoid arthritis. J Rheumatol 1990; 17(5): 603-8. 
100. Tikiz C, Utuk O, Pirildar T, et al. Effects of Angiotensin-converting enzyme inhibition and statin treatment 
on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis. J 
Rheumatol 2005; 32(11): 2095-101. 
101. Cohen Tervaert JW. Hypertension: an autoimmune disease? Hypertens Res 2011; 34(4): 443-4. 
102. Dessein PH, Norton GR. Should patients with RA be aggressively monitored for hypertension? Nat Clin 
Pract Rheumatol 2008; 4(1): 18-9.
103. Gurevich V, Shovman O, Slutzky L, Meroni P, Shoenfeld Y. Statins and autoimmune diseases. Autoimmun 
Rev 2005; 4(3): 123-9. 
104. Peters SAE, Palmer MK, Grobbee DE, Crouse JR, O’Leary DH, Raichlen JS, Bots ML. C-reactive protein 
lowering with rosuvastatin in the METEOR study. J Intern Med 2010; 268(2): 155-61.  
105. Yoon SS, Dillon CF, Carroll M, Illoh K, Ostchega Y. Effects of statins on serum inflammatory markers: the U.S. 
National Health and Nutrition Examination Survey 1999-2004. J Atheroscler Thromb 2010; 17(11): 1176-82.  
106. Lyngdoh T, Vollenweider P, Waeber G, Marques-Vidal P. Association of statins with inflammatory 
cytokines: a population-based Colaus study. Atherosclerosis 2011; 219(1): 253-8.  
107. Cherfan P, Tompa A, Wikby A, Löfgren S, Jonasson L. Effects of simvastatin on human T cells in vivo. 
Atherosclerosis 2007; 193(1): 186-92. 
108. Albert MA, Danielson E, Rifai N, Ridker PM, PRINCE Investigators. Effect of statin therapy on C-reactive 
protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort 
study. JAMA 2001; 286(1): 64-70. 
109. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women 
with elevated C-reactive protein. N Engl J Med 2008; 359(21): 2195-207. 
110. Arora M, Chen L, Paglia M, et al. Simvastatin promotes Th2-type responses through the induction of the 
chitinase family member Ym1 in dendritic cells. Proc Natl Acad Sci U S A 2006; 103(20): 7777-82.
111. Fosso CK, Miller MJ, Solomon WR, Baker JR, Jr. Adverse effects of 3-hydroxy-3-methylglutaryl coenzyme 
A reductase inhibitors associated with elevated serum IgE and eosinophilia. J Allergy Clin Immunol 1995; 
95(5 Pt 1): 1053-5. 
112. Mulder DJ, Van Haelst PL, Wobbes MH, et al. The effect of aggressive versus conventional lipid-lowering 
therapy on markers of inflammatory and oxidative stress. Cardiovasc Drugs Ther 2007; 21(2): 91-7. 
113. Fehr T, Kahlert C, Fierz W, et al. Statin-induced immunomodulatory effects on human T cells in vivo. 
Atherosclerosis 2004; 175(1): 83-90. 
114. Walter RB, Fuchs D, Weiss G, Walter TR, Reinhart WH. HMG-CoA reductase inhibitors are associated 
with decreased serum neopterin levels in stable coronary artery disease. Clin Chem Lab Med 2003; 
41(10): 1314-9.  
115. Van Haelst PL, Van Doormaal JJ, May JF, Gans RO, Crijns HJ, Tervaert JW. Secondary prevention with 
fluvastatin decreases levels of adhesion molecules, neopterin and C-reactive protein. Eur J Intern Med 
2001; 12(6): 503-9.  
116. Bevaart L, Vervoordeldonk MJ, Tak PP. Collagen-induced arthritis in mice. Methods Mol Biol 2010; 602: 
181-92.  
117. Ho PP, Higgins JP, Kidd BA, et al. Tolerizing DNA vaccines for autoimmune arthritis. Autoimmunity 2006; 
39(8): 675-82.  
118. Yamagata T, Kinoshita K, Nozaki Y, Sugiyama M, Ikoma S, Funauchi M. Effects of pravastatin in murine 
collagen-induced arthritis. Rheumatol Int 2007; 27(7): 631-9. 
119. Palmer G, Chobaz V, Talabot-Ayer D, Taylor S, So A, Gabay C, Busso N. Assessment of the efficacy of 
different statins in murine collagen-induced arthritis. Arthritis Rheum 2004; 50(12): 4051-9. 
120. Kagami S, Owada T, Kanari H, et al. Protein geranylgeranylation regulates the balance between Th17 
cells and Foxp3 regulatory T cells. Int Immunol 2009; 21(6): 679-89. 
121. Esensten JH, Wofsy D, Bluestone JA. Regulatory T cells as therapeutic targets in rheumatoid arthritis. 
Nat Rev Rheumatol 2009; 5(10): 560-5. 
122. Tang TT, Song Y, Ding YJ, et al. Atorvastatin up-regulates regulatory T-cell and improves clinical disease 
activity in patients with rheumatoid arthritis. J Lipid Res 2011; 52(5): 1023-32.
220
CHAPTER 6
123. Zhou X, Bailey-Bucktrout SL, Jeker LT, et al. Instability of the transcription factor Foxp3 leads to the 
generation of pathogenic memory T cells in vivo. Nat Immunol 2009; 10(9): 1000-7.  
124. Komatsu N, Mariotti-Ferrandiz ME, Wang Y, Malissen B, Waldmann H, Hori S. Heterogeneity of natural 
Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining 
plasticity. Proc Natl Acad Sci U S A 2009; 106(6): 1903-8.  
125. Chapman-Shimshoni D, Yuklea M, Radnay J, Shapiro H, Lishner M. Simvastatin induces apoptosis of 
B-CLL cells by activation of mitochondrial caspase 9. Exp Hematol 2003; 31(9): 779-83. 
126. Mevorach D. Systemic lupus erythematosus and apoptosis: a question of balance. Clin Rev Allergy 
Immunol 2003; 25(1): 49-60.
127. Dieker JW, Van Der Vlag J, Berden JH. Deranged removal of apoptotic cells: its role in the genesis of 
lupus. Nephrol Dial Transplant 2004; 19(2): 282-5. 
128. Smeenk RJ. Antinuclear antibodies: cause of disease or caused by disease? Rheumatology (Oxford) 
2000; 39(6): 581-4.  
129. Grable-Esposito P, Katzberg HD, Greenberg SA, Srinivasan J, Katz J, Amato AA. Immune-mediated 
necrotizing myopathy associated with statins. Muscle Nerve 2010; 41(2): 185-90. 
130. Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL. A novel 
autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated 
necrotizing myopathy. Arthritis Rheum 2010; 62(9): 2757-66.   
131. Haas D, Hoffmann GF. Mevalonate kinase deficiency and autoinflammatory disorders. N Engl J Med 
2007; 356(26): 2671-3.  
132. Steffens S, Mach F. Drug insight: Immunomodulatory effects of statins--potential benefits for renal 
patients? Nat Clin Pract Nephrol 2006; 2(7): 378-87.  
133. Schotte P, Denecker G, Van Den Broeke A, Vandenabeele P, Cornelis GR, Beyaert R. Targeting Rac1 by 
the Yersinia effector protein YopE inhibits caspase-1-mediated maturation and release of interleukin-1be-
ta. J Biol Chem 2004; 279(24): 25134-42. 
134. Coward WR, Marei A, Yang A, Vasa-Nicotera MM, Chow SC. Statin-induced proinflammatory response 
in mitogen-activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 
secretion in monocytes. J Immunol 2006; 176(9): 5284-92.  
135. Lalor SJ, Dungan LS, Sutton CE, Basdeo SA, Fletcher JM, Mills KH. Caspase-1-processed cytokines 
IL-1beta and IL-18 promote IL-17 production by gammadelta and CD4 T cells that mediate autoimmunity. 
J Immunol 2011; 186(10): 5738-48. 
136. Park SJ, Shin JI. Role of interleukin-12 and - 18 in lupus-like syndrome patients with statin use: comment 
on: Association between statin use and lupus-like syndrome using spontaneous reports. Semin Arthritis 
Rheum 2012; 41(6): e2-3.  
137. Fairweather D. Autoimmune disease: mechanisms. In: Essential Immunology: Encyclopedia of Lifes 
Sciences. Delves PJ, Martin S, Burton DR, Roitt JM, eds. Hoboken: Wiley-Blackwell, 2007. p1-6.  
138. Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y. Infections and autoimmunity--friends or foes? Trends 
Immunol 2009; 30(8): 409-14.  
139. Antoniou T, Zheng H, Singh S, Juurlink DN, Mamdani MM, Gomes T. Statins and the risk of herpes zoster: 
a population-based cohort study. Clin Infect Dis 2014; 58(3): 350-6. 
140. Pirmohamed M. Statins, immunomodulation, and infections: a complex and unresolved relationship. Clin 
Infect Dis 2014; 58(3): 357-8.  
141. Magulick JP, Frei CR, Ali SK, et al. The effect of statin therapy on the incidence of infections: a retrospective 
cohort analysis. Am J Med Sci 2014; 347(3): 211-6. 
142. Vandenbroucke JP. Observational research, randomised trials, and two views of medical science. PLoS 
Med 2008; 5(3): e67. 
143. Meyboom RH, Hekster YA, Egberts AC, Gribnau FW, Edwards IR. Causal or casual? The role of causality 
assessment in pharmacovigilance. Drug Saf 1997; 17(6): 374-89. 
144. Meyboom RH. Causality assessment revisited. Pharmacoepidemiol Drug Saf 1998; 7 Suppl 1: S63-5.  
145. Macedo AF, Marques FB, Ribeiro CF, Teixeira F. Causality assessment of adverse drug reactions: 
comparison of the results obtained from published decisional algorithms and from the evaluations of an 
expert panel, according to different levels of imputability. J Clin Pharm Ther 2003; 28(2): 137-43.  
221
SUMMARY AND GENERAL DISCUSSION
6
146. Meyboom RH, Edwards IR. Rosuvastatin and the statin wars--the way to peace. Lancet 2004; 364(9450): 
1997-9. 
147. Wilson AM, Thabane L, Holbrook A. Application of data mining techniques in pharmacovigilance. Br J 
Clin Pharmacol 2004; 57(2): 127-34.  
148. Bégaud B, Martin K, Haramburu F, Moore N. Rates of spontaneous reporting of adverse drug reactions 
in France. JAMA 2002; 288(13): 1588. 
149. De Boer A. When to publish measures of disproportionality derived from spontaneous reporting 
databases? Br J Clin Pharmacol 2011; 72(6): 909-11. 
150. Schellevis FG, Westert GP, De Bakker DH. The actual role of general practice in the dutch health-care 
system. Results of the second dutch national survey of general practice. Med Klin (Munich) 2005; 100(10): 
656-61.  
151. Kennerfalk A, Ruigómez A, Wallander MA, Wilhelmsen L, Johansson S. Geriatric drug therapy and 
healthcare utilization in the United kingdom. Ann Pharmacother 2002; 36(5): 797-803.  
152. Walley T, Mantgani A. The UK General Practice Research Database. Lancet 1997; 350(9084): 1097-9. 
153. Stirbu-Wagner I, Dorsman S, Visscher S, et al. [Landelijk Informatienetwerk Huisartsenzorg. Feiten en 
cijfers over huisartsenzorg in Nederland]. Utrecht/Nijmegen, The Netherlands: Nivel/IQ, 2010 [report in 
Dutch]. 
154. Preston C, Cheater F, Baker R, Hearnshaw H. Left in limbo: patients’ views on care across the primary/
secondary interface. Qual Health Care 1999; 8(1): 16-21. 
155. Kvamme OJ, Olesen F, Samuelson M. Improving the interface between primary and secondary care: a 
statement from the European Working Party on Quality in Family Practice (EQuiP). Qual Health Care 2001; 
10(1): 33-9. 
156. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in 
epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 2006; 15(5): 291-303.  
157. Sibbald B, Roland M. Understanding controlled trials. Why are randomised controlled trials important? 
BMJ 1998; 316(7126): 201.  
158. Gardner TL, Dovey SM, Tilyard MW, Gurr E. Differences between prescribed and dispensed medications. 
N Z Med J 1996; 109(1017): 69-72.  
159. Lau HS, de Boer A, Beuning KS, Porsius A. Validation of pharmacy records in drug exposure assessment. 
J Clin Epidemiol 1997; 50(5): 619-25.  
160. Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPR guidelines for the management of polymyalgia 
rheumatica. Rheumatology (Oxford) 2010; 49(1): 186-90. 
161. Petri M. Review of classification criteria for systemic lupus erythematosus. Rheum Dis Clin North Am 
2005; 31(2): 245,54, vi. 
162. Lindquist M, Edwards IR. The WHO Programme for International Drug Monitoring, its database, and the 
technical support of the Uppsala Monitoring Center. J Rheumatol 2001; 28(5): 1180-7.  
163. Thomas SL, Edwards CJ, Smeeth L, Cooper C, Hall AJ. How accurate are diagnoses for rheumatoid 
arthritis and juvenile idiopathic arthritis in the general practice research database? Arthritis Rheum 2008; 
59(9): 1314-21. 
164. Vandenbroucke JP. Oral contraceptives and rheumatoid arthritis. Lancet 1983; 2(8343): 228-9. 
165. Chan KW, Felson DT, Yood RA, Walker AM. The lag time between onset of symptoms and diagnosis of 
rheumatoid arthritis. Arthritis Rheum 1994; 37(6): 814-20. 
166. Delgado-Rodríguez M, Llorca J. Bias. J Epidemiol Community Health 2004; 58(8): 635-41. 
167. Sathasivam S, Lecky B. Statin induced myopathy. BMJ 2008; 337: a2286. 
168. Mansi I, Mortensen E. The controversy of a wider statin utilization: why? Expert Opin Drug Saf 2013; 12(3): 
327-37.  
169. Walker AM. Confounding by indication. Epidemiology 1996; 7(4): 335-6. 
170. Grobbee DE, Hoes AW. Confounding and indication for treatment in evaluation of drug treatment for 
hypertension. BMJ 1997; 315(7116): 1151-4.  
171. Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med 2008; 
121(10 Suppl 1): S21-31. 
222
CHAPTER 6
172. Van Halm VP, Nielen MM, Nurmohamed MT, et al. Lipids and inflammation: serial measurements of the 
lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis 2007; 66(2): 184-8. 
173. Steiner G, Urowitz MB. Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of 
treatment. Semin Arthritis Rheum 2009; 38(5): 372-81.
174. Alipour A, Van Oostrom AJ, Izraeljan A, et al. Leukocyte activation by triglyceride-rich lipoproteins. 
Arterioscler Thromb Vasc Biol 2008; 28(4): 792-7. 
175. Van Oostrom AJ, Rabelink TJ, Verseyden C, Sijmonsma TP, Plokker HW, De Jaegere PP, Cabezas MC. 
Activation of leukocytes by postprandial lipemia in healthy volunteers. Atherosclerosis 2004; 177(1): 175-82. 
176. Meijssen S, Van Dijk H, Verseyden C, Erkelens DW, Cabezas MC. Delayed and exaggerated postprandial 
complement component 3 response in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 
2002; 22(5): 811-6.  
177. Hak E, Verheij TJ, Grobbee DE, Nichol KL, Hoes AW. Confounding by indication in non-experimental 
evaluation of vaccine effectiveness: the example of prevention of influenza complications. J Epidemiol 
Community Health 2002; 56(12): 951-5. 
178. McMahon AD. Approaches to combat with confounding by indication in observational studies of 
intended drug effects. Pharmacoepidemiol Drug Saf 2003; 12(7): 551-8. 
179. Klungel OH, Martens EP, Psaty BM, et al. Methods to assess intended effects of drug treatment in 
observational studies are reviewed. J Clin Epidemiol 2004; 57(12): 1223-31. 
180. Nurmohamed MT. Cardiovascular risk in rheumatoid arthritis. Autoimmun Rev 2009; 8(8): 663-7.  
181. Nurmohamed MT, Dijkmans BA. Dyslipidaemia, statins and rheumatoid arthritis. Ann Rheum Dis 2009; 
68(4): 453-5. 
182. Perk J, De Backer G, Gohlke H, et al. European Guidelines on Cardiovascular Disease Prevention in 
Clinical Practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and 
other societies on cardiovascular disease prevention in clinical practice (constituted by representatives 
of nine societies and by invited experts). G Ital Cardiol (Rome) 2013; 14(5): 328-92. 
183. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment 
of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol 
Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106(25): 3143-421. 
184. Shah BR, Laupacis A, Hux JE, Austin PC. Propensity score methods gave similar results to traditional 
regression modeling in observational studies: a systematic review. J Clin Epidemiol 2005; 58(6): 550-9.
185. Stürmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S. A review of the application of 
propensity score methods yielded increasing use, advantages in specific settings, but not substantially 
different estimates compared with conventional multivariable methods. J Clin Epidemiol 2006; 59(5): 
437-47.  
186. Collet JP, Boivin JF. Bias and confounding in pharmacoepidemiology. In: Strom BL, editor. Pharmacoep-
idemiology. 3th ed. Chichester: John Wiley & Sons Ltd.; 2000. p.765-84. 
187.    Lin DY, Psaty BM, Kronmal RA. Assessing the sensitivity of regression results to unmeasured confounders 
in observational studies. Biometrics 1998; 54(3): 948-63. 
188. Velthove K. Markers for disease severity. Pharmacoepidemiological studies on obstructive lung disease 
(PhD Thesis). Utrecht, The Netherlands: Utrecht University 2010. 
189. Project Mondriaan. [Project Mondriaan Privacy. Trusted Third Party]. July 2011. Available from: http://
www.projectmondriaan.nl/privacy.html. [accessed 12 Apr 2014] [website in Dutch]. 
190. Elffers B, Verheij R. Verantwoording gegevenskoppeling Uit: NIVEL Zorgregistraties eerste lijn [internet]. 
December 2013. Available from: www.nivel.nl/node/3532. [accessed 24 Aug 2014] [website in Dutch]. 
191. Nguyen-Nielsen M, Svensson E, Vogel I, Ehrenstein V, Sunde L. Existing data sources for clinical 
epidemiology: Danish registries for studies of medical genetic diseases. Clin Epidemiol 2013; 5: 249-62. 
192. Erichsen R, Lash TL, Hamilton-Dutoit SJ, Bjerregaard B, Vyberg M, Pedersen L. Existing data sources for 
clinical epidemiology: the Danish National Pathology Registry and Data Bank. Clin Epidemiol 2010; 2: 51-6. 
193. Van Hunsel F, Härmark L, Pal S, Olsson S, van Grootheest K. Experiences with adverse drug reaction 
reporting by patients: an 11-country survey. Drug Saf 2012; 35(1): 45-60.  
223
SUMMARY AND GENERAL DISCUSSION
6
194. The European Commission (EC). Regulation (EC) No 726/2004 of the European Parliament and of the 
Council. March 2004; Available from: http://ec.europa.eu/health/human-use/pharmacovigilance/index_
en.htm [accessed 23 December, 2013].  
195. Watson R. New rules will allow EU patients to report drug concerns directly. BMJ 2010; 341: c5344. 
196. Borg JJ, Aislaitner G, Pirozynski M, Mifsud S. Strengthening and rationalizing pharmacovigilance in the 
EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance. Drug Saf 
2011; 34(3): 187-97. 
197. Netherlands Pharmacovigilance Centre. [Bijwerking? Melden!]. April 2014; Available from: http://www.
lareb.nl/Meld-bijwerking/Werkwijze-Lareb [accessed 18 April, 2014] [website in Dutch]. 
198. Rolfes L, Van Hunsel F, Van Puijenbroek E, Van Grootheest K. ADR reports of patients and healthcare 
professionals; how different are they? Pharmacoepidemiol Drug Saf 2013; 22: S315. 
199.  Blenkinsopp A, Wilkie P, Wang M, Routledge PA. Patient reporting of suspected adverse drug reactions: 
a review of published literature and international experience. Br J Clin Pharmacol 2007; 63(2): 148-56.
200.  Alsheikh Ali A, Ambrose M, Kuvin J, Karas R. The safety of rosuvastatin as used in common clinical 
practice: a postmarketing analysis. Circulation 2005; 111(23): 3051-7.  
201.  Jellinger PS, Smith DA, Mehta AE, et al. American Association of Clinical Endocrinologists’ Guidelines for 
Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract 2012; 18 Suppl 1: 1-78. 
202. National Collaborating Centre for Primary Care. Lipid modification: cardiovascular risk assessment and 
the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. NICE 
clinical guideline 67. London, UK: National Institute for Health and Clinical Excellence, 2008 (reissued 
2010). 
203.   Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA Guideline on the Assessment of 
Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task 
Force on Practice Guidelines. Circulation 2013 Nov 12. [Epub ahead of print].  
204.   British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care 
Cardiovascular Society, Stroke Association. JBS 2: Joint British Societies’ guidelines on prevention of 
cardiovascular disease in clinical practice. Heart 2005; 91 Suppl 5: v1-52. 
205.  Wiersma T, Smulders YM, Stehouwer CD, Konings KT, Lanphen J. [Summary of the multidisciplinary 
guideline on cardiovascular risk management (revision 2011)]. Ned Tijdschr Geneeskd 2012; 
156(36):A5104 [article in Dutch]. 
206.  Summary of product characteristics Advisory Group. A guideline on summary of product characteristics 
(SmPC). Brussels, Belgium: European Commission, Enterprise and Industry Directorate-General, 2009. 
207. Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Doering KR, Casciola-Rosen LA. 
Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-asso-
ciated autoimmune myopathy. Arthritis Rheum 2011; 63(3): 713-21. 
208.  Mammen AL, Pak K, Williams EK, Brisson D, Coresh J, Selvin E, Gaudet D. Rarity of anti-3-hy-
droxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited 
musculoskeletal side effects. Arthritis Care Res (Hoboken) 2012; 64(2): 269-72. 
209.   Dutch Biobanking and Biomolecular Resource Research Infrastructure (BBMRI-NL). Managing 
resources for the future of biomedical research. Rainbow Projects. January 2014. Available from: http://
www.bbmri.nl/en-gb/activities/rainbow-projects [accessed 14 March, 2014].
210.   Etminan M. Pharmacoepidemiology II: the nested case-control study--a novel approach in pharmaco-
epidemiologic research. Pharmacotherapy 2004; 24(9): 1105-9. 
 211.  Lévesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example 
using statins for preventing progression of diabetes. BMJ 2010; 340: b5087.

VALORISATION ADDENDUM
CHAPTER
7

227
VALORISATION ADDENDUM
7
INTRODUCTION
Several studies have demonstrated that environmental components play a major role 
in this process of autoimmunity 1–5 and may be responsible for the increased 
prevalence of autoimmune disorders in highly industrialised countries 6. Many drugs 
are associated with the development of certain autoimmune disorders, e.g., lupus-like 
syndrome and vasculitis 7–19. 
Statins, angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor 
blockers (ARBs) are widely prescribed to reduce the risk of cardiovascular morbidity 
and mortality in patients with or at risk for coronary heart disease 20–25. In addition to 
their cholesterol and blood pressure lowering effects, several studies have shown that 
these drugs also have anti-inflammatory and immunomodulatory properties 26–43, and 
are thereby also effective in the treatment of certain autoimmune disorders. The beneficial 
effects of these drugs are well described, but interestingly, such immuno modulating 
effects may, on the other hand, adversely influence immune regulation. Therefore, we 
hypothesise that statins, ACE inhibitors and ARBs facilitate the development of 
autoimmunity, potentially resulting in autoimmune disorders. In this thesis, we have 
examined whether there is an association between the use of cardiovascular drugs 
(statins, ACE inhibitors and ARBs) and the incidence of autoimmune diseases.
Based on the findings reported in this thesis we recommend several implications for 
daily practice. The implications for daily practice are:
·	 	Reporting adverse drug reactions by health care professionals and patients
·	 	Inform physicians and pharmacists of statin-associated autoimmune disorders
·	 	Physicians should be conservative in prescribing statins in low cardiovascular 
risk patients
·	 	Update drug labels for statins
·	 	Develop a validated risk tool to predict statin-associated autoimmune disorder 
All these implications are described in detail below.
Reporting adverse drug reactions by health care professionals and patients
Despite the pro-active and routine approaches used in pharmacovigilance, under- 
reporting of the ADRs is extremely high and expected to be approximately 90% 44. 
Additionally, selective underreporting may have occurred since the reporter may 
not always be alert on the ADR, and therefore; the assessment of an association 
between drug intake and an adverse event remains a challenge. However, collection 
of ADRs is warranted for signal detection (hypothesis strengthening) and hypothesis 
generation. In this thesis, we have shown that two decades after approval for marketing, 
reporting of lupus-like syndrome and PMR occurred more often with statins than with 
other drugs.
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We urge physicians, pharmacists and other healthcare providers, and above all, 
patients to report potential side effects to pharmacovigilance centres. Patients have 
been invited to report ADRs directly in the US, Canada and New Zealand 45. Since the 
European Parliament legislative resolution on pharmacovigilance of medicinal 
products for human use (Regulation [EC] No 726/2004) which was launched in July 
2012 46, patients from all European member states are allowed to report concerns 
regarding drugs, directly to the competent authorities by web-based structured forms 
47,48. At the Dutch pharmacovigilance centre, Lareb, every ADR from patients is 
stored in a database and compared with previous national and international ADRs. 
All potential ADR signals are sent to the Dutch regulatory authority and European 
Medicines Agency 49.
The information reported by patients and healthcare professionals is generally 
comparable, although patients’ reports on ADRs tend to provide more information on 
the impact of the reported ADRs whereas reports from healthcare professionals 
focus on diagnosis related information. Both types of information are valuable to 
pharmacovigilance centres 50,51. In studies using databases containing spontaneously 
reported ADRs, we have shown that excluding ADRs submitted by patients did not 
change our findings (chapters 2.1 and 2.2), indicating that ADRs submitted by 
patients are useful for signal detection and hypothesis generation.
Inform physicians and pharmacists of statin-associated autoimmune 
disorders
In general, statins are considered to be safe although the market withdrawal of 
cerivastatin has demonstrated that some serious adverse effects are not always 
detected in clinical trials. The most commonly reported side effects of statins are 
marked elevation of liver enzymes and muscular abnormalities 52. Our findings raise 
awareness about the possibility of developing lupus-like syndrome, PMR or RA in 
patients treated with statins. For instance, when a patient on statin therapy presents 
with myalgia of hip and shoulder region in combination with morning stiffness, one 
should consider the possibility of PMR. Physicians and pharmacists should be 
informed about these possible statin-associated autoimmune disorders.
Physicians should be conservative in prescribing statins in low 
cardiovascular risk patients
According to several guidelines, patients with a high risk of cardiovascular disease 
should be treated with statins 53–59. For instance, according to the European guideline 
on cardiovascular disease prevention in clinical practice, patients with a 10-year risk 
of cardiovascular disease death of ≥5% (based on the Systematic Coronary Risk 
Evaluation Project (SCORE) chart) should be on statin treatment 53. In patients with a 
low cardiovascular risk (SCORE level of ≤ 5%), statin therapy may be considered 
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when lifestyle modification such as smoking cessation, regular physical activity and/
or dietary changes is not sufficient 53. However, the findings in this thesis shed new 
light on the benefit-risk ratio of statins. We found that statin use was associated with an 
increased occurrence or risk of developing lupus-like syndrome, PMR or RA. Our findings 
may slightly alter the ‘risk’ component of the benefit-risk ratio. However, others have 
not corroborated these findings 60–64, and therefore; more definitive studies in healthy 
(low-risk) subjects are needed. Until this question is resolved, one should be conservative 
in prescribing statins to individuals with a low cardiovascular risk.
Update drug labels for statins
In daily clinical practice, drug labels can play a pivotal role in signalling the risk of rare 
autoimmune disorders. Drug labels inform healthcare professionals on the safe and 
effective use of a specific drug. According to the guideline for the summary of product 
characteristics 65, a list of all adverse reactions with their respective frequency and 
the source of the safety database (e.g. from clinical trials, post-authorisation safety 
studies or spontaneous reporting) should be enclosed. So far, data on statin-associ-
ated immune-mediated disorders has only been based on case reports. In this thesis, 
we have conducted several studies with different designs (e.g. observational, 
experimental, case history) and data sources (e.g. spontaneous reporting, electronic 
health records, laboratory and in vivo), and all of them showed an increased 
occurrence or risk of developing autoimmune disorders when individuals were 
treated with statins. Based on this information, we suggest that it is time to update the 
information on the label.
Develop a validated risk tool to predict statin-associated autoimmune 
disorders  
Despite the increase in statin use in last two decades, only a small number of patients 
who were treated with these drugs over a prolonged period of time developed a 
systemic statin-induced syndrome 8. While the absolute number of patients is low, 
statin-associated autoimmune disorders may potentially impose a heavy burden on 
public health, since these disorders can be chronic, with long-term morbidity and 
may account for high healthcare costs, loss of quality of life and loss of productivity. 
Therefore, careful risk assessment should be considered. Patients who are susceptible 
to autoimmune disorders may have a high risk of developing these disorders when 
treated with a statin. A validated risk prediction tool, such as developing biomarkers 
may therefore be useful to predict statin-associated autoimmune disorders. Recently, 
autoantibodies, that recognise 3-hydroxy-3-methylglutaryl-coenzyme A reductase 
(HMGCR) have been identified in patients with statin-associated autoimmune 
myopathy 66, whereas in a large population of statin exposed patients without myopathy 
no anti-HMGCR antibodies were found 67. Although to date, no validated biomarkers 
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are available for predicting statin-associated autoimmune disorders, we propose that 
such risk prediction tools could potentially help healthcare professionals to categorise 
patients based on risk profiles.
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NEDERLANDSE SAMENVATTING
Het immuunsysteem is een verdedigingssysteem met als doel om indringers, zoals 
virussen, bacteriën, parasieten, tumorcellen, of veranderde eigen cellen te bestrijden. 
Wanneer het immuunsysteem niet meer het verschil kan maken tussen de indringers 
en het lichaamseigen weefsel, valt het immuunsysteem de lichaamseigen cellen aan. 
We spreken dan van auto-immuniteit. De ontstekingsziekten die hierbij ontstaan 
noemt men auto-immuunziekten. Momenteel zijn er meer dan 80 ziekten die tot de 
familie van auto-immuunziekten behoren. Voorbeelden van auto-immuunziekten zijn 
reumatoïde artritis (RA), systemische lupus erythematodes (SLE), diabetes type I en 
auto-immuun schildklierziekten.
Het ontstaan van auto-immuniteit is een proces dat bestaat uit meerdere factoren, 
waaronder erfelijke- en omgevingsfactoren. Ondanks vele jaren van uitgebreid 
onderzoek is het exacte mechanisme dat verantwoordelijk is voor het ontstaan van 
auto-immuniteit nog niet opgehelderd. Meerdere onderzoeken laten zien dat de 
 omgevingsfactoren zoals roken, voeding, blootstelling aan geneesmiddelen en/of 
chemische stoffen een belangrijke rol spelen in het ontstaan van auto-immuniteit. De 
omgevingsfactoren zijn mogelijk verantwoordelijk voor de grote aantallen auto- 
immuunziekten in de Westerse wereld. Uit verscheidene onderzoeken is gebleken 
dat bepaalde geneesmiddelen gerelateerd zijn aan het ontwikkelen van auto- 
immuunziekten. De cholesterol- en bloeddruk verlagende geneesmiddelen: statines, 
angiotensine I converterend enzym (ACE) remmers en angiotensine receptor 
blokkers (ARB’s) worden wereldwijd voorgeschreven aan patiënten die nog geen 
hart- en vaatziekten hebben doorgemaakt, maar die wel een verhoogd risico op  hart- 
en vaatziekten (primaire preventie) hebben. Ook worden deze medicijnen voor- 
geschreven aan patiënten die al bekend zijn met hart- en vaatziekten (secundaire 
preventie). Naast de cholesterol- en bloeddruk verlagende effecten, laten veel 
onderzoeken zien dat deze drie geneesmiddelen ook ontstekingsremmende en 
 immuun-modulerende (effect op het immuunsysteem) eigenschappen hebben. Deze 
eigenschappen kunnen effectief zijn in het behandelen van bepaalde auto-immuun-
ziekten. De behandelingseffecten van statines, ACE remmers of ARB’s zijn uitvoerig 
in de literatuur beschreven. De immuun-modulerende eigenschappen van deze drie 
geneesmiddelen kunnen naast de behandelingseffecten ook een ongewenste 
invloed hebben op het immuunsysteem. Daarom veronderstellen we dat statines, 
ACE remmers en ARB’s mogelijk de ontwikkeling van auto-immuniteit vergemakkelijken, 
wat zou kunnen resulteren in een auto-immuunziekte.
Op het moment van toelating van een geneesmiddel op de markt is niet alles bekend 
over de veiligheid van het geneesmiddel. Pas jaren nadat het geneesmiddel op de 
markt gebracht is, kan het volledige veiligheidsprofiel verkregen worden. Dit gebrek 
aan kennis kan mogelijk liggen aan de tekortkomingen van een klinische trial. Een 
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klinische trial is een wetenschappelijke methode om te bepalen of een behandeling 
met bijvoorbeeld een geneesmiddel werkt. Mogelijke tekortkomingen van klinische 
trials kunnen zijn dat ze een te kleine groep patiënten bevatten of alleen patiënten 
bevatten die nagenoeg dezelfde karakteristieken en medische geschiedenis hebben. 
Een andere oorzaak kan zijn dat ze een beperkte duur hebben en er geen rekening 
wordt gehouden met hoe het geneesmiddel in de dagelijkse praktijk wordt gebruikt 
door de patiënten. In de praktijk blijkt het ook nog eens een uitdaging te zijn om een 
auto-immuun gerelateerde bijwerking op te sporen, aangezien deze bijwerkingen vrij 
zeldzaam zijn, ze pas na langdurig geneesmiddelen gebruik verschijnen en niet altijd 
verdwijnen na het stoppen met het geneesmiddel. 
In dit proefschrift onderzoeken wij of er een relatie is tussen het gebruik van 
geneesmiddelen voor hart- en vaatziekten (statines, ACE remmers en ARB’s ) en het 
risico op het ontwikkelen van auto-immuunziekten. Om onze hypothese kracht bij te 
zetten hebben we drie onderzoeken uitgevoerd met gegevens uit een database van 
spontaan gerapporteerde bijwerkingen tijdens het gebruik van statines in de 
dagelijkse praktijk (hoofdstuk 2). In hoofdstuk 2.1 hebben we door middel van een 
case (een specifieke bijwerking) /non-case (alle andere bijwerkingen) onderzoeks-
opzet, onderzocht of er een relatie is tussen statinegebruik en de aanwezigheid van 
lupusachtig syndroom. In dit onderzoek vonden we dat het statinegebruik vaker was 
gerapporteerd in patiënten met een lupusachtig syndroom dan in patiënten die een 
andere bijwerking hadden doorgemaakt. Deze bevinding ligt in lijn met een eerder 
uitgevoerd onderzoek, dat gebruik maakte van gegevens uit de Franse bijwerkingen 
database. Door dezelfde onderzoeksopzet te gebruiken, zijn we in hoofdstuk 2.2 
nagegaan of er een relatie is tussen statinegebruik en de aanwezigheid van 
polymyalgia rheumatica (PMR). Ook in dit onderzoek vonden we dat statinegebruik 
vaker was gerapporteerd in patiënten met een PMR dan in patiënten die een andere 
bijwerking hadden doorgemaakt. Verder waren er zes individuele veiligheidsrappor-
ten waarin PMR als een bijwerking na herhaald gebruik van een statine werd 
gerapporteerd. Deze bevindingen versterken de verdenking van een oorzakelijk 
verband tussen statinegebruik en de aanwezigheid van PMR. Onze bevindingen uit 
hoofdstuk 2.1 en 2.2 komen overeen met de casussen die staan beschreven in de 
literatuur, wat een aanwijzing suggereert (signaaldetectie) van statinegerelateerde 
lupusachtige syndroom en PMR. Om onze bevinding van statinegerelateerd PMR 
kracht bij te zetten, hebben we de gegevens van één patiënt opgevraagd en in detail 
in een rapport beschreven (hoofdstuk 2.3). Bij deze patiënt zagen we na het stoppen 
met statinegebruik dat PMR was verdwenen. Echter, toen de patiënt opnieuw werd 
behandeld met statines, verschenen de symptomen van PMR wederom met daarbij 
arteriitis temporalis (reuscelarteriitis), een ziekte die zeer nauw verbonden is met 
PMR. Op basis van dit patiëntenrapport hebben we mogelijk het oorzakelijke verband 
van statinegerelateerd PMR/arteriitis temporalis weergegeven. Het gebruik van een 
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database van spontaan gerapporteerde bijwerkingen is voornamelijk gericht op het 
versterken van de hypothese en niet op het testen van een hypothese. 
We hebben onze hypothese getest door gebruik te maken van databases met 
elektronische medische patiëntengegevens. In hoofdstuk 3 hebben we twee 
onderzoeken uitgevoerd om te bepalen of er een relatie is tussen statinegebruik en 
een verhoogd risico op het ontwikkelen van RA. In hoofdstuk 3.1 hebben we de 
gegevens over statinegebruik en de eerste diagnose van RA afgeleid van de 
gegevens uit het Landelijk Informatie Netwerk Huisartszorg (LINH). In deze database 
staan van de patiënten de voorgeschreven medicatie, ziekten en verwijzingen naar 
specialisten beschreven. Door het uitvoeren van een patiënt(case)-controle-onder-
zoek vonden we een verhoogd risico op RA in patiënten die zes maanden lang 
statines gebruikten. Daarnaast zagen we een kleine trend tussen een toegenomen 
potentie (kracht) van de statines en het risico op het ontwikkelen van RA. Er werd 
door ons geen trend gevonden in de duur van gebruik, aanbevolen dagelijkse dosis 
(ADD) en het aantal voorgeschreven recepten. Een patiënt-controle-onderzoek heeft 
een aantal tekortkomingen. Om deze tekortkomingen te beperken, hebben we een 
tweede onderzoek uitgevoerd naar de relatie tussen statinegebruik en het risico op 
het ontwikkelen van RA. In het tweede onderzoek, hoofdstuk 3.2, hebben we gebruik 
gemaakt van een tijdsafhankelijke analyse, wat betekent dat het statinegebruik in de 
tijd wordt uitgezet en gevolgd. In dit onderzoek hebben we niet alleen de onder-
zoeksresultaten uit hoofdstuk 3.1 willen bevestigen, maar ook willen uitbreiden. Dit 
is gedaan met behulp van een patroon-analyse van de risico’s op het ontwikkelen 
van RA door de veranderingen in statinegebruik gedurende de tijd. De gegevens van 
het statinegebruik en de eerste diagnose van RA komen voort uit de recepten, 
diagnose van ziekten en verwijzingen naar specialisten. Deze patiëntengegevens zijn 
opgeslagen in de Engelse Clinical Practice Research Datalink (CPRD) database. Ook 
in een grote groep patiënten (cohort), waar we terug kijken naar het verleden van 
deze patiënten (retrospectief onderzoek), zien we opnieuw dat statinegebruik is 
gerelateerd aan een verhoogd risico op het ontwikkelen van RA. Daarnaast zien we 
dat het risico op RA aanzienlijk is verhoogd in het eerste jaar na de start van het 
statinegebruik en dat daarna de relatie tussen statinegebruik en het risico op het 
ontwikkelen van RA is verdwenen. Wanneer we de statine-gebruikers indelen in 
nieuwe gebruikers en voormalige gebruikers vinden we dezelfde resultaten. Omdat 
het risico op het ontwikkelen van RA kort na de start van het statinegebruik was 
verhoogd, kunnen statines mogelijk als een katalysator werken voor het ontstaan van 
RA in patiënten die gevoelig zijn voor het ontwikkelen van RA. We hebben dit 
aangetoond in een proefdieronderzoek, dat later zal worden besproken. In een 
onderzoek van verscheidene patiëntenrapporten van statinegerelateerde lupusachtig 
syndroom, laat het grootste deel van deze patiënten zien dat de periode tot het 
ontstaan van lupusachtige syndroom minder dan een jaar is. Hieruit voortvloeiend, 
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denken wij dat het langdurig gebruik van statines in patiënten die niet gevoelig zijn 
voor het ontwikkelen van RA als veilig kan worden ervaren. Daarnaast zien we in 
dezelfde studie (hoofdstuk 3.2) alleen de relatie tussen statinegebruik en een 
verhoogd risico op het ontwikkelen van RA in hergebruikers van statines en vrouwen. 
Tot op heden zijn er vijf andere studies uitgevoerd die de relatie tussen statinegebruik 
en het ontwikkelen van RA hebben onderzocht. Deze vijf studies laten geen eenduidig 
resultaat zien, maar géén van deze studies toont een verhoogd risico op het 
ontwikkelen van RA na statinegebruik. Een mogelijke verklaring voor het verschil in 
de resultaten van onze studies (hoofdstuk 3.1 en 3.2) met de andere vijf studies kan 
zijn dat we geen latency (reactie)-tijd in ons onderzoek hebben meegenomen. Ook al 
gebruikten wij twee verschillende onderzoeksopzetten en databases in hoofdstuk 
3.1 en 3.2, de verdeling van patiënten met hart- en vaatziekten en de daarbij 
behorende risicofactoren (bijvoorbeeld hyperlipidemie (een verzamelnaam voor 
uiteenlopende stoornissen in de vetstofwisseling)) waren niet gelijk verdeeld tussen 
de twee onderzochte groepen. In hoofdstuk 3.1 vergeleken we de patiënten met RA 
met de controles en in hoofdstuk 3.2 vergeleken we de statine-gebruikers met de 
niet-gebruikers.
We hebben onze hypothese verder getest door na te gaan of het gebruik van ACE 
remmers of ARB’s gerelateerd is aan het risico op het ontwikkelen van RA. In dit 
 patiënt-controle-onderzoek namen we alleen gebruikers van ACE remmers of ARB’s 
en andere bloeddruk verlagende geneesmiddelen uit de Nederlandse huisartsen 
database (LINH) mee (hoofdstuk 3.3). Er werd geen relatie tussen ACE remmers of 
ARB’s en het risico op het ontwikkelen van RA waargenomen. De resultaten waren 
hetzelfde wanneer we de blootstelling aan ACE remmers of ARB’s hadden ingedeeld 
in huidig en voormalig gebruik, duur- of zelfs dosering van het gebruik. Deze 
resultaten ondersteunen niet de hypotheses dat ACE remmers of ARB’s, RA op gang 
kunnen brengen of juist kunnen beschermen tegen RA. Voor zover wij weten is er, 
uitgezonderd ons onderzoek, geen enkel onderzoek dat de relatie tussen ACE 
remmers of ARB’s en het ontwikkelen van RA heeft bestudeerd. Bewijs voor de relatie 
tussen deze twee geneesmiddelen en de aanwezigheid van auto-immuunziekten 
komt voort uit patiëntenrapporten, proefdierstudies en patiënten met een bepaalde 
auto-immuunziekte. Deze studies laten tegengestelde resultaten zien. In onze studie 
laten we het risico op RA zien in patiënten die geen medische geschiedenis hebben 
van RA maar die wel zijn behandeld met ACE remmers of ARB’s. Hypertensie (een 
hoge bloeddruk) kan worden gezien als een aandoening waarbij het immuunsysteem 
een rol speelt en dit is meer aanwezig in RA patiënten dan in de algemene bevolking. 
Met betrekking tot de immuun-modulerende eigenschappen en de hoge aanwezig - 
heid van hypertensie in RA patiënten, kunnen behandelingen met ACE remmers of 
ARB’s effectief zijn in patiënten met hypertensie en RA.
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In de introductie van het proefschrift wordt beschreven dat de statines de ontwikkeling 
van auto-immuniteit kunnen vergemakkelijken. Er wordt algemeen gedacht dat 
statines, naast een ontstekingsremmende werking, ook een directe immuun-modu-
lerende werking hebben op T-cellen. T-cellen zijn afweercellen die verantwoordelijk 
zijn voor de cellulaire immuniteit. Cellulaire immuniteit is een immuunreactie die 
gericht is op het onschadelijk maken van virussen en bacteriën. Eén van de typen 
T-cellen zijn de T-helper cellen die vervolgens weer onderverdeeld zijn in onder 
andere T-helper (Th) 1 en Th2 cellen. Statines kunnen ook een verschuiving van Th1 
naar Th2 immuunreactie bevorderen, met als gevolg een ontregeling in de immuun 
homeostase. Homeostase is het in evenwicht zijn van allerlei functies (zoals 
temperatuur- en zuurgraad) en het vermogen van het lichaam om dit evenwicht te 
behouden, ondanks omgevingsinvloeden. In de voorgaande studies konden we de 
bovenstaande hypothese over het directe effect van de statines op T-cellen niet 
bestuderen, maar doordat we gebruik hebben kunnen maken van sera (het bloed 
zonder bloedcellen) uit de Doetinchem Cohort Studie in combinatie met de uitgiften 
van statines uit PHARMO-RLS, een database die alle uitgiften van geneesmiddelen 
van apothekers bijhoudt, kan het nu wel. In hoofdstuk 4 hebben we de effecten van 
statinegebruik op de aangeboren (“innate”) en verworven (“adaptive”) afweer 
(immuniteit) en zelfs de tolerantie van het immuunsysteem onderzocht. De effecten 
van het statinegebruik op het immuunsysteem werden bepaald door het meten van 
serum concentraties van het acute fase eiwit (C-reactieve protein (CRP)), neopterine 
en immunoglobuline (Ig) E. Daarnaast werd er getest op de aanwezigheid van de 
autoantilichamen, antinucleaire antilichamen (ANA) en reumatoïde factor (RF). Het 
onderzoek werd uitgevoerd onder personen uit de algemene bevolking die al of niet 
waren blootgesteld aan statines. In verscheidene studies werd al aangetoond dat 
statinegebruik de concentratie CRP kan verlagen. In de lijn der verwachting, waren 
de concentraties CRP lager in de statine-gebruikers dan in de niet-gebruikers. Verder 
vonden we in de statine-gebruikers een trend naar een hogere concentratie IgE 
antilichamen, dat is een merkstof voor een Th2 immuunreactie. Er werden geen 
verschillen waargenomen in de concentraties neopterine, een merkstof voor een Th1 
immuunreactie, en de aanwezigheid van de autoantilichamen tussen de statine-ge-
bruikers en niet-gebruikers. Onze bevindingen suggereren dat de statines een ont-
stekingsremmende werking hebben, maar er is niet voldoende bewijs dat de statines 
een effect uitoefenen op een Th1 immuunreactie en/of het verlies van zelf-tolerantie 
van het immuunsysteem. Een immuun-modulerend effect op een Th2 immuunreactie 
kan echter niet worden uitgesloten. Onze bevinding van de Th2 reactie komt overeen 
met twee eerdere studies die beide aantonen dat statines een Th2 immuunreactie 
bevorderen. Aangezien we geen effect van het statinegebruik op de aanwezigheid 
van autoantilichamen hebben gevonden, lijkt het erop dat statines zelf geen defect 
in de immuuntolerantie veroorzaken, maar ze kunnen mogelijk een bestaande 
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auto-immuun gevoelige conditie laten ontwikkelen tot het openbaren van een klinische 
ziekte.
Gebaseerd op de bevindingen die gepresenteerd zijn in hoofdstuk 3, vinden we een 
relatie tussen statinegebruik en een verhoogd risico op het ontwikkelen van RA. 
Echter, onze bevindingen zijn niet bevestigd in andere studies. Om het oorzakelijke 
verband tussen statinegebruik en het risico op het ontwikkelen van RA te onderzoeken, 
hebben we een proefdierstudie uitgevoerd (hoofdstuk 5). In deze proefdierstudie, is 
een specifiek muismodel gebruikt, dat karakteristiek is voor RA. De muizen werden 
dagelijks via het voedsel gedurende 4 weken behandeld met één van de twee typen 
statines (pravastatine of atorvastatine), of met een zoutoplossing, voor of na de 
opwekking van artritis. We vonden dat een behandeling met 40 mg/kg pravastatine 
of 10 mg/kg atorvastatine, voor of na het opwekken van artritis resulteerde in een 
vervroegde artritis. Dit in vergelijking met geen behandeling met statines. Daarnaast 
zagen we dat een behandeling met atorvastatine of pravastatine na de het opwekken 
van artritis, resulteerde in een vroegere aanvang van artritis dan behandeling met 
dezelfde statines vóór artritis opwekking. De bevinding van een vroegere aanvang 
van artritis na behandeling met statines vóór de opwekking van artritis, ondersteunt 
de bevindingen uit hoofdstuk 3.1 en 3.2. Vier andere proefdierstudies die hetzelfde 
muismodel hebben gebruikt, laten gunstige of geen effecten van behandelingen met 
statines op de aanvang van artritis zien. Deze studies gebruiken echter verschillende 
types, trajecten en doses, start en duur van het statinegebruik. Dit betekent dat het 
moeilijk is om de resultaten van deze vier studies met onze resultaten te vergelijken. 
Desondanks ondersteunen onze bevindingen een oorzakelijk verband tussen 
statinegebruik en het risico op het ontwikkelen van RA.
In hoofdstuk 6 zijn de belangrijkste bevindingen van de in dit proefschrift onderzochte 
relaties tussen statines, ACE remmers en ARB’s en het risico op het ontwikkelen van 
een aantal auto-immuunziekten beschreven en bediscussieerd in het licht van de 
bestaande literatuur. Dit is zowel vanuit immunologisch als epidemiologisch 
perspectief uitgevoerd. We hebben verscheidene immunologische verklaringen 
gegeven voor onze bevindingen. Eén van de verklaringen is dat we geen effect van 
statinegebruik op de aanwezigheid van autoantilichamen hebben gevonden, wat er 
op lijkt te duiden dat statines zelf geen defect in de immuuntolerantie kunnen 
veroorzaken, maar mogelijk een bestaande auto-immuun gevoelige conditie kunnen 
laten ontwikkelen tot een klinische ziekte. Vervolgens zijn er tal van methodologische 
beschouwingen over de onderzoeksopzetten, de definitie van het gebruik van 
statines, ACE remmers en ARBs  en auto-immuunziekten beschreven, en worden 
ook andere methodologische beperkingen in dit proefschrift bediscussieerd, 
waaronder ‘protopathic bias’, ‘ascertainment bias’, ‘detectie bias’, verschillen in het 
voorschrijfgedrag van huisartsen, ‘confounding by indication’ en het ontbreken van 
verstorende variabelen (“confounders”). Deze methodologische beperkingen 
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hebben zeker invloed gehad op onze bevindingen. Eén van de discussiepunten is 
het gebruik van de juiste definitie voor auto-immuunziekten en de verstorende 
variabelen. Door het verkrijgen van een complete medische geschiedenis van de 
patiënt, door bijvoorbeeld het koppelen van verscheidene datasets, kan de misclas-
sificatie van het lupusachtig syndroom, PMR of RA, of ‘protopathic bias’ worden 
verkleind. Een ander belangrijk punt is dat statines, ACE remmers of ARB’s kunnen 
dienen als een soort maatstaf voor hyperlipidemie of hypertensie. Meer onderzoek 
zal moeten worden uitgevoerd om na te gaan of bijvoorbeeld hyperlipidemie of de 
immuun-modulerende eigenschappen van statines voornamelijk verantwoordelijk is 
voor de verhoogde kans op het ontwikkelen van auto-immuunziekten.
Ten slotte is er een eindconclusie getrokken over de bevindingen die in dit proefschrift 
zijn gepresenteerd. Samenvattend zagen we dat statinegebruik is gerelateerd aan 
een verhoogd risico op het ontwikkelen van auto-immuunziekten. Huidig bewijs laat 
zien dat statines zijn gerelateerd aan een verhoogde aanwezigheid van, of risico op 
het ontwikkelen van lupusachtig syndroom, PMR of RA. Het risico op het ontwikkelen 
van RA is verhoogd in het eerste jaar na de start van het gebruik. Bovendien is er een 
oorzakelijk verband tussen statinegebruik en het risico op auto-immuunziekten 
aangetoond. Anderzijds was er geen relatie tussen statinegebruik en het verlies van 
zelf-tolerantie van het immuunsysteem onder personen uit de algemene bevolking. In 
tegenstelling tot het gebruik van statines kan het gebruik van ACE remmers and 
ARB’s als veilig worden ervaren, zelfs na langdurig gebruik. 
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Het is dan eindelijk af! Een proefschrift schrijven doe je natuurlijk niet alleen. Velen 
hebben op verschillende wijzen een bijdrage geleverd aan de totstandkoming van dit 
proefschrift. In het bijzonder wil ik graag de volgende mensen bedanken.
Allereerst wil ik mijn promotoren, Prof. dr. H. van Loveren en Prof. dr. JW Cohen 
Tervaert, en mijn copromotoren, dr. R.J. Vandebriel en dr. O.H. Klungel, bedanken.
Beste Henk, graag wil ik jou danken voor de kans die je me hebt geboden om mijn 
promotie te starten en te voltooien. In het bijzonder wil ik jou bedanken voor de 
vrijheid en de verantwoordelijkheden die ik van jou kreeg om in dit project nieuwe 
studies en de daarbij behorende samenwerkingen op te zetten. Ondanks deze mate 
van vrijheid hield je altijd wel de vinger aan de pols over de invulling van het proefschrift.
Beste Jan Willem, jouw praktijkgerichte inbreng gaf vanaf het begin af aan, een enorme 
impuls aan het project. Jouw enthousiasme, bevlogenheid en positieve instelling 
heeft me altijd geboeid en gaf me veel energie. Samenwerken met jou heb ik als zeer 
inspirerend ervaren. Niet alleen tijdens het promotieonderzoek was je van onschatbare 
waarde, maar je hebt ook een grote rol gespeeld bij het tot stand brengen van de 
samenwerking tussen de Universiteit Maastricht en University of British Columbia 
(UBC). Met deze samenwerking heb ik mijn postdoctorale positie bij UBC kunnen 
behouden. Daar ben ik jou ontzettend dankbaar voor. Ik ben erg blij dat we onze 
samenwerking verder kunnen voortzetten.
Beste Rob, ondanks onze verschillende wetenschappelijke achtergronden, heb ik 
jouw rol in mijn promotieonderzoek erg gewaardeerd. Voornamelijk bij het opzetten 
en het uitwerken van het proefdieronderzoek. Zonder jouw hulp was dit onderzoek 
niet tot stand gekomen. Verder kon ik altijd rekenen op je snelle en kritische reactie 
op mijn manuscripten.
Beste Olaf, al vrij snel in het promotieonderzoek kwamen we er achter dat de datasets 
niet toereikend waren voor het bestuderen van onze onderzoeksvraag. Door jouw 
netwerk heb je me kennnis laten maken met verschillende nationale en internationale 
onderzoeksgroepen. Deze onderzoeksgroepen konden ons voorzien van datasets 
die passend waren voor onze onderzoeksvraag. Daarnaast heb ik jouw kennis in de 
epidemiologie en je kritische blik op mijn manuscripten zeer gewaardeerd. 
Naast mijn promotieteam heb ik de nodige hulp van anderen gehad, waarvoor mijn 
dank. 
Prof. dr. H.M.G. Leufkens en dr. J-W. van der Laan, beste Bert en Jan-Willem, jullie 
stonden niet alleen aan de wieg van dit onderzoeksproject, maar bleven me tijdens 
het onderzoek ook met goede raad en advies bijstaan. Bedankt!
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Dr. R.H.B. Meijboom, beste Ron, bedankt voor je bijdrage aan de twee studies met 
de WHO database en bij het uitwerken van één specifieke melding uit de WHO 
database tot een casus. Het was een erg leerzaam proces om tot de resultaten te 
komen die in de hoofdstukken 2.1, 2.2 en 2.3 zijn beschreven. Door jouw samenwerking 
kreeg ik de kans om ook een kijkje te nemen in de keuken van de farmacovigilantie. 
Dank daarvoor! Ook dr. J.M.L. Passier, beste Anneke, bedankt voor het verstrekken 
van informatie ten behoeve van het Nederlandse registratiesysteem voor de 
bijwerkingen van geneesmiddelen. I would also like to thank Kristina Star for her help 
with the WHO database and her critical notes to the manuscripts presented in chapter 
2.1 and 2.2 of this thesis. Furthermore, I would like to thank prof. dr. L. Niskanen and 
dr. Markku for providing me with patient information for the case report as described 
in chapter 2.3. Last but not least, with regards to the studies using WHO database, I 
would like to thank ‘my student’ Siti Rizny Saldi for her support in the data analyses, 
as presented in chapter 2.1 and 2.2. In addition, thank you for helping me out with the 
data analysis for chapter 3.3. Congratulations on your position as an epidemiologist 
at the Centre for Clinical Epidemiology and Evidence-Based Medicine in Jakarta, 
Indonesia! 
Mijn speciale dank gaat uit naar Liset van Dijk. Beste Liset, jouw input op de twee 
studies met de LINH data (hoofdstuk 3.1 en 3.3) waren zeer waardevol voor mij. Jouw 
enthousiasme, doortastendheid en opbouwende feedback tijdens onze besprekingen 
zorgden ervoor dat ik weer met een frisse blik aan de slag kon gaan. Daarnaast 
volgde je op de voet de voortgang van mijn promotieonderzoek. Na mijn officiële 
promotietraject bood je mij een tijdelijke positie als farmaco-epidemioloog aan bij het 
NIVEL. Naast de werkzaamheden voor het NIVEL, gaf je me ook de ruimte om mijn 
promotieonderzoek af te ronden en maakte je het mogelijk om mijn droom te 
verwezenlijken. Met jouw creativiteit en vastberadenreid werd er een samenwerking 
opgezet met UBC waardoor ik voor de eerste keer de grote overstap kon maken naar 
Vancouver, Canada. Hier ben ik jou nog altijd heel erg dankbaar voor.
Mijn dank is groot aan prof. dr. T.P. van Staa. Beste Tjeerd, in de laatste fase van mijn 
promotieonderzoek kreeg ik zowaar de kans om met jou samen te werken. Ik ben je 
nog steeds dankbaar dat jij mijn uitkomsten van de auto-immuunziekten in jouw 
protocol opnam. Hierdoor mocht ik gebruik maken van jouw speciaal gecreëerde 
cohort van de CPRD data dat uiteindelijk heeft geresulteerd in een studie, zoals staat 
beschreven in hoofdstuk 3.2. Dr. A. Lalmohamed en dr. F. de Vries, beste Arief en 
Frank, bedankt voor jullie ondersteuning bij de interpretatie van de CPRD data en het 
programmeren in SAS.
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Dr. P.C. Souverein, beste Patrick, waar zou een farmaco-epidemiologische afdeling 
zijn zonder een goede datamanager? Vele malen was je bereid mij de helpende hand 
te bieden als ik weer eens met een verzoek voor data kwam of vastzat met het 
programmeren. Jouw inzet met betrekking tot de Doetinchem cohort is zeer waardevol 
voor mij. 
Svetlana Belitser, beste Svetlana, op het moment dat ik, zeer ingewikkelde analyses 
met meerdere metingen in de tijd, uit moest voeren heb jij mij voorzien van goede 
statistische adviezen. Dank je wel!
Dr. W.M.M. Verschuren, beste Monique, bedankt dat jij mij het vertrouwen hebt 
gegeven om een onderzoek uit te voeren met de serum monsters van de Doetinchem 
cohort. Ook jouw kennis in de epidemiologie was heel erg waardevol voor het 
opzetten en analyseren van de studie, en het uiteindelijke manuscript (hoofdstuk 4). 
Bedankt!
Toen ik eenmaal groen licht van de Doetinchem onderzoeksgroep had gekregen, 
hadden Liset de la Fonteyne, Arja de Klerk, Bhawanie Nagarajah, Henny Verhagen, 
Bert Verlaan, Jolanda Vermeulen en Ilse Tonk, met alle ontberingen van dien, de 
monsters uit de vriezers gelicht. Daar ben ik jullie allen dankbaar voor! 
Eenmaal met de serum monsters in Maastricht aangekomen, namen Mia Wolfs en 
Jos Austen mij gelijk onder hen hoede. Beste Mia en Jos, bedankt dat jullie mij 
wegwijs hebben gemaakt in het laboratorium van de klinische immunologie. Vanaf 
de eerste dag voelde ik mij daar erg welkom. Verder wil ik ook José Barron-Houben, 
Yvon Knapen-Portz, Jolanda Knops-Janssen, Carla Langejans, Kathleen Mallet, 
Joyce Niessen, Dionne van Opbergen, Marie-Paule Paulissen en Claire Wieczorek 
bedanken voor alle hulp die ik van jullie heb gekregen bij het bepalen van de (auto) 
immune markers. Met mijn beperkte ervaring in het laboratorium heb ik ontzettend 
veel van jullie allen geleerd. Ook was ik onder de indruk van jullie gastvrijheid. 
Bedaank!
Beste Eric Gremmer, ik wil jou in het bijzonder bedanken voor de grote rol die je hebt 
gespeeld in het bepalen van de (auto) immuun markers uit het serum van de 
deelnemers uit de Doetinchem cohort. Elke week bleef je één nacht over in Maastricht 
om zo vol gas zoveel mogelijk monsters door te meten. Maar na gedane arbeid is het 
goed rusten, en daarom wil ik jou ook bedanken voor de gezellige avonden in 
Maastricht. Beste Eugéne Jansen, bedankt dat je van alle monsters het CRP gehalte 
hebt bepaald. 
Dr. J.G.M.C. Damoiseaux, beste Jan, al ben ik een ‘groentje’ in de immunologie, 
graag wil ik jou bedanken voor jouw immunologische input, de brainstorm sessies en 
jouw feedback op het manuscript (hoofdstuk 4). 
Dank aan dr. M.P. Hoevenaar-Blom, de datamanagers A. Blokstra, J. van der Laan en 
RJ. de Klein en alle andere medewerkers van de Doetinchem cohort (ook de veld-
medewerkers van de GGD). Beste Marieke, Anneke, Jan en Robert Jan, ook al werkten 
252
ACKNOWLEDGEMENTS | DANKWOORD
jullie aan vele projecten, er was altijd wel een gaatje in jullie drukke agenda’s te vinden. 
Bedankt voor jullie ondersteuning in het verstrekken van de data, programmeren en 
de statistische suggesties, wat heeft bijgedragen aan de resultaten die zijn beschreven 
in hoofdstuk 4 van dit proefschrift.
Prof. dr. W. Slob, beste Wout, ook al was ik niet direct betrokken bij het proefdier -
onderzoek, jouw raad en daad met betrekking tot het programma ‘PROAST’ waren 
zeer waardevol en droegen bij aan het resultaat uit hoofdstuk 5. 
De leden van de beoordelingscommissie, prof. dr. H. ten Cate, prof. dr. W. van den 
Berg, prof. dr. A.C.G. Egberts, prof. dr. J. Kleinjans, en prof. dr. P.W. de Leeuw ben ik 
zeer erkentelijk voor het doornemen van mijn proefschrift.
De vormgeving van dit proefschrift was in handen van Harald Pieper. Beste Harald, 
met jouw precisie en creatieve inbreng is het een mooi proefschrift geworden. Bedankt!
Furthermore, I would like to thank Annette Spedding, Annette Herzog and Elaine Kingwell 
for editing my thesis. Your English is superb!
Als je al enige tijd in het buitenland vertoeft, merk je toch dat het Nederlands iets 
minder goed uit de verf komt. Tessa Dillerop, bedankt voor het doornemen van de 
Nederlandse samenvatting.
Tijdens mijn promotie heb ik op vier verschillende afdelingen gewerkt. Dank aan alle 
dames (Addy, Ineke, Suzanne en Anja van Farmacoepidemiologie, Universiteit Utrecht; 
Nanette en Anita van Klinische en Experimentele Immunologie, Universiteit Maastricht; 
Willy en Janet van het laboratorium voor gezondheidsbeschermend onderzoek (GBO), 
RIVM; en Marie Claire, Sandrien en Christa van Toxicogenomics, Universiteit Maastricht) 
van de secretariaten voor de ondersteuning en belangstelling voor mijn promotie-
onderzoek.
Al mijn collega’s van de afdeling farmaco-epidemiologie, bedankt voor jullie onder-
steuning, gezelligheid, de vrijdagnamiddag borrels, en de gezamenlijke lunches en 
dineetjes. Simone, Mira, Hans, Jacqueline, Renate, Miriam en Suzanne, ik vond het 
erg prettig jullie allen als kamergenoten te hebben gehad. Bedankt voor de 
gezelligheid! Mijn speciale dank gaat uit naar Ellen Koster. Ik heb jou niet alleen leren 
kennen als een fijne collega, maar in de loop der jaren is onze samenwerking 
uitgegroeid tot een bijzondere vriendschap. Bedankt dat ik met jou kon sparren over 
een aantal epidemiologische vraagstukken, je hulp in het programmeren en alle 
gezellige uitjes. Ik had je graag aan mijn zijde op de promotie gehad, maar op het 
moment dat de magische woorden ‘hora est’ worden uitgesproken, ben jij op rondreis 
in Australië. Heel veel plezier daar!
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Naast mijn collega’s van de afdeling farmaco-epidemiologie wil ik ook de collega’s 
(waaronder mijn kamergenoten Marten en Maria) van Toxicogenomics bedanken 
voor jullie gastvrijheid, warmte en behulpzaamheid. Thank you, Christina, Daneida, Maria, 
Marieke and Marlon for enjoying my company after work. In het bijzonder wil ik 
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as presented in chapter 3.2, and supporting me in the last phase of my PhD. 
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